<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Bull World Health Organ</journal-id><journal-id journal-id-type="iso-abbrev">Bull. World Health Organ</journal-id><journal-id journal-id-type="publisher-id">BLT</journal-id><journal-title-group><journal-title>Bulletin of the World Health Organization</journal-title></journal-title-group><issn pub-type="ppub">0042-9686</issn><issn pub-type="epub">1564-0604</issn><publisher><publisher-name>World Health Organization</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25883410</article-id><article-id pub-id-type="pmc">4371493</article-id><article-id pub-id-type="publisher-id">BLT.14.141390</article-id><article-id pub-id-type="doi">10.2471/BLT.14.141390</article-id><article-categories><subj-group subj-group-type="heading"><subject>Systematic Reviews</subject></subj-group></article-categories><title-group><article-title>Participants&#x02019; understanding of informed consent in clinical trials over three decades: systematic review and meta-analysis</article-title><trans-title-group xml:lang="fr"><trans-title xml:lang="fr">Compr&#x000e9;hension du consentement &#x000e9;clair&#x000e9; par les participants &#x000e0; des essais cliniques sur trois d&#x000e9;cennies: revue syst&#x000e9;matique et m&#x000e9;ta-analyse</trans-title></trans-title-group><trans-title-group xml:lang="es"><trans-title xml:lang="es">La comprensi&#x000f3;n del consentimiento informado por parte de los participantes de ensayos cl&#x000ed;nicos a lo largo de tres d&#x000e9;cadas: revisi&#x000f3;n sistem&#x000e1;tica y metaan&#x000e1;lisis</trans-title></trans-title-group><trans-title-group xml:lang="ar"><trans-title xml:lang="ar">&#x00641;&#x00647;&#x00645; &#x00627;&#x00644;&#x00645;&#x00634;&#x00627;&#x00631;&#x00643;&#x0064a;&#x00646; &#x00644;&#x00644;&#x00645;&#x00648;&#x00627;&#x00641;&#x00642;&#x00629; &#x00627;&#x00644;&#x00645;&#x00633;&#x0062a;&#x00646;&#x0064a;&#x00631;&#x00629; &#x00641;&#x0064a; &#x00627;&#x00644;&#x0062a;&#x0062c;&#x00627;&#x00631;&#x00628; &#x00627;&#x00644;&#x00633;&#x00631;&#x0064a;&#x00631;&#x0064a;&#x00629; &#x00639;&#x00644;&#x00649; &#x00645;&#x0062f;&#x00649; &#x0062b;&#x00644;&#x00627;&#x0062b;&#x00629; &#x00639;&#x00642;&#x00648;&#x0062f;: &#x00627;&#x00633;&#x0062a;&#x00639;&#x00631;&#x00627;&#x00636; &#x00645;&#x00646;&#x00647;&#x0062c;&#x0064a; &#x00648;&#x0062a;&#x0062d;&#x00644;&#x0064a;&#x00644; &#x0062a;&#x00627;&#x00644;&#x0064d; </trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title xml:lang="zh">&#x04e09;&#x05341;&#x05e74;&#x06765;&#x04e34;&#x05e8a;&#x08bd5;&#x09a8c;&#x04e2d;&#x053c2;&#x04e0e;&#x08005;&#x05bf9;&#x077e5;&#x060c5;&#x0540c;&#x0610f;&#x07684;&#x07406;&#x089e3;&#x0ff1a;&#x07cfb;&#x07edf;&#x056de;&#x0987e;&#x0548c;&#x0835f;&#x08403;&#x05206;&#x06790;</trans-title></trans-title-group><trans-title-group xml:lang="ru"><trans-title xml:lang="ru">&#x0041f;&#x0043e;&#x0043d;&#x00438;&#x0043c;&#x00430;&#x0043d;&#x00438;&#x00435; &#x00443;&#x00447;&#x00430;&#x00441;&#x00442;&#x0043d;&#x00438;&#x0043a;&#x00430;&#x0043c;&#x00438; &#x0043a;&#x0043b;&#x00438;&#x0043d;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x00438;&#x00445; &#x00438;&#x00441;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x00439; &#x00438;&#x0043d;&#x00444;&#x0043e;&#x00440;&#x0043c;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x00441;&#x0043e;&#x00433;&#x0043b;&#x00430;&#x00441;&#x00438;&#x0044f; &#x00437;&#x00430; &#x00442;&#x00440;&#x00438; &#x00434;&#x00435;&#x00441;&#x0044f;&#x00442;&#x00438;&#x0043b;&#x00435;&#x00442;&#x00438;&#x0044f;: &#x00441;&#x00438;&#x00441;&#x00442;&#x00435;&#x0043c;&#x00430;&#x00442;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x00438;&#x00439; &#x0043e;&#x00431;&#x00437;&#x0043e;&#x00440; &#x00438; &#x0043c;&#x00435;&#x00442;&#x00430;-&#x00430;&#x0043d;&#x00430;&#x0043b;&#x00438;&#x00437;</trans-title></trans-title-group><alt-title alt-title-type="author-running-head">Nguyen Thanh Tam et al.</alt-title><alt-title alt-title-type="title-running-head">Trial participants&#x02019; understanding of informed consent</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tam</surname><given-names>Nguyen Thanh</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Huy</surname><given-names>Nguyen Tien</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Thoa</surname><given-names>Le Thi Bich</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Long</surname><given-names>Nguyen Phuoc</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Trang</surname><given-names>Nguyen Thi Huyen</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hirayama</surname><given-names>Kenji</given-names></name><xref ref-type="aff" rid="aff4"><sup>d</sup></xref></contrib><contrib contrib-type="author"><name><surname>Karbwang</surname><given-names>Juntra</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><aff id="aff1"><label>a</label>Ho Chi Minh City University of Medicine and Pharmacy, Ho Chi Minh City, <country>Viet Nam</country>.</aff><aff id="aff2"><label>b</label>Department of Clinical Product Development, Institute of Tropical Medicine (NEKKEN), Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, <country>Japan</country>.</aff><aff id="aff3"><label>c</label>Hue University of Medicine and Pharmacy, Hue City, <country>Viet Nam</country>.</aff><aff id="aff4"><label>d</label>Department of Immunogenetics, Institute of Tropical Medicine (NEKKEN), Nagasaki, <country>Japan</country>.</aff></contrib-group><author-notes><corresp id="cor1">Correspondence to Nguyen Tien Huy (email: <email xlink:href="tienhuy@nagasaki-u.ac.jp">tienhuy@nagasaki-u.ac.jp</email>).</corresp></author-notes><pub-date pub-type="ppub"><day>01</day><month>3</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>22</day><month>1</month><year>2015</year></pub-date><volume>93</volume><issue>3</issue><fpage>186</fpage><lpage>198H</lpage><history><date date-type="received"><day>13</day><month>5</month><year>2014</year></date><date date-type="rev-recd"><day>29</day><month>10</month><year>2014</year></date><date date-type="accepted"><day>26</day><month>11</month><year>2014</year></date></history><permissions><copyright-statement>(c) 2015 The authors; licensee World Health Organization.</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution IGO License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/igo/legalcode">http://creativecommons.org/licenses/by/3.0/igo/legalcode</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any reproduction of this article there should not be any suggestion that WHO or this article endorse any specific organization or products. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL.</license-p></license></permissions><abstract><title>Abstract</title><sec><title>Objective</title><p>To estimate the proportion of participants in clinical trials who understand different components of informed consent.</p></sec><sec><title>Methods</title><p>Relevant studies were identified by a systematic review of PubMed, Scopus and Google Scholar and by manually reviewing reference lists for publications up to October 2013. A meta-analysis of study results was performed using a random-effects model to take account of heterogeneity.</p></sec><sec><title>Findings</title><p>The analysis included 103 studies evaluating 135 cohorts of participants. The pooled proportion of participants who understood components of informed consent was 75.8% for freedom to withdraw at any time, 74.7% for the nature of study, 74.7% for the voluntary nature of participation, 74.0% for potential benefits, 69.6% for the study&#x02019;s purpose, 67.0% for potential risks and side-effects, 66.2% for confidentiality, 64.1% for the availability of alternative treatment if withdrawn, 62.9% for knowing that treatments were being compared, 53.3% for placebo and 52.1% for randomization. Most participants, 62.4%, had no therapeutic misconceptions and 54.9% could name at least one risk. Subgroup and meta-regression analyses identified covariates, such as age, educational level, critical illness, the study phase and location, that significantly affected understanding and indicated that the proportion of participants who understood informed consent had not increased over 30&#x000a0;years.</p></sec><sec><title>Conclusion</title><p>The proportion of participants in clinical trials who understood different components of informed consent varied from 52.1% to 75.8%. Investigators could do more to help participants achieve a complete understanding. </p></sec></abstract><trans-abstract xml:lang="fr"><title>R&#x000e9;sum&#x000e9;</title><sec><title>Objectif</title><p>Estimer la proportion des participants &#x000e0; des essais cliniques qui comprennent les diff&#x000e9;rents composants du consentement &#x000e9;clair&#x000e9;.</p></sec><sec><title>M&#x000e9;thodes</title><p>Les &#x000e9;tudes pertinentes ont &#x000e9;t&#x000e9; identifi&#x000e9;es par une revue syst&#x000e9;matique de PubMed, Scopus et Google Scholar et par l'examen manuel des listes des r&#x000e9;f&#x000e9;rences des publications allant jusqu'&#x000e0; octobre&#x000a0;2013. Une m&#x000e9;ta-analyse des r&#x000e9;sultats de l'&#x000e9;tude a &#x000e9;t&#x000e9; r&#x000e9;alis&#x000e9;e &#x000e0; l'aide du mod&#x000e8;le &#x000e0; effets al&#x000e9;atoires pour tenir compte de l'h&#x000e9;t&#x000e9;rog&#x000e9;n&#x000e9;it&#x000e9;.</p></sec><sec><title>R&#x000e9;sultats</title><p>L'analyse a inclus 103&#x000a0;&#x000e9;tudes &#x000e9;valuant 135&#x000a0;cohortes de participants. La proportion regroup&#x000e9;e des participants qui ont compris les composants du consentement &#x000e9;clair&#x000e9; &#x000e9;tait de 75,8% pour la libert&#x000e9; de se retirer &#x000e0; tout moment, de 74,7% pour la nature de l'&#x000e9;tude, de 74,7% pour la nature volontaire de la participation, de 74,0% pour les b&#x000e9;n&#x000e9;fices potentiels, de 69,6% pour l'objectif de l'&#x000e9;tude, de 67,0% pour les risques et effets ind&#x000e9;sirables potentiels, de 66,2% pour la confidentialit&#x000e9;, de 64,1% pour la disponibilit&#x000e9; d'un traitement alternatif en cas de retrait de l'&#x000e9;tude, de 62,9% pour la connaissance des traitements &#x000e9;valu&#x000e9;s, de 53,3% pour le placebo et de 52,1% pour la randomisation. La plupart des participants (62,4%) n'avaient pas d'id&#x000e9;es fausses sur le traitement, et 54,9% d'entre eux pouvaient citer au moins un risque. Les analyses de sous-groupe et de m&#x000e9;tar&#x000e9;gression ont identifi&#x000e9; des covariables, telles que l'&#x000e2;ge, le niveau d'&#x000e9;ducation, la maladie grave, la phase et le site de l'&#x000e9;tude, qui affectaient significativement la compr&#x000e9;hension et indiquaient que la proportion des participants ayant compris le consentement &#x000e9;clair&#x000e9; n'avait pas augment&#x000e9; sur une p&#x000e9;riode de 30&#x000a0;ans.</p></sec><sec><title>Conclusion</title><p>La proportion des participants &#x000e0; des essais cliniques, qui ont compris les diff&#x000e9;rents composants du consentement &#x000e9;clair&#x000e9;, variait de 52,1% &#x000e0; 75,8%. Les investigateurs pourraient en faire davantage pour aider les participants &#x000e0; parvenir &#x000e0; la compr&#x000e9;hension compl&#x000e8;te. </p></sec></trans-abstract><trans-abstract xml:lang="es"><title>Resumen</title><sec><title>Objetivo</title><p>Estimar la proporci&#x000f3;n de participantes de ensayos cl&#x000ed;nicos que comprende los distintos componentes del consentimiento informado.</p></sec><sec><title>M&#x000e9;todos</title><p>Se identificaron los estudios pertinentes mediante una revisi&#x000f3;n sistem&#x000e1;tica de PubMed, Scopus y Google Scholar y el examen manual de listas de referencia a fin de hallar publicaciones anteriores a octubre de 2013. Se realiz&#x000f3; un metan&#x000e1;lisis de los resultados del estudio mediante un modelo de efectos aleatorios para tener en cuenta la heterogeneidad.</p></sec><sec><title>Resultados</title><p>El an&#x000e1;lisis incluy&#x000f3; 103 estudios que evaluaron 135 cohortes de participantes. La proporci&#x000f3;n combinada de participantes que entend&#x000ed;a los componentes del consentimiento informado fue del 75,8 % para la libertad de retirarse en cualquier momento, 74,7 % para la naturaleza del estudio, 74,7 % para el car&#x000e1;cter voluntario de la participaci&#x000f3;n, 74,0 % para los beneficios potenciales, 69,6 % para el prop&#x000f3;sito del estudio, 67,0 % para los riesgos y efectos secundarios potenciales, 66,2 % para la confidencialidad, 64,1 % para la disponibilidad de tratamiento alternativo si el paciente se retira, 62,9 % para saber que se comparaban tratamientos, 53,3 % para el placebo y 52,1 % para la aleatorizaci&#x000f3;n. La mayor&#x000ed;a de los participantes, el 62,4 %, no ten&#x000ed;a una idea equivocada sobre la terapia y el 54,9 % no fue capaz de nombrar al menos un riesgo. Los an&#x000e1;lisis de subgrupos y la metarregresi&#x000f3;n identificaron covariables, como edad, nivel educativo, enfermedad cr&#x000ed;tica, fase de estudio y ubicaci&#x000f3;n, que influ&#x000ed;an considerablemente en la comprensi&#x000f3;n y se&#x000f1;alaron que la proporci&#x000f3;n de participantes que entend&#x000ed;a el consentimiento informado no hab&#x000ed;a aumentado en 30 a&#x000f1;os.</p></sec><sec><title>Conclusi&#x000f3;n</title><p>La proporci&#x000f3;n de participantes de ensayos cl&#x000ed;nicos que entend&#x000ed;a los diferentes componentes del consentimiento informado vari&#x000f3; del 52,1 % al 75,8 %. Los investigadores podr&#x000ed;an realizar esfuerzos mayores para ayudar a los pacientes a lograr una comprensi&#x000f3;n total.</p></sec></trans-abstract><trans-abstract xml:lang="ar"><title>&#x00645;&#x00644;&#x0062e;&#x00635; </title><sec><title>&#x00627;&#x00644;&#x0063a;&#x00631;&#x00636; </title><p>&#x0062a;&#x00642;&#x0062f;&#x0064a;&#x00631; &#x00646;&#x00633;&#x00628;&#x00629; &#x00627;&#x00644;&#x00645;&#x00634;&#x00627;&#x00631;&#x00643;&#x0064a;&#x00646; &#x00641;&#x0064a; &#x00627;&#x00644;&#x0062a;&#x0062c;&#x00627;&#x00631;&#x00628; &#x00627;&#x00644;&#x00633;&#x00631;&#x0064a;&#x00631;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00630;&#x0064a;&#x00646; &#x0064a;&#x00641;&#x00647;&#x00645;&#x00648;&#x00646; &#x00627;&#x00644;&#x00639;&#x00646;&#x00627;&#x00635;&#x00631; &#x00627;&#x00644;&#x00645;&#x0062e;&#x0062a;&#x00644;&#x00641;&#x00629; &#x00644;&#x00644;&#x00645;&#x00648;&#x00627;&#x00641;&#x00642;&#x00629; &#x00627;&#x00644;&#x00645;&#x00633;&#x0062a;&#x00646;&#x0064a;&#x00631;&#x00629;. </p></sec><sec><title>&#x00627;&#x00644;&#x00637;&#x00631;&#x0064a;&#x00642;&#x00629; </title><p>&#x0062a;&#x00645; &#x0062a;&#x0062d;&#x0062f;&#x0064a;&#x0062f; &#x00627;&#x00644;&#x0062f;&#x00631;&#x00627;&#x00633;&#x00627;&#x0062a; &#x00630;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00635;&#x00644;&#x00629; &#x00639;&#x00646; &#x00637;&#x00631;&#x0064a;&#x00642; &#x00627;&#x00633;&#x0062a;&#x00639;&#x00631;&#x00627;&#x00636; &#x00645;&#x00646;&#x00647;&#x0062c;&#x0064a; &#x00644;&#x00642;&#x00648;&#x00627;&#x00639;&#x0062f; &#x00628;&#x0064a;&#x00627;&#x00646;&#x00627;&#x0062a; PubMed &#x00648;Scopus &#x00648;Google Scholar &#x00648;&#x00639;&#x00646; &#x00637;&#x00631;&#x0064a;&#x00642; &#x00627;&#x00633;&#x0062a;&#x00639;&#x00631;&#x00627;&#x00636; &#x0064a;&#x0062f;&#x00648;&#x0064a; &#x00644;&#x00642;&#x00648;&#x00627;&#x00626;&#x00645; &#x00627;&#x00644;&#x00645;&#x00631;&#x00627;&#x0062c;&#x00639; &#x00627;&#x00644;&#x0062e;&#x00627;&#x00635;&#x00629; &#x00628;&#x00627;&#x00644;&#x00645;&#x00646;&#x00634;&#x00648;&#x00631;&#x00627;&#x0062a; &#x0062d;&#x0062a;&#x00649; &#x0062a;&#x00634;&#x00631;&#x0064a;&#x00646; &#x00627;&#x00644;&#x00623;&#x00648;&#x00644;/&#x00623;&#x00643;&#x0062a;&#x00648;&#x00628;&#x00631; 2013. &#x00648;&#x0062a;&#x00645; &#x00625;&#x0062c;&#x00631;&#x00627;&#x00621; &#x0062a;&#x0062d;&#x00644;&#x0064a;&#x00644; &#x0062a;&#x00627;&#x00644; &#x00644;&#x00646;&#x0062a;&#x00627;&#x00626;&#x0062c; &#x00627;&#x00644;&#x0062f;&#x00631;&#x00627;&#x00633;&#x00629; &#x00628;&#x00627;&#x00633;&#x0062a;&#x0062e;&#x0062f;&#x00627;&#x00645; &#x00646;&#x00645;&#x00648;&#x00630;&#x0062c; &#x00627;&#x00644;&#x0062a;&#x00623;&#x0062b;&#x0064a;&#x00631;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00639;&#x00634;&#x00648;&#x00627;&#x00626;&#x0064a;&#x00629; &#x00644;&#x00648;&#x00636;&#x00639; &#x00627;&#x00644;&#x0062a;&#x0063a;&#x00627;&#x0064a;&#x00631;&#x0064a;&#x00629; &#x00641;&#x0064a; &#x00627;&#x00644;&#x0062d;&#x00633;&#x00628;&#x00627;&#x00646;. </p></sec><sec><title>&#x00627;&#x00644;&#x00646;&#x0062a;&#x00627;&#x00626;&#x0062c; </title><p>&#x00627;&#x00634;&#x0062a;&#x00645;&#x00644; &#x00627;&#x00644;&#x0062a;&#x0062d;&#x00644;&#x0064a;&#x00644; &#x00639;&#x00644;&#x00649; 103 &#x0062f;&#x00631;&#x00627;&#x00633;&#x00629; &#x0062a;&#x00642;&#x00648;&#x00645; &#x00628;&#x0062a;&#x00642;&#x0064a;&#x0064a;&#x00645; 135 &#x00645;&#x0062c;&#x00645;&#x00648;&#x00639;&#x00629; &#x00645;&#x00646; &#x00627;&#x00644;&#x00645;&#x00634;&#x00627;&#x00631;&#x00643;&#x0064a;&#x00646;. &#x00648;&#x00643;&#x00627;&#x00646;&#x0062a; &#x00627;&#x00644;&#x00646;&#x00633;&#x00628;&#x00629; &#x00627;&#x00644;&#x00645;&#x0062c;&#x00645;&#x00639;&#x00629; &#x00644;&#x00644;&#x00645;&#x00634;&#x00627;&#x00631;&#x00643;&#x0064a;&#x00646; &#x00627;&#x00644;&#x00630;&#x0064a;&#x00646; &#x00641;&#x00647;&#x00645;&#x00648;&#x00627; &#x00639;&#x00646;&#x00627;&#x00635;&#x00631; &#x00627;&#x00644;&#x00645;&#x00648;&#x00627;&#x00641;&#x00642;&#x00629; &#x00627;&#x00644;&#x00645;&#x00633;&#x0062a;&#x00646;&#x0064a;&#x00631;&#x00629; <styled-content style-type="direction" style="direction:ltr;">75.8&#x000a0;% </styled-content>&#x00628;&#x00627;&#x00644;&#x00646;&#x00633;&#x00628;&#x00629; &#x00644;&#x0062d;&#x00631;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00627;&#x00646;&#x00633;&#x0062d;&#x00627;&#x00628; &#x00641;&#x0064a; &#x00623;&#x0064a; &#x00648;&#x00642;&#x0062a; <styled-content style-type="direction" style="direction:ltr;">&#x00648;74.7&#x000a0;% </styled-content>&#x00628;&#x00627;&#x00644;&#x00646;&#x00633;&#x00628;&#x00629; &#x00644;&#x00637;&#x00628;&#x0064a;&#x00639;&#x00629; &#x00627;&#x00644;&#x0062f;&#x00631;&#x00627;&#x00633;&#x00629; <styled-content style-type="direction" style="direction:ltr;">&#x00648;74.7&#x000a0;% </styled-content>&#x00628;&#x00627;&#x00644;&#x00646;&#x00633;&#x00628;&#x00629; &#x00644;&#x00637;&#x00628;&#x0064a;&#x00639;&#x00629; &#x00627;&#x00644;&#x00645;&#x00634;&#x00627;&#x00631;&#x00643;&#x00629; &#x00627;&#x00644;&#x00637;&#x00648;&#x00639;&#x0064a;&#x00629; <styled-content style-type="direction" style="direction:ltr;">&#x00648;74.0&#x000a0;% </styled-content>&#x00628;&#x00627;&#x00644;&#x00646;&#x00633;&#x00628;&#x00629; &#x00644;&#x00644;&#x00641;&#x00648;&#x00627;&#x00626;&#x0062f; &#x00627;&#x00644;&#x00645;&#x0062d;&#x0062a;&#x00645;&#x00644;&#x00629; <styled-content style-type="direction" style="direction:ltr;">&#x00648;69.6&#x000a0;% </styled-content>&#x00628;&#x00627;&#x00644;&#x00646;&#x00633;&#x00628;&#x00629; &#x00644;&#x0063a;&#x00631;&#x00636; &#x00627;&#x00644;&#x0062f;&#x00631;&#x00627;&#x00633;&#x00629; <styled-content style-type="direction" style="direction:ltr;">&#x00648;67.0&#x000a0;% </styled-content>&#x00628;&#x00627;&#x00644;&#x00646;&#x00633;&#x00628;&#x00629; &#x00644;&#x00644;&#x00645;&#x0062e;&#x00627;&#x00637;&#x00631; &#x00648;&#x00627;&#x00644;&#x00622;&#x0062b;&#x00627;&#x00631; &#x00627;&#x00644;&#x0062c;&#x00627;&#x00646;&#x00628;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00645;&#x0062d;&#x0062a;&#x00645;&#x00644;&#x00629; <styled-content style-type="direction" style="direction:ltr;">&#x00648;66.2&#x000a0;% </styled-content>&#x00628;&#x00627;&#x00644;&#x00646;&#x00633;&#x00628;&#x00629; &#x00644;&#x00633;&#x00631;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00645;&#x00639;&#x00644;&#x00648;&#x00645;&#x00627;&#x0062a; <styled-content style-type="direction" style="direction:ltr;">&#x00648;64.1&#x000a0;% </styled-content>&#x00628;&#x00627;&#x00644;&#x00646;&#x00633;&#x00628;&#x00629; &#x00644;&#x00625;&#x0062a;&#x00627;&#x0062d;&#x00629; &#x00627;&#x00644;&#x00639;&#x00644;&#x00627;&#x0062c; &#x00627;&#x00644;&#x00628;&#x0062f;&#x0064a;&#x00644; &#x00641;&#x0064a; &#x0062d;&#x00627;&#x00644;&#x00629; &#x00627;&#x00644;&#x00627;&#x00646;&#x00633;&#x0062d;&#x00627;&#x00628; &#x00645;&#x00646; &#x00627;&#x00644;&#x0062a;&#x0062c;&#x00631;&#x00628;&#x00629; &#x00627;&#x00644;&#x00633;&#x00631;&#x0064a;&#x00631;&#x0064a;&#x00629; <styled-content style-type="direction" style="direction:ltr;">&#x00648;62.9&#x000a0;% </styled-content>&#x00628;&#x00627;&#x00644;&#x00646;&#x00633;&#x00628;&#x00629; &#x00644;&#x00645;&#x00639;&#x00631;&#x00641;&#x00629; &#x00625;&#x0062c;&#x00631;&#x00627;&#x00621; &#x00645;&#x00642;&#x00627;&#x00631;&#x00646;&#x00627;&#x0062a; &#x00628;&#x0064a;&#x00646; &#x00627;&#x00644;&#x00639;&#x00644;&#x00627;&#x0062c;&#x00627;&#x0062a; <styled-content style-type="direction" style="direction:ltr;">&#x00648;53.3&#x000a0;% </styled-content>&#x00628;&#x00627;&#x00644;&#x00646;&#x00633;&#x00628;&#x00629; &#x00644;&#x00644;&#x0062f;&#x00648;&#x00627;&#x00621; &#x00627;&#x00644;&#x00648;&#x00647;&#x00645;&#x0064a; <styled-content style-type="direction" style="direction:ltr;">&#x00648;52.1&#x000a0;% </styled-content>&#x00628;&#x00627;&#x00644;&#x00646;&#x00633;&#x00628;&#x00629; &#x00644;&#x00644;&#x0062a;&#x00648;&#x00632;&#x0064a;&#x00639; &#x00627;&#x00644;&#x00639;&#x00634;&#x00648;&#x00627;&#x00626;&#x0064a;. &#x00648;&#x00644;&#x00645; &#x0064a;&#x00643;&#x00646; &#x00644;&#x0062f;&#x00649; &#x00645;&#x00639;&#x00638;&#x00645; &#x00627;&#x00644;&#x00645;&#x00634;&#x00627;&#x00631;&#x00643;&#x0064a;&#x00646;&#x0060c; <styled-content style-type="direction" style="direction:ltr;">62.4&#x000a0;%</styled-content>&#x0060c; &#x00645;&#x00641;&#x00627;&#x00647;&#x0064a;&#x00645; &#x00639;&#x00644;&#x00627;&#x0062c;&#x0064a;&#x00629; &#x0062e;&#x00627;&#x00637;&#x00626;&#x00629; &#x00648;&#x00627;&#x00633;&#x0062a;&#x00637;&#x00627;&#x00639; <styled-content style-type="direction" style="direction:ltr;">54.9&#x000a0;% </styled-content>&#x0062a;&#x0062d;&#x0062f;&#x0064a;&#x0062f; &#x0062e;&#x00637;&#x00631; &#x00648;&#x00627;&#x0062d;&#x0062f; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x00623;&#x00642;&#x00644;. &#x00648;&#x0062d;&#x0062f;&#x0062f;&#x0062a; &#x0062a;&#x0062d;&#x00644;&#x0064a;&#x00644;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00641;&#x00626;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00641;&#x00631;&#x00639;&#x0064a;&#x00629; &#x00648;&#x0062a;&#x0062d;&#x00644;&#x0064a;&#x00644;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00627;&#x00631;&#x0062a;&#x0062f;&#x00627;&#x0062f; &#x00627;&#x00644;&#x0062a;&#x00627;&#x00644;&#x0064a; &#x00627;&#x00644;&#x00645;&#x0062a;&#x0063a;&#x0064a;&#x00631;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00645;&#x00635;&#x00627;&#x0062d;&#x00628;&#x00629;&#x0060c; &#x00645;&#x0062b;&#x00644; &#x00627;&#x00644;&#x00633;&#x00646; &#x00648;&#x00627;&#x00644;&#x00645;&#x00633;&#x0062a;&#x00648;&#x00649; &#x00627;&#x00644;&#x0062a;&#x00639;&#x00644;&#x0064a;&#x00645;&#x0064a; &#x00648;&#x00627;&#x00644;&#x00627;&#x00639;&#x0062a;&#x00644;&#x00627;&#x00644;&#x00627;&#x0062a; &#x00627;&#x00644;&#x0062d;&#x00631;&#x0062c;&#x00629; &#x00648;&#x00645;&#x00631;&#x0062d;&#x00644;&#x00629; &#x00627;&#x00644;&#x0062f;&#x00631;&#x00627;&#x00633;&#x00629; &#x00648;&#x00645;&#x00648;&#x00642;&#x00639;&#x00647;&#x00627;&#x0060c; &#x00648;&#x00627;&#x00644;&#x0062a;&#x0064a; &#x00623;&#x0062b;&#x00631;&#x0062a; &#x00628;&#x00634;&#x00643;&#x00644; &#x00643;&#x00628;&#x0064a;&#x00631; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x00641;&#x00647;&#x00645; &#x00648;&#x00623;&#x00634;&#x00627;&#x00631;&#x0062a; &#x00625;&#x00644;&#x00649; &#x00623;&#x00646; &#x00646;&#x00633;&#x00628;&#x00629; &#x00627;&#x00644;&#x00645;&#x00634;&#x00627;&#x00631;&#x00643;&#x0064a;&#x00646; &#x00627;&#x00644;&#x00630;&#x0064a;&#x00646; &#x00641;&#x00647;&#x00645;&#x00648;&#x00627; &#x00627;&#x00644;&#x00645;&#x00648;&#x00627;&#x00641;&#x00642;&#x00629; &#x00627;&#x00644;&#x00645;&#x00633;&#x0062a;&#x00646;&#x0064a;&#x00631;&#x00629; &#x00644;&#x00645; &#x0062a;&#x00634;&#x00647;&#x0062f; &#x00632;&#x0064a;&#x00627;&#x0062f;&#x00629; &#x00639;&#x00644;&#x00649; &#x00645;&#x0062f;&#x00627;&#x00631; 30 &#x00633;&#x00646;&#x00629;. </p></sec><sec><title>&#x00627;&#x00644;&#x00627;&#x00633;&#x0062a;&#x00646;&#x0062a;&#x00627;&#x0062c; </title><p>&#x0062a;&#x00631;&#x00627;&#x00648;&#x0062d;&#x0062a; &#x00646;&#x00633;&#x00628;&#x00629; &#x00627;&#x00644;&#x00645;&#x00634;&#x00627;&#x00631;&#x00643;&#x0064a;&#x00646; &#x00641;&#x0064a; &#x00627;&#x00644;&#x0062a;&#x0062c;&#x00627;&#x00631;&#x00628; &#x00627;&#x00644;&#x00633;&#x00631;&#x0064a;&#x00631;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00630;&#x0064a;&#x00646; &#x00641;&#x00647;&#x00645;&#x00648;&#x00627; &#x00627;&#x00644;&#x00639;&#x00646;&#x00627;&#x00635;&#x00631; &#x00627;&#x00644;&#x00645;&#x0062e;&#x0062a;&#x00644;&#x00641;&#x00629; &#x00644;&#x00644;&#x00645;&#x00648;&#x00627;&#x00641;&#x00642;&#x00629; &#x00627;&#x00644;&#x00645;&#x00633;&#x0062a;&#x00646;&#x0064a;&#x00631;&#x00629; &#x00645;&#x00646; <styled-content style-type="direction" style="direction:ltr;">52.1&#x000a0;% </styled-content>&#x00625;&#x00644;&#x00649; <styled-content style-type="direction" style="direction:ltr;">75.8&#x000a0;%</styled-content>. &#x00648;&#x0064a;&#x00633;&#x0062a;&#x00637;&#x0064a;&#x00639; &#x00627;&#x00644;&#x0062e;&#x00628;&#x00631;&#x00627;&#x00621; &#x0062a;&#x00642;&#x0062f;&#x0064a;&#x00645; &#x00627;&#x00644;&#x00645;&#x00632;&#x0064a;&#x0062f; &#x00644;&#x00645;&#x00633;&#x00627;&#x00639;&#x0062f;&#x00629; &#x00627;&#x00644;&#x00645;&#x00634;&#x00627;&#x00631;&#x00643;&#x0064a;&#x00646; &#x00641;&#x0064a; &#x0062a;&#x0062d;&#x00642;&#x0064a;&#x00642; &#x00627;&#x00644;&#x00641;&#x00647;&#x00645; &#x00627;&#x00644;&#x00643;&#x00627;&#x00645;&#x00644;. </p></sec></trans-abstract><trans-abstract xml:lang="zh"><title>&#x06458;&#x08981;</title><sec><title>&#x076ee;&#x07684;</title><p>&#x04f30;&#x07b97;&#x04e34;&#x05e8a;&#x08bd5;&#x09a8c;&#x04e2d;&#x053c2;&#x04e0e;&#x08005;&#x07406;&#x089e3;&#x077e5;&#x060c5;&#x0540c;&#x0610f;&#x04e0d;&#x0540c;&#x07ec4;&#x06210;&#x090e8;&#x05206;&#x07684;&#x06bd4;&#x04f8b;&#x03002;</p></sec><sec><title>&#x065b9;&#x06cd5;</title><p>&#x07cfb;&#x07edf;&#x056de;&#x0987e;PubMed&#x03001;Scopus&#x0548c;Google Scholar&#x06765;&#x08bc6;&#x0522b;&#x076f8;&#x05173;&#x07814;&#x07a76;&#x03002;&#x04f7f;&#x07528;&#x0968f;&#x0673a;&#x05f71;&#x054cd;&#x06a21;&#x0578b;&#x06267;&#x0884c;&#x07814;&#x07a76;&#x07ed3;&#x0679c;&#x0835f;&#x08403;&#x05206;&#x06790;&#x0ff0c;&#x04ee5;&#x04fbf;&#x05c06;&#x05f02;&#x08d28;&#x06027;&#x08003;&#x08651;&#x05728;&#x05185;&#x03002;</p></sec><sec><title>&#x07ed3;&#x0679c;</title><p>&#x05206;&#x06790;&#x05305;&#x062ec;&#x08bc4;&#x04f30;135&#x07ec4;&#x053c2;&#x04e0e;&#x08005;&#x07684;103&#x09879;&#x07814;&#x07a76;&#x03002;&#x053c2;&#x04e0e;&#x08005;&#x07406;&#x089e3;&#x077e5;&#x060c5;&#x0540c;&#x0610f;&#x07ec4;&#x06210;&#x090e8;&#x05206;&#x07684;&#x06df7;&#x05408;&#x06bd4;&#x04f8b;&#x04e3a;&#x0ff1a;75.8%&#x07406;&#x089e3;&#x0968f;&#x065f6;&#x09000;&#x051fa;&#x07684;&#x081ea;&#x07531;&#x0ff0c;74.7%&#x07406;&#x089e3;&#x07814;&#x07a76;&#x07684;&#x06027;&#x08d28;&#x0ff0c;74.7%&#x07406;&#x089e3;&#x053c2;&#x04e0e;&#x07684;&#x081ea;&#x0613f;&#x06027;&#x08d28;&#x0ff0c;74.0%&#x07406;&#x089e3;&#x06f5c;&#x05728;&#x06536;&#x076ca;&#x0ff0c;69.6%&#x07406;&#x089e3;&#x07814;&#x07a76;&#x076ee;&#x07684;&#x0ff0c;67.0%&#x07406;&#x089e3;&#x06f5c;&#x05728;&#x07684;&#x098ce;&#x09669;&#x0548c;&#x0526f;&#x04f5c;&#x07528;&#x0ff0c;66.2%&#x07406;&#x089e3;&#x04fdd;&#x05bc6;&#x06027;&#x0ff0c;64.1%&#x07406;&#x089e3;&#x09000;&#x051fa;&#x060c5;&#x051b5;&#x04e0b;&#x066ff;&#x04ee3;&#x06cbb;&#x07597;&#x07684;&#x063d0;&#x04f9b;&#x0ff0c;62.9%&#x077e5;&#x09053;&#x06cbb;&#x07597;&#x06b63;&#x05728;&#x063a5;&#x053d7;&#x06bd4;&#x08f83;&#x0ff0c;53.3%&#x07406;&#x089e3;&#x05b89;&#x06170;&#x05242;&#x0ff0c;52.1%&#x07406;&#x089e3;&#x0968f;&#x0673a;&#x05316;&#x03002;&#x05927;&#x0591a;&#x06570;&#x053c2;&#x04e0e;&#x08005;&#x0ff08;62.4%&#x0ff09;&#x06ca1;&#x06709;&#x06cbb;&#x07597;&#x08bef;&#x0533a;&#x0ff0c;54.9%&#x080fd;&#x0591f;&#x08bf4;&#x051fa;&#x081f3;&#x05c11;&#x04e00;&#x04e2a;&#x098ce;&#x09669;&#x03002;&#x05b50;&#x07fa4;&#x0548c;meta&#x056de;&#x05f52;&#x05206;&#x06790;&#x08bc6;&#x0522b;&#x051fa;&#x05e74;&#x09f84;&#x03001;&#x06559;&#x080b2;&#x06c34;&#x05e73;&#x03001;&#x091cd;&#x08981;&#x075be;&#x075c5;&#x03001;&#x07814;&#x07a76;&#x05206;&#x0671f;&#x0548c;&#x04f4d;&#x07f6e;&#x07b49;&#x05bf9;&#x07406;&#x089e3;&#x04ea7;&#x0751f;&#x0663e;&#x08457;&#x05f71;&#x054cd;&#x07684;&#x0534f;&#x053d8;&#x091cf;&#x0ff0c;&#x05e76;&#x06307;&#x0660e;30&#x0591a;&#x05e74;&#x06765;&#x053c2;&#x04e0e;&#x08005;&#x07406;&#x089e3;&#x077e5;&#x060c5;&#x0540c;&#x0610f;&#x07684;&#x06bd4;&#x04f8b;&#x05e76;&#x06ca1;&#x06709;&#x0589e;&#x052a0;&#x03002;</p></sec><sec><title>&#x07ed3;&#x08bba;</title><p>&#x04e34;&#x05e8a;&#x08bd5;&#x09a8c;&#x053c2;&#x04e0e;&#x08005;&#x07406;&#x089e3;&#x077e5;&#x060c5;&#x0540c;&#x0610f;&#x05404;&#x04e2a;&#x07ec4;&#x06210;&#x07684;&#x06bd4;&#x04f8b;&#x04e3a;52.1%&#x05230;75.8%&#x04e0d;&#x07b49;&#x03002;&#x07814;&#x07a76;&#x08005;&#x053ef;&#x04ee5;&#x0505a;&#x066f4;&#x0591a;&#x07684;&#x05de5;&#x04f5c;&#x06765;&#x05e2e;&#x052a9;&#x053c2;&#x04e0e;&#x08005;&#x05b8c;&#x05168;&#x07406;&#x089e3;&#x05404;&#x04e2a;&#x07ec4;&#x06210;&#x090e8;&#x05206;&#x03002;</p></sec></trans-abstract><trans-abstract xml:lang="ru"><title>&#x00420;&#x00435;&#x00437;&#x0044e;&#x0043c;&#x00435;</title><sec><title>&#x00426;&#x00435;&#x0043b;&#x0044c;</title><p>&#x0041e;&#x0043f;&#x00440;&#x00435;&#x00434;&#x00435;&#x0043b;&#x00438;&#x00442;&#x0044c; &#x00434;&#x0043e;&#x0043b;&#x0044e; &#x00443;&#x00447;&#x00430;&#x00441;&#x00442;&#x0043d;&#x00438;&#x0043a;&#x0043e;&#x00432; &#x0043a;&#x0043b;&#x00438;&#x0043d;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x00438;&#x00445; &#x00438;&#x00441;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x00439;, &#x0043a;&#x0043e;&#x00442;&#x0043e;&#x00440;&#x0044b;&#x00435; &#x0043f;&#x0043e;&#x0043d;&#x00438;&#x0043c;&#x00430;&#x0044e;&#x00442; &#x00440;&#x00430;&#x00437;&#x0043b;&#x00438;&#x00447;&#x0043d;&#x0044b;&#x00435; &#x00434;&#x00435;&#x00442;&#x00430;&#x0043b;&#x00438; &#x00438;&#x0043d;&#x00444;&#x0043e;&#x00440;&#x0043c;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x00441;&#x0043e;&#x00433;&#x0043b;&#x00430;&#x00441;&#x00438;&#x0044f;.</p></sec><sec><title>&#x0041c;&#x00435;&#x00442;&#x0043e;&#x00434;&#x0044b;</title><p>&#x00421;&#x0043e;&#x0043e;&#x00442;&#x00432;&#x00435;&#x00442;&#x00441;&#x00442;&#x00432;&#x00443;&#x0044e;&#x00449;&#x00438;&#x00435; &#x00438;&#x00441;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x0044f; &#x00431;&#x0044b;&#x0043b;&#x00438; &#x00432;&#x0044b;&#x0044f;&#x00432;&#x0043b;&#x00435;&#x0043d;&#x0044b; &#x0043f;&#x0043e;&#x00441;&#x00440;&#x00435;&#x00434;&#x00441;&#x00442;&#x00432;&#x0043e;&#x0043c; &#x00441;&#x00438;&#x00441;&#x00442;&#x00435;&#x0043c;&#x00430;&#x00442;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x0043e;&#x00433;&#x0043e; &#x0043e;&#x00431;&#x00437;&#x0043e;&#x00440;&#x00430; PubMed, Scopus &#x00438; Google Scholar, &#x00430; &#x00442;&#x00430;&#x0043a;&#x00436;&#x00435; &#x0043f;&#x00443;&#x00442;&#x00435;&#x0043c; &#x0043f;&#x00440;&#x0043e;&#x00441;&#x0043c;&#x0043e;&#x00442;&#x00440;&#x00430; &#x00432;&#x00440;&#x00443;&#x00447;&#x0043d;&#x00443;&#x0044e; &#x00431;&#x00438;&#x00431;&#x0043b;&#x00438;&#x0043e;&#x00433;&#x00440;&#x00430;&#x00444;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x00438;&#x00445; &#x00441;&#x0043f;&#x00438;&#x00441;&#x0043a;&#x0043e;&#x00432; &#x0043f;&#x00443;&#x00431;&#x0043b;&#x00438;&#x0043a;&#x00430;&#x00446;&#x00438;&#x00439;, &#x00438;&#x00437;&#x00434;&#x00430;&#x0043d;&#x0043d;&#x0044b;&#x00445; &#x00434;&#x0043e; &#x0043e;&#x0043a;&#x00442;&#x0044f;&#x00431;&#x00440;&#x0044f; 2013&#x000a0;&#x00433;. &#x0041c;&#x00435;&#x00442;&#x00430;-&#x00430;&#x0043d;&#x00430;&#x0043b;&#x00438;&#x00437; &#x00440;&#x00435;&#x00437;&#x00443;&#x0043b;&#x0044c;&#x00442;&#x00430;&#x00442;&#x0043e;&#x00432; &#x00438;&#x00441;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x00439; &#x0043f;&#x00440;&#x0043e;&#x00432;&#x0043e;&#x00434;&#x00438;&#x0043b;&#x00441;&#x0044f; &#x00441; &#x0043f;&#x0043e;&#x0043c;&#x0043e;&#x00449;&#x0044c;&#x0044e; &#x0043c;&#x0043e;&#x00434;&#x00435;&#x0043b;&#x00438; &#x00441;&#x0043e; &#x00441;&#x0043b;&#x00443;&#x00447;&#x00430;&#x00439;&#x0043d;&#x0044b;&#x0043c;&#x00438; &#x0044d;&#x00444;&#x00444;&#x00435;&#x0043a;&#x00442;&#x00430;&#x0043c;&#x00438; &#x00434;&#x0043b;&#x0044f; &#x00443;&#x00447;&#x00435;&#x00442;&#x00430; &#x00440;&#x00430;&#x00437;&#x0043d;&#x0043e;&#x00440;&#x0043e;&#x00434;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x00438;.</p></sec><sec><title>&#x00420;&#x00435;&#x00437;&#x00443;&#x0043b;&#x0044c;&#x00442;&#x00430;&#x00442;&#x0044b;</title><p>&#x00410;&#x0043d;&#x00430;&#x0043b;&#x00438;&#x00437; &#x00432;&#x0043a;&#x0043b;&#x0044e;&#x00447;&#x00430;&#x0043b; 103&#x000a0;&#x00438;&#x00441;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x0044f; &#x00441; &#x0043e;&#x00446;&#x00435;&#x0043d;&#x0043a;&#x0043e;&#x00439; 135&#x000a0;&#x00433;&#x00440;&#x00443;&#x0043f;&#x0043f; &#x00443;&#x00447;&#x00430;&#x00441;&#x00442;&#x0043d;&#x00438;&#x0043a;&#x0043e;&#x00432;. &#x0041e;&#x00431;&#x00449;&#x00438;&#x00435; &#x00434;&#x0043e;&#x0043b;&#x00438; &#x00443;&#x00447;&#x00430;&#x00441;&#x00442;&#x0043d;&#x00438;&#x0043a;&#x0043e;&#x00432;, &#x0043a;&#x0043e;&#x00442;&#x0043e;&#x00440;&#x0044b;&#x00435; &#x0043f;&#x0043e;&#x0043d;&#x00438;&#x0043c;&#x00430;&#x0043b;&#x00438; &#x00441;&#x0043b;&#x00435;&#x00434;&#x00443;&#x0044e;&#x00449;&#x00438;&#x00435; &#x0043a;&#x0043e;&#x0043c;&#x0043f;&#x0043e;&#x0043d;&#x00435;&#x0043d;&#x00442;&#x0044b; &#x00438;&#x0043d;&#x00444;&#x0043e;&#x00440;&#x0043c;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x00441;&#x0043e;&#x00433;&#x0043b;&#x00430;&#x00441;&#x00438;&#x0044f;, &#x00441;&#x0043e;&#x00441;&#x00442;&#x00430;&#x00432;&#x0043b;&#x0044f;&#x0043b;&#x00438;: 75,8% &#x02014; &#x0043e; &#x0043f;&#x00440;&#x00430;&#x00432;&#x00435; &#x0043f;&#x00440;&#x00435;&#x0043a;&#x00440;&#x00430;&#x00442;&#x00438;&#x00442;&#x0044c; &#x00443;&#x00447;&#x00430;&#x00441;&#x00442;&#x00438;&#x00435; &#x00432; &#x00438;&#x00441;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x00438; &#x00432; &#x0043b;&#x0044e;&#x00431;&#x0043e;&#x00435; &#x00432;&#x00440;&#x00435;&#x0043c;&#x0044f;, 74,7%&#x000a0;&#x02014; &#x0043e; &#x0043f;&#x00440;&#x00438;&#x00440;&#x0043e;&#x00434;&#x00435; &#x00438;&#x00441;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x0044f;, 74,7%&#x000a0;&#x02014; &#x0043e; &#x00434;&#x0043e;&#x00431;&#x00440;&#x0043e;&#x00432;&#x0043e;&#x0043b;&#x0044c;&#x0043d;&#x0043e;&#x0043c; &#x00443;&#x00447;&#x00430;&#x00441;&#x00442;&#x00438;&#x00438;, 74,0%&#x000a0;&#x02014; &#x0043e; &#x0043f;&#x0043e;&#x00442;&#x00435;&#x0043d;&#x00446;&#x00438;&#x00430;&#x0043b;&#x0044c;&#x0043d;&#x0043e;&#x00439; &#x0043f;&#x0043e;&#x0043b;&#x0044c;&#x00437;&#x00435;, 69,6&#x000a0;&#x02014; &#x0043e; &#x00446;&#x00435;&#x0043b;&#x0044f;&#x00445; &#x00438;&#x00441;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x0044f;, 67,0%&#x000a0;&#x02014; &#x0043e; &#x0043f;&#x0043e;&#x00442;&#x00435;&#x0043d;&#x00446;&#x00438;&#x00430;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x00445; &#x00440;&#x00438;&#x00441;&#x0043a;&#x00430;&#x00445; &#x00438; &#x0043d;&#x00435;&#x00436;&#x00435;&#x0043b;&#x00430;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x00445; &#x0044f;&#x00432;&#x0043b;&#x00435;&#x0043d;&#x00438;&#x0044f;&#x00445;, 66,2%&#x000a0;&#x02014; &#x0043e; &#x0043a;&#x0043e;&#x0043d;&#x00444;&#x00438;&#x00434;&#x00435;&#x0043d;&#x00446;&#x00438;&#x00430;&#x0043b;&#x0044c;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x00438;, 64,1%&#x000a0;&#x02014; &#x0043e; &#x0043d;&#x00430;&#x0043b;&#x00438;&#x00447;&#x00438;&#x00438; &#x00430;&#x0043b;&#x0044c;&#x00442;&#x00435;&#x00440;&#x0043d;&#x00430;&#x00442;&#x00438;&#x00432;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x0043b;&#x00435;&#x00447;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x0043f;&#x00440;&#x00438; &#x00432;&#x0044b;&#x00445;&#x0043e;&#x00434;&#x00435; &#x00438;&#x00437; &#x00438;&#x00441;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x0044f;, 62,9%&#x000a0;&#x02014; &#x0043e; &#x00437;&#x0043d;&#x00430;&#x0043d;&#x00438;&#x00438; &#x00441;&#x00440;&#x00430;&#x00432;&#x0043d;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00442;&#x00435;&#x00440;&#x00430;&#x0043f;&#x00438;&#x00439;, 53,3%&#x000a0;&#x02014; &#x0043e; &#x0043f;&#x0043b;&#x00430;&#x00446;&#x00435;&#x00431;&#x0043e; &#x00438; 52,1%&#x000a0;&#x02014; &#x0043e; &#x00440;&#x00430;&#x0043d;&#x00434;&#x0043e;&#x0043c;&#x00438;&#x00437;&#x00430;&#x00446;&#x00438;&#x00438;. &#x00411;&#x0043e;&#x0043b;&#x0044c;&#x00448;&#x00438;&#x0043d;&#x00441;&#x00442;&#x00432;&#x0043e; &#x00443;&#x00447;&#x00430;&#x00441;&#x00442;&#x0043d;&#x00438;&#x0043a;&#x0043e;&#x00432;, &#x00430; &#x00438;&#x0043c;&#x00435;&#x0043d;&#x0043d;&#x0043e; 62,4%, &#x00438;&#x0043c;&#x00435;&#x0043b;&#x00438; &#x0043f;&#x00440;&#x00430;&#x00432;&#x00438;&#x0043b;&#x0044c;&#x0043d;&#x0043e;&#x00435; &#x0043f;&#x00440;&#x00435;&#x00434;&#x00441;&#x00442;&#x00430;&#x00432;&#x0043b;&#x00435;&#x0043d;&#x00438;&#x00435; &#x0043e; &#x00442;&#x00435;&#x00440;&#x00430;&#x0043f;&#x00438;&#x00438; &#x00438; 54,9% &#x0043c;&#x0043e;&#x00433;&#x0043b;&#x00438; &#x0043d;&#x00430;&#x00437;&#x00432;&#x00430;&#x00442;&#x0044c; &#x0043f;&#x0043e; &#x0043c;&#x00435;&#x0043d;&#x0044c;&#x00448;&#x00435;&#x00439; &#x0043c;&#x00435;&#x00440;&#x00435; &#x0043e;&#x00434;&#x00438;&#x0043d; &#x00440;&#x00438;&#x00441;&#x0043a;. &#x00421;&#x000a0;&#x0043f;&#x0043e;&#x0043c;&#x0043e;&#x00449;&#x0044c;&#x0044e; &#x00430;&#x0043d;&#x00430;&#x0043b;&#x00438;&#x00437;&#x00430; &#x00434;&#x00430;&#x0043d;&#x0043d;&#x0044b;&#x00445; &#x00432; &#x0043f;&#x0043e;&#x00434;&#x00433;&#x00440;&#x00443;&#x0043f;&#x0043f;&#x00430;&#x00445; &#x00438; &#x0043c;&#x00435;&#x00442;&#x00430;-&#x00440;&#x00435;&#x00433;&#x00440;&#x00435;&#x00441;&#x00441;&#x00438;&#x0043e;&#x0043d;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x00430;&#x0043d;&#x00430;&#x0043b;&#x00438;&#x00437;&#x00430; &#x00431;&#x0044b;&#x0043b;&#x00438; &#x0043e;&#x0043f;&#x00440;&#x00435;&#x00434;&#x00435;&#x0043b;&#x00435;&#x0043d;&#x0044b; &#x0043d;&#x00435;&#x00437;&#x00430;&#x00432;&#x00438;&#x00441;&#x00438;&#x0043c;&#x0044b;&#x00435; &#x0043f;&#x00435;&#x00440;&#x00435;&#x0043c;&#x00435;&#x0043d;&#x0043d;&#x0044b;&#x00435;, &#x00442;&#x00430;&#x0043a;&#x00438;&#x00435; &#x0043a;&#x00430;&#x0043a; &#x00432;&#x0043e;&#x00437;&#x00440;&#x00430;&#x00441;&#x00442;, &#x00443;&#x00440;&#x0043e;&#x00432;&#x00435;&#x0043d;&#x0044c; &#x0043e;&#x00431;&#x00440;&#x00430;&#x00437;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x0044f;, &#x0043a;&#x00440;&#x00438;&#x00442;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x0043e;&#x00435; &#x00437;&#x00430;&#x00431;&#x0043e;&#x0043b;&#x00435;&#x00432;&#x00430;&#x0043d;&#x00438;&#x00435;, &#x0043c;&#x00435;&#x00441;&#x00442;&#x0043e; &#x0043f;&#x00440;&#x0043e;&#x00432;&#x00435;&#x00434;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00438; &#x00444;&#x00430;&#x00437;&#x00430; &#x00438;&#x00441;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x0044f;, &#x0043a;&#x0043e;&#x00442;&#x0043e;&#x00440;&#x0044b;&#x00435; &#x0043e;&#x0043a;&#x00430;&#x00437;&#x0044b;&#x00432;&#x00430;&#x0043b;&#x00438; &#x00437;&#x0043d;&#x00430;&#x00447;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0043e;&#x00435; &#x00432;&#x0043b;&#x00438;&#x0044f;&#x0043d;&#x00438;&#x00435; &#x0043d;&#x00430; &#x0043f;&#x0043e;&#x0043d;&#x00438;&#x0043c;&#x00430;&#x0043d;&#x00438;&#x00435; &#x00438; &#x00443;&#x0043a;&#x00430;&#x00437;&#x0044b;&#x00432;&#x00430;&#x0043b;&#x00438; &#x0043d;&#x00430; &#x00442;&#x0043e;, &#x00447;&#x00442;&#x0043e; &#x00434;&#x0043e;&#x0043b;&#x0044f; &#x00443;&#x00447;&#x00430;&#x00441;&#x00442;&#x0043d;&#x00438;&#x0043a;&#x0043e;&#x00432;, &#x0043f;&#x0043e;&#x0043d;&#x00438;&#x0043c;&#x00430;&#x0044e;&#x00449;&#x00438;&#x00445; &#x00438;&#x0043d;&#x00444;&#x0043e;&#x00440;&#x0043c;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x0043d;&#x0043e;&#x00435; &#x00441;&#x0043e;&#x00433;&#x0043b;&#x00430;&#x00441;&#x00438;&#x00435;, &#x0043d;&#x00435; &#x00443;&#x00432;&#x00435;&#x0043b;&#x00438;&#x00447;&#x00438;&#x0043b;&#x00430;&#x00441;&#x0044c; &#x00437;&#x00430; 30&#x000a0;&#x0043b;&#x00435;&#x00442;.</p></sec><sec><title>&#x00412;&#x0044b;&#x00432;&#x0043e;&#x00434;</title><p>&#x00414;&#x0043e;&#x0043b;&#x0044f; &#x00443;&#x00447;&#x00430;&#x00441;&#x00442;&#x0043d;&#x00438;&#x0043a;&#x0043e;&#x00432; &#x0043a;&#x0043b;&#x00438;&#x0043d;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x00438;&#x00445; &#x00438;&#x00441;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x00439;, &#x0043a;&#x0043e;&#x00442;&#x0043e;&#x00440;&#x0044b;&#x00435; &#x0043f;&#x0043e;&#x0043d;&#x00438;&#x0043c;&#x00430;&#x0043b;&#x00438; &#x00440;&#x00430;&#x00437;&#x0043b;&#x00438;&#x00447;&#x0043d;&#x0044b;&#x00435; &#x0043a;&#x0043e;&#x0043c;&#x0043f;&#x0043e;&#x0043d;&#x00435;&#x0043d;&#x00442;&#x0044b; &#x00438;&#x0043d;&#x00444;&#x0043e;&#x00440;&#x0043c;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x00441;&#x0043e;&#x00433;&#x0043b;&#x00430;&#x00441;&#x00438;&#x0044f;, &#x00432;&#x00430;&#x00440;&#x0044c;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043b;&#x00430;&#x00441;&#x0044c; &#x00432; &#x00434;&#x00438;&#x00430;&#x0043f;&#x00430;&#x00437;&#x0043e;&#x0043d;&#x00435; &#x0043e;&#x00442; 52,1% &#x00434;&#x0043e; 75,8%. &#x00418;&#x00441;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x00442;&#x00435;&#x0043b;&#x00438; &#x0043c;&#x0043e;&#x00433;&#x0043b;&#x00438; &#x00431;&#x0044b; &#x0043f;&#x00440;&#x00435;&#x00434;&#x0043f;&#x00440;&#x00438;&#x0043d;&#x0044f;&#x00442;&#x0044c; &#x00434;&#x0043e;&#x0043f;&#x0043e;&#x0043b;&#x0043d;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x00435; &#x0043c;&#x00435;&#x00440;&#x0044b;, &#x00447;&#x00442;&#x0043e;&#x00431;&#x0044b; &#x00443;&#x00447;&#x00430;&#x00441;&#x00442;&#x0043d;&#x00438;&#x0043a;&#x00438; &#x00438;&#x00441;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x00439; &#x00432; &#x00431;&#x0043e;&#x0043b;&#x00435;&#x00435; &#x0043f;&#x0043e;&#x0043b;&#x0043d;&#x0043e;&#x00439; &#x0043c;&#x00435;&#x00440;&#x00435; &#x0043f;&#x0043e;&#x0043d;&#x0044f;&#x0043b;&#x00438; &#x00441;&#x00443;&#x00442;&#x0044c; &#x00438;&#x0043d;&#x00444;&#x0043e;&#x00440;&#x0043c;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x00441;&#x0043e;&#x00433;&#x0043b;&#x00430;&#x00441;&#x00438;&#x0044f;.</p></sec></trans-abstract></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Informed consent has its roots in the 1947 Nuremberg Code and the 1964 Declaration of Helsinki and is now a guiding principle for conduct in medical research.<xref rid="R1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="R2" ref-type="bibr"><sup>2</sup></xref> Within its ethical and legal foundations,<xref rid="R3" ref-type="bibr"><sup>3</sup></xref> informed consent has two specific goals in clinical research: (i)&#x000a0;to respect and promote a participant&#x02019;s autonomy; and (ii)&#x000a0;to protect participants from harm.<xref rid="R4" ref-type="bibr"><sup>4</sup></xref><sup>,</sup><xref rid="R5" ref-type="bibr"><sup>5</sup></xref> Obtaining written informed consent from participants before enrolment in a study is an internationally accepted standard.<xref rid="R6" ref-type="bibr"><sup>6</sup></xref><sup>&#x02013;</sup><xref rid="R10" ref-type="bibr"><sup>10</sup></xref></p><p>Five concepts must be considered in establishing informed consent: voluntariness, capacity, disclosure, understanding and decision.<xref rid="R11" ref-type="bibr"><sup>11</sup></xref><sup>,</sup><xref rid="R12" ref-type="bibr"><sup>12</sup></xref> Voluntariness means that an individual&#x02019;s decision to participate is made without coercion or persuasion. Capacity relates to an individual&#x02019;s ability to make decisions that stems from his or her ability to understand the information provided. Disclosure involves giving research participants all relevant information about the research, including its nature, purpose, risks and potential benefits as well as the alternatives available.<xref rid="R13" ref-type="bibr"><sup>13</sup></xref> Understanding implies that research participants are able to comprehend the information provided and appreciate its relevance to their personal situations. Decision is that made to participate, or not.<xref rid="R11" ref-type="bibr"><sup>11</sup></xref><sup>,</sup><xref rid="R12" ref-type="bibr"><sup>12</sup></xref></p><p>The quality of informed consent in clinical research is determined by the extent to which participants understand the process of informed consent.<xref rid="R14" ref-type="bibr"><sup>14</sup></xref> Understanding plays a pivotal role in clinical research because it directly affects how ethical principles are applied in practice.<xref rid="R15" ref-type="bibr"><sup>15</sup></xref><sup>&#x02013;</sup><xref rid="R17" ref-type="bibr"><sup>17</sup></xref> Although the literature on informed consent began to accumulate in the 1980s, little is known about how patients&#x02019; understanding has evolved as no meta-analysis has been previously performed. A systematic review considering literature up to 2006 found that only around 50% of participants understood all components of informed consent in surgical and clinical trials.<xref rid="R18" ref-type="bibr"><sup>18</sup></xref> Another systemic review, which included data up to 2010, compared only the quality of informed consent in developing and developed countries.<xref rid="R19" ref-type="bibr"><sup>19</sup></xref> The objective of this study was, therefore, to investigate the quality of informed consent in clinical trials in recent decades by performing a systematic review and meta-analysis of the data available.</p></sec><sec sec-type="methods"><title>Methods</title><p>We conducted a literature search of PubMed and Scopus using the following terms: &#x0201c;informed consent[mh] AND (comprehension[mh] OR decision making[mh] OR knowledge[mh] OR perception[mh] OR communication[mh] OR understanding) AND (randomized controlled trials as topic[mh] OR clinical trial as topic[mh])&#x0201d;. In addition, in a simple search of Scopus, we used: &#x0201c;allintitle: understanding OR comprehension OR knowledge OR decision OR perception OR communication &#x0201c;informed consent&#x0201d;.&#x0201d; In Google Scholar, we used the keywords &#x0201c;informed consent&#x0201d; as the exact phrase and &#x0201c;understanding, comprehension, knowledge, decision, perception, communication&#x0201d; with the option with at least one of the words and selected &#x0201c;where my words occur in the title of the article&#x0201d;. The search strategy was developed as previously described.<xref rid="R20" ref-type="bibr"><sup>20</sup></xref> The searches covered all data entered up to October 2013. In addition, we analysed the reference lists of relevant articles. All studies identified were reviewed independently for eligibility by two of five authors and conflicts were resolved by seeking a consensus with other authors.</p><p>A study was eligible for inclusion if it assessed the participant&#x02019;s or the participant&#x02019;s guardian&#x02019;s understanding of informed consent<xref rid="R1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="R2" ref-type="bibr"><sup>2</sup></xref> and at least one of the following components of the informed consent process:<xref rid="R8" ref-type="bibr"><sup>8</sup></xref><sup>,</sup><xref rid="R21" ref-type="bibr"><sup>21</sup></xref> therapeutic misconception (i.e. lack of awareness of the uncertainty of success); ability to name at least one risk; knowing that treatments were being compared; or understanding of: (i)&#x000a0;the nature of the study (i.e. awareness of participating in research); (ii)&#x000a0;the purpose of the study; (iii)&#x000a0;the risks and side-effects; (iv)&#x000a0;the direct benefits; (v)&#x000a0;placebo; (vi)&#x000a0;randomization; (vii)&#x000a0;the voluntary nature of participation; (viii)&#x000a0;freedom to withdraw from the study at any time; (ix)&#x000a0;the availability of alternative treatment if withdrawn from a trial; or (x)&#x000a0;confidentiality (i.e. personal information will not be revealed). There was no restriction by language, age (i.e. children or adults) or study design. French and Japanese articles were translated into English by authors with a good command of these languages. We excluded articles on studies that: (i)&#x000a0;compared or evaluated methods of informed consent; (ii)&#x000a0;used an intervention to improve participants&#x02019; knowledge of informed consent; (iii)&#x000a0;involved animals or included only healthy volunteers (e.g. simulated studies); (iv)&#x000a0;involved patients with cognitive deficits; (v)&#x000a0;were published as posters, in conference proceedings or as a thesis; or (vi)&#x000a0;were not clinical trials. Our study protocol was registered with the international prospective register of systematic reviews (PROSPERO) with the identifier CRD42013005526. The study selection process, which was carried out in accordance with MOOSE guidelines for meta-analyses and systematic reviews of observational studies, is shown in <xref ref-type="fig" rid="F1">Fig.&#x000a0;1</xref>.<xref rid="R22" ref-type="bibr"><sup>22</sup></xref></p><fig id="F1" fig-type="figure" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Flow diagram for the selection of studies on participants&#x02019; understanding of informed consent in clinical trials</p></caption><graphic xlink:href="BLT.14.141390-F1"/></fig><sec><title>Quality of evaluation</title><p>The quality of the informed consent evaluation was assessed independently by two authors using seven metrics: (i)&#x000a0;the description of participants; (ii)&#x000a0;whether or not interviewers were members of the original trial&#x02019;s staff; (iii)&#x000a0;the description of the evaluation method (i.e. by questionnaire or interview); (iv)&#x000a0;the description of the questionnaire; (v)&#x000a0;the selection of participants (i.e. consecutive participants or a random or cross-sectional selection); (vi)&#x000a0;the description of exclusion criteria; and (vii)&#x000a0;the timing of the evaluations. Quality scores for the studies included are shown in Appendix&#x000a0;A (available at: <ext-link ext-link-type="uri" xlink:href="https://www.researchgate.net/publication/270506278_Online_Only_Supplements_for_Three_decades_of_participants_understanding_of_informed_consent_in_clinical_trials_a_systematic_review_and_meta-analysis">https://www.researchgate.net/publication/270506278_Online_Only_Supplements_for_Three_decades_of_participants_understanding_of_informed_consent_in_clinical_trials_a_systematic_review_and_meta-analysis</ext-link>).</p></sec><sec><title>Study data</title><p>Data were extracted for each study on: (i)&#x000a0;the year of publication; (ii)&#x000a0;the study language and the country where the study was conducted; (iii)&#x000a0;the phase of the study; (iv)&#x000a0;the baseline characteristics of the study population, including the source of the population, the number of participants and their age, sex and educational level; (v)&#x000a0;the medical specialty of the clinical research, including the seriousness of the disease studied; (vi)&#x000a0;the method and timing of the informed consent evaluation; (vii)&#x000a0;the type of questions participants had to answer; and (viii)&#x000a0;the components of informed consent assessed, including understanding of the nature and purpose of the study, knowing that treatments were being compared, therapeutic misconceptions, participants&#x02019; ability to name risks, awareness of potential risks and side-effects and understanding of potential benefits, randomization, placebo, the voluntary nature of participation, freedom to withdraw at any time, confidentiality and the availability of alternative treatment.</p></sec><sec><title>Statistical analysis and data synthesis</title><p>If a study investigated more than one population, a data set was created for each population. The proportion of participants who understood the different components of informed consent was pooled across studies using Comprehensive Meta-Analysis software version 2.0 (Biostat, Englewood, United States of America) and was expressed as a percentage with 95% confidence intervals (CIs). The heterogeneity of study findings was evaluated using the <italic>Q</italic> statistic and the <italic>I</italic><sup>2</sup> test and was considered significant if the <italic>P</italic>-value was &#x0003c;&#x02009;0.10. Since studies gave heterogeneous results for all components, the proportion of participants who understood each component was pooled using a random-effects model that included weighting for each study. In examining the effect of covariates on these proportions, we used a subgroup or meta-regression analysis when eight or more studies assessed a particular covariate. Differences between subgroups and trends were considered significant if the <italic>P</italic>-value of Cochran&#x02019;s <italic>Q</italic> test was &#x0003c;&#x02009;0.05.<xref rid="R23" ref-type="bibr"><sup>23</sup></xref> To determine if publication bias was present, we used Begg&#x02019;s funnel plot and Egger&#x02019;s regression test: a <italic>P</italic>-value &#x0003c;&#x02009;0.10 indicated significant publication bias.<xref rid="R24" ref-type="bibr"><sup>24</sup></xref> When publication bias was present, we used Duvall and Tweedie&#x02019;s trim-and-fill method to enhance symmetry by adjusting for studies that appeared to be missing.<xref rid="R25" ref-type="bibr"><sup>25</sup></xref><sup>&#x02013;</sup><xref rid="R27" ref-type="bibr"><sup>27</sup></xref> The final proportion of participants who understood each component was computed after adjustment for missing studies.</p></sec></sec><sec sec-type="results"><title>Results</title><p>The final analysis included 103 studies: 85 from the database search and 18 from reviewing reference lists.<xref rid="R28" ref-type="bibr"><sup>28</sup></xref><sup>&#x02013;</sup><xref rid="R130" ref-type="bibr"><sup>130</sup></xref> Ultimately 135 data sets were included because some studies evaluated more than one population (Appendix&#x000a0;A). The sample size ranged from 8 to 1789 participants and the response rate to interview questions ranged from 9.3% to 100%. Participants were adults in 95 data sets, parents or guardians in 34, adult and child patients in three, child patients in two and adult patients or parents in one. Overall, 79% (106) of data sets were conducted in middle- or high-income countries &#x02013; as classified by the World Bank<xref rid="R131" ref-type="bibr"><sup>131</sup></xref> &#x02013; and 67% (90) did not report the phase of the clinical trial. The medical specialty was cancer in 33% (44) of data sets, infectious disease in 14% (19), vaccines in 10%, (13) cardiovascular disease in 7% (9), neurology in 6% (8) and other in 31% (42). Moreover, 98% (132) were published in English and only 1% each in Japanese (1) and French (2). Details of the studies and data sets are presented in <xref ref-type="table" rid="T1">Table&#x000a0;1</xref> (available at: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/bulletin/volumes/93/3/14-141390">http://www.who.int/bulletin/volumes/93/3/14-141390</ext-link>).</p><table-wrap id="T1" specific-use="online" orientation="portrait" position="float"><label>Table 1</label><caption><title>Studies and data sets in the meta-analysis of participants&#x02019; understanding of informed consent in clinical trials</title></caption><table frame="hsides" rules="groups"><col width="97" span="1"/><col width="37" span="1"/><col width="110" span="1"/><col width="65" span="1"/><col width="37" span="1"/><col width="68" span="1"/><col width="101" span="1"/><col width="46" span="1"/><col width="71" span="1"/><col width="88" span="1"/><col width="129" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Study</th><th rowspan="2" valign="top" align="center" scope="col" colspan="1">Year</th><th rowspan="2" valign="top" align="center" scope="col" colspan="1">Country (data set, if applicable)</th><th colspan="3" valign="top" align="center" scope="colgroup" rowspan="1">Participants<hr/></th><th rowspan="2" valign="top" align="center" scope="col" colspan="1">Subject</th><th rowspan="2" valign="top" align="center" scope="col" colspan="1">Phase of trial</th><th rowspan="2" valign="top" align="center" scope="col" colspan="1">Involved patients with critical conditions</th><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1">Evaluation of understanding of informed consent<hr/></th></tr><tr><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">Type</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">No.</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Age,<sup>a</sup> years</th><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">Method</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Timing</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ellis<xref rid="R28" ref-type="bibr"><sup>28</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2010</td><td valign="top" align="left" rowspan="1" colspan="1">USA</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">171</td><td valign="top" align="left" rowspan="1" colspan="1">30 (18&#x02013;50)</td><td valign="top" align="left" rowspan="1" colspan="1">Malaria vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">After ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ellis<xref rid="R28" ref-type="bibr"><sup>28</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2010</td><td valign="top" align="left" rowspan="1" colspan="1">Mali</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">89</td><td valign="top" align="left" rowspan="1" colspan="1">27 (18&#x02013;50)</td><td valign="top" align="left" rowspan="1" colspan="1">Malaria vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">After ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ellis<xref rid="R28" ref-type="bibr"><sup>28</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2010</td><td valign="top" align="left" rowspan="1" colspan="1">Mali</td><td valign="top" align="left" rowspan="1" colspan="1">Parents or guardians</td><td valign="top" align="left" rowspan="1" colspan="1">700</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Malaria vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">After ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Vallely<xref rid="R29" ref-type="bibr"><sup>29</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2010</td><td valign="top" align="left" rowspan="1" colspan="1">United Republic of Tanzania</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">99</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Infectious disease</td><td valign="top" align="left" rowspan="1" colspan="1">III</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Interviews</td><td valign="top" align="left" rowspan="1" colspan="1">4&#x000a0;weeks after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Hill<xref rid="R30" ref-type="bibr"><sup>30</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2008</td><td valign="top" align="left" rowspan="1" colspan="1">Ghana</td><td valign="top" align="left" rowspan="1" colspan="1">Adult and child patients</td><td valign="top" align="left" rowspan="1" colspan="1">1245</td><td valign="top" align="left" rowspan="1" colspan="1">15&#x02013;45 (68% were under 35)</td><td valign="top" align="left" rowspan="1" colspan="1">Vitamin A supplementation</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Semi-structured interviews</td><td valign="top" align="left" rowspan="1" colspan="1">After ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Minnies<xref rid="R31" ref-type="bibr"><sup>31</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2008</td><td valign="top" align="left" rowspan="1" colspan="1">South Africa</td><td valign="top" align="left" rowspan="1" colspan="1">Parents or guardians</td><td valign="top" align="left" rowspan="1" colspan="1">192</td><td valign="top" align="left" rowspan="1" colspan="1">26 (16&#x02013;44)</td><td valign="top" align="left" rowspan="1" colspan="1">Infectious disease</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire with staff assistance</td><td valign="top" align="left" rowspan="1" colspan="1">Within 1&#x000a0;hour of ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Kaewpoonsri<xref rid="R32" ref-type="bibr"><sup>32</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2006</td><td valign="top" align="left" rowspan="1" colspan="1">Thailand</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">81</td><td valign="top" align="left" rowspan="1" colspan="1">32 (18&#x02013;58)</td><td valign="top" align="left" rowspan="1" colspan="1">Infectious disease</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Semi-structured questionnaire and non-participant observation</td><td valign="top" align="left" rowspan="1" colspan="1">At third follow-up visit</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Krosin<xref rid="R33" ref-type="bibr"><sup>33</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2006</td><td valign="top" align="left" rowspan="1" colspan="1">Mali (rural population)</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">78</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Malaria vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">Within 48&#x000a0;hours of consent</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Krosin<xref rid="R33" ref-type="bibr"><sup>33</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2006</td><td valign="top" align="left" rowspan="1" colspan="1">Mali (urban population)</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">85</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Malaria vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">Within 48&#x000a0;hours of consent</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Moodley<xref rid="R34" ref-type="bibr"><sup>34</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2005</td><td valign="top" align="left" rowspan="1" colspan="1">South Africa</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">334</td><td valign="top" align="left" rowspan="1" colspan="1">68 (60&#x02013;80)</td><td valign="top" align="left" rowspan="1" colspan="1">Influenza vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Interviews</td><td valign="top" align="left" rowspan="1" colspan="1">4&#x02013;12 months after the trial</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Pace<xref rid="R35" ref-type="bibr"><sup>35</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2005</td><td valign="top" align="left" rowspan="1" colspan="1">Thailand</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">141</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003e;&#x02009;18</td><td valign="top" align="left" rowspan="1" colspan="1">Infectious disease</td><td valign="top" align="left" rowspan="1" colspan="1">III</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Interviews</td><td valign="top" align="left" rowspan="1" colspan="1">Immediately after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Pace<xref rid="R36" ref-type="bibr"><sup>36</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2005</td><td valign="top" align="left" rowspan="1" colspan="1">Uganda</td><td valign="top" align="left" rowspan="1" colspan="1">Parents or guardians</td><td valign="top" align="left" rowspan="1" colspan="1">347</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Infectious disease</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Interviews</td><td valign="top" align="left" rowspan="1" colspan="1">Immediately after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ekouevi<xref rid="R37" ref-type="bibr"><sup>37</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2004</td><td valign="top" align="left" rowspan="1" colspan="1">C&#x000f4;te d'Ivoire</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">55</td><td valign="top" align="left" rowspan="1" colspan="1">26</td><td valign="top" align="left" rowspan="1" colspan="1">Infectious disease</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Interviews</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Joubert<xref rid="R38" ref-type="bibr"><sup>38</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2003</td><td valign="top" align="left" rowspan="1" colspan="1">South Africa</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">92</td><td valign="top" align="left" rowspan="1" colspan="1">27</td><td valign="top" align="left" rowspan="1" colspan="1">Vitamin A supplementation</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Interviews</td><td valign="top" align="left" rowspan="1" colspan="1">Median of 14&#x000a0;months after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Lyn&#x000f6;e<xref rid="R39" ref-type="bibr"><sup>39</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2001</td><td valign="top" align="left" rowspan="1" colspan="1">Bangladesh</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">105</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Iron supplementation</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Structured questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">After ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Lyn&#x000f6;e<xref rid="R40" ref-type="bibr"><sup>40</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2004</td><td valign="top" align="left" rowspan="1" colspan="1">Sweden</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">44</td><td valign="top" align="left" rowspan="1" colspan="1">67.8 (39&#x02013;82)</td><td valign="top" align="left" rowspan="1" colspan="1">Lipid-lowering treatment</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">1&#x000a0;week after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Lyn&#x000f6;e<xref rid="R41" ref-type="bibr"><sup>41</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">1991</td><td valign="top" align="left" rowspan="1" colspan="1">Sweden</td><td valign="top" align="left" rowspan="1" colspan="1">Adult and child patients</td><td valign="top" align="left" rowspan="1" colspan="1">43</td><td valign="top" align="left" rowspan="1" colspan="1">23 (16&#x02013;35)</td><td valign="top" align="left" rowspan="1" colspan="1">Gynaecology</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire by mail</td><td valign="top" align="left" rowspan="1" colspan="1">18&#x000a0;months after the trial</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Lyn&#x000f6;e<xref rid="R42" ref-type="bibr"><sup>42</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2004</td><td valign="top" align="left" rowspan="1" colspan="1">Sweden</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">40</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Oncology</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Lyn&#x000f6;e<xref rid="R43" ref-type="bibr"><sup>43</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2001</td><td valign="top" align="left" rowspan="1" colspan="1">Sweden</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">26</td><td valign="top" align="left" rowspan="1" colspan="1">33 (21&#x02013;50)</td><td valign="top" align="left" rowspan="1" colspan="1">Auricular acupuncture</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">4&#x000a0;weeks after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Lyn&#x000f6;e<xref rid="R43" ref-type="bibr"><sup>43</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2001</td><td valign="top" align="left" rowspan="1" colspan="1">Sweden</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1">38 (26&#x02013;45)</td><td valign="top" align="left" rowspan="1" colspan="1">Auricular acupuncture</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">4&#x000a0;weeks after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Leach<xref rid="R44" ref-type="bibr"><sup>44</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">1999</td><td valign="top" align="left" rowspan="1" colspan="1">Gambia (rural population)</td><td valign="top" align="left" rowspan="1" colspan="1">Parents or guardians</td><td valign="top" align="left" rowspan="1" colspan="1">73</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>Haemophilus influenza</italic> type B vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Interviews</td><td valign="top" align="left" rowspan="1" colspan="1">Within 1&#x000a0;week of ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Leach<xref rid="R44" ref-type="bibr"><sup>44</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">1999</td><td valign="top" align="left" rowspan="1" colspan="1">Gambia (urban population)</td><td valign="top" align="left" rowspan="1" colspan="1">Parents or guardians</td><td valign="top" align="left" rowspan="1" colspan="1">64</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>Haemophilus influenza</italic> type B vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Interviews</td><td valign="top" align="left" rowspan="1" colspan="1">Within 1&#x000a0;week of ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Pitisuttithum<xref rid="R45" ref-type="bibr"><sup>45</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">1997</td><td valign="top" align="left" rowspan="1" colspan="1">Thailand</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">33</td><td valign="top" align="left" rowspan="1" colspan="1">55.3 (43&#x02013;69)</td><td valign="top" align="left" rowspan="1" colspan="1">HIV vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">I, II</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">Prior to ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Bergenmar<xref rid="R46" ref-type="bibr"><sup>46</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2008</td><td valign="top" align="left" rowspan="1" colspan="1">Sweden</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">282</td><td valign="top" align="left" rowspan="1" colspan="1">60 (32&#x02013;82)</td><td valign="top" align="left" rowspan="1" colspan="1">Oncology</td><td valign="top" align="left" rowspan="1" colspan="1">II, III</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">75% within 3&#x000a0;days of ICP, 99% within 2&#x000a0;weeks</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Knifed<xref rid="R47" ref-type="bibr"><sup>47</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2008</td><td valign="top" align="left" rowspan="1" colspan="1">Canada</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">21</td><td valign="top" align="left" rowspan="1" colspan="1">52 (26&#x02013;65)</td><td valign="top" align="left" rowspan="1" colspan="1">Neuro-oncology</td><td valign="top" align="left" rowspan="1" colspan="1">I, II, III</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Face-to-face interviews</td><td valign="top" align="left" rowspan="1" colspan="1">Within 1&#x000a0;month of ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Agrawal<xref rid="R48" ref-type="bibr"><sup>48</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2006</td><td valign="top" align="left" rowspan="1" colspan="1">USA</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">163</td><td valign="top" align="left" rowspan="1" colspan="1">57.7 (IQR: 48&#x02013;68)</td><td valign="top" align="left" rowspan="1" colspan="1">Oncology</td><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Structured interview</td><td valign="top" align="left" rowspan="1" colspan="1">Immediately after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Franck<xref rid="R49" ref-type="bibr"><sup>49</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2007</td><td valign="top" align="left" rowspan="1" colspan="1">United Kingdom</td><td valign="top" align="left" rowspan="1" colspan="1">Parents or guardians</td><td valign="top" align="left" rowspan="1" colspan="1">109</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">25 paediatric trials</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">Immediately after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Gammelgaard<xref rid="R50" ref-type="bibr"><sup>50</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2004</td><td valign="top" align="left" rowspan="1" colspan="1">Denmark (patients participating in trial)</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">103</td><td valign="top" align="left" rowspan="1" colspan="1">60</td><td valign="top" align="left" rowspan="1" colspan="1">Acute myocardial infarction</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Gammelgaard<xref rid="R50" ref-type="bibr"><sup>50</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2004</td><td valign="top" align="left" rowspan="1" colspan="1">Denmark (patients declining participation)</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">78</td><td valign="top" align="left" rowspan="1" colspan="1">61</td><td valign="top" align="left" rowspan="1" colspan="1">Acute myocardial infarction</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Kodish<xref rid="R51" ref-type="bibr"><sup>51</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2004</td><td valign="top" align="left" rowspan="1" colspan="1">USA (participants with nurse present at ICP)</td><td valign="top" align="left" rowspan="1" colspan="1">Parents or guardians</td><td valign="top" align="left" rowspan="1" colspan="1">65</td><td valign="top" align="left" rowspan="1" colspan="1">35 (18&#x02013;51)</td><td valign="top" align="left" rowspan="1" colspan="1">Paediatric oncology</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Interview</td><td valign="top" align="left" rowspan="1" colspan="1">Within 48 hours of ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Kodish<xref rid="R51" ref-type="bibr"><sup>51</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2004</td><td valign="top" align="left" rowspan="1" colspan="1">USA (participants with nurse not present at ICP)</td><td valign="top" align="left" rowspan="1" colspan="1">Parents or guardians</td><td valign="top" align="left" rowspan="1" colspan="1">72</td><td valign="top" align="left" rowspan="1" colspan="1">35 (18&#x02013;51)</td><td valign="top" align="left" rowspan="1" colspan="1">Paediatric oncology</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Interview</td><td valign="top" align="left" rowspan="1" colspan="1">Within 48 hours of ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Criscione<xref rid="R52" ref-type="bibr"><sup>52</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2003</td><td valign="top" align="left" rowspan="1" colspan="1">USA</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">30</td><td valign="top" align="left" rowspan="1" colspan="1">44.9&#x02009;&#x000b1;&#x02009;9.8</td><td valign="top" align="left" rowspan="1" colspan="1">Rheumatology</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">7&#x02013;28&#x000a0;days after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Kupst<xref rid="R53" ref-type="bibr"><sup>53</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2003</td><td valign="top" align="left" rowspan="1" colspan="1">USA</td><td valign="top" align="left" rowspan="1" colspan="1">Parents or guardians</td><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Paediatric oncology</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Structured interview</td><td valign="top" align="left" rowspan="1" colspan="1">1&#x000a0;month after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Pope<xref rid="R54" ref-type="bibr"><sup>54</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2003</td><td valign="top" align="left" rowspan="1" colspan="1">Canada</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">190</td><td valign="top" align="left" rowspan="1" colspan="1">63 (22&#x02013;84)</td><td valign="top" align="left" rowspan="1" colspan="1">Cardiology, ophthalmology and rheumatology</td><td valign="top" align="left" rowspan="1" colspan="1">III</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">2&#x000a0;months to 5&#x000a0;years after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Schats<xref rid="R55" ref-type="bibr"><sup>55</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2003</td><td valign="top" align="left" rowspan="1" colspan="1">Netherlands (patient consented, patients&#x02019; understanding of ICP assessed)</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">37</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Neurology</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">Structured interview</td><td valign="top" align="left" rowspan="1" colspan="1">7&#x02013;31&#x000a0;months after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Schats<xref rid="R55" ref-type="bibr"><sup>55</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2003</td><td valign="top" align="left" rowspan="1" colspan="1">Netherlands (patient consented, relatives&#x02019; understanding of ICP assessed)</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">30</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Neurology</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">Structured interview</td><td valign="top" align="left" rowspan="1" colspan="1">7&#x02013;31&#x000a0;months after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Schats<xref rid="R55" ref-type="bibr"><sup>55</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2003</td><td valign="top" align="left" rowspan="1" colspan="1">Netherlands (relative consented, patients&#x02019; understanding of ICP assessed)</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">17</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Neurology</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">Structured interview</td><td valign="top" align="left" rowspan="1" colspan="1">7&#x02013;31&#x000a0;months after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Schats<xref rid="R55" ref-type="bibr"><sup>55</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2003</td><td valign="top" align="left" rowspan="1" colspan="1">Netherlands (relative consented, relatives&#x02019; understanding of ICP assessed)</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">17</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Neurology</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">Structured interview</td><td valign="top" align="left" rowspan="1" colspan="1">7&#x02013;31&#x000a0;months after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Simon<xref rid="R56" ref-type="bibr"><sup>56</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2003</td><td valign="top" align="left" rowspan="1" colspan="1">USA (ethnic majority)</td><td valign="top" align="left" rowspan="1" colspan="1">Parents or guardians</td><td valign="top" align="left" rowspan="1" colspan="1">60</td><td valign="top" align="left" rowspan="1" colspan="1">36 (19&#x02013;51)</td><td valign="top" align="left" rowspan="1" colspan="1">Paediatric oncology</td><td valign="top" align="left" rowspan="1" colspan="1">III</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Interview</td><td valign="top" align="left" rowspan="1" colspan="1">48&#x000a0;hours after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Simon<xref rid="R56" ref-type="bibr"><sup>56</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2003</td><td valign="top" align="left" rowspan="1" colspan="1">USA (non-English-speaking ethnic minority)</td><td valign="top" align="left" rowspan="1" colspan="1">Parents or guardians</td><td valign="top" align="left" rowspan="1" colspan="1">21</td><td valign="top" align="left" rowspan="1" colspan="1">34 (21&#x02013;46)</td><td valign="top" align="left" rowspan="1" colspan="1">Paediatric oncology</td><td valign="top" align="left" rowspan="1" colspan="1">III</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Interview</td><td valign="top" align="left" rowspan="1" colspan="1">48&#x000a0;hours after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Simon<xref rid="R56" ref-type="bibr"><sup>56</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2003</td><td valign="top" align="left" rowspan="1" colspan="1">USA (English-speaking ethnic minority)</td><td valign="top" align="left" rowspan="1" colspan="1">Parents or guardians</td><td valign="top" align="left" rowspan="1" colspan="1">27</td><td valign="top" align="left" rowspan="1" colspan="1">33 (18&#x02013;45)</td><td valign="top" align="left" rowspan="1" colspan="1">Paediatric oncology</td><td valign="top" align="left" rowspan="1" colspan="1">III</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Interview</td><td valign="top" align="left" rowspan="1" colspan="1">48&#x000a0;hours after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Joffe<xref rid="R57" ref-type="bibr"><sup>57</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2001</td><td valign="top" align="left" rowspan="1" colspan="1">USA</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">207</td><td valign="top" align="left" rowspan="1" colspan="1">55 (57% were aged 45&#x02013;64)</td><td valign="top" align="left" rowspan="1" colspan="1">Oncology</td><td valign="top" align="left" rowspan="1" colspan="1">I, II, III</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire by mail</td><td valign="top" align="left" rowspan="1" colspan="1">3&#x02013;14&#x000a0;days after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Daugherty<xref rid="R58" ref-type="bibr"><sup>58</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">1995</td><td valign="top" align="left" rowspan="1" colspan="1">USA</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">27</td><td valign="top" align="left" rowspan="1" colspan="1">58 (32&#x02013;80)</td><td valign="top" align="left" rowspan="1" colspan="1">Oncology</td><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Structured interview</td><td valign="top" align="left" rowspan="1" colspan="1">Before receiving investigational treatment</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Daugherty<xref rid="R59" ref-type="bibr"><sup>59</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2000</td><td valign="top" align="left" rowspan="1" colspan="1">USA</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">144</td><td valign="top" align="left" rowspan="1" colspan="1">59 (26&#x02013;82)</td><td valign="top" align="left" rowspan="1" colspan="1">Oncology</td><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Structured interview</td><td valign="top" align="left" rowspan="1" colspan="1">Before receiving investigational treatment</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Hietanen<xref rid="R60" ref-type="bibr"><sup>60</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2000</td><td valign="top" align="left" rowspan="1" colspan="1">Finland</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">261</td><td valign="top" align="left" rowspan="1" colspan="1">65 (48&#x02013;87)</td><td valign="top" align="left" rowspan="1" colspan="1">Oncology</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire by mail</td><td valign="top" align="left" rowspan="1" colspan="1">5&#x02013;17&#x000a0;months after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Montgomery<xref rid="R61" ref-type="bibr"><sup>61</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">1998</td><td valign="top" align="left" rowspan="1" colspan="1">United Kingdom</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">158</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Anaesthesia</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire by mail</td><td valign="top" align="left" rowspan="1" colspan="1">6&#x02013;24&#x000a0;months after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">van Stuijvenberg<xref rid="R62" ref-type="bibr"><sup>62</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">1998</td><td valign="top" align="left" rowspan="1" colspan="1">Netherlands</td><td valign="top" align="left" rowspan="1" colspan="1">Parents or guardians</td><td valign="top" align="left" rowspan="1" colspan="1">181</td><td valign="top" align="left" rowspan="1" colspan="1">34</td><td valign="top" align="left" rowspan="1" colspan="1">Paediatrics</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">1&#x02013;3&#x000a0;years after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Harrison<xref rid="R63" ref-type="bibr"><sup>63</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">1995</td><td valign="top" align="left" rowspan="1" colspan="1">USA (injection-drug users)</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">71</td><td valign="top" align="left" rowspan="1" colspan="1">37 (18&#x02013;56)</td><td valign="top" align="left" rowspan="1" colspan="1">HIV vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">II</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">Before ICP signature</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Harrison<xref rid="R63" ref-type="bibr"><sup>63</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">1995</td><td valign="top" align="left" rowspan="1" colspan="1">USA (injection-drug users and other high-risk individuals)</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">71</td><td valign="top" align="left" rowspan="1" colspan="1">37 (18&#x02013;56)</td><td valign="top" align="left" rowspan="1" colspan="1">HIV vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">II</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">Before ICP signature</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Harth<xref rid="R64" ref-type="bibr"><sup>64</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">1995</td><td valign="top" align="left" rowspan="1" colspan="1">Australia</td><td valign="top" align="left" rowspan="1" colspan="1">Parents or guardians</td><td valign="top" align="left" rowspan="1" colspan="1">62</td><td valign="top" align="left" rowspan="1" colspan="1">31</td><td valign="top" align="left" rowspan="1" colspan="1">Asthma</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Interview by telephone</td><td valign="top" align="left" rowspan="1" colspan="1">6&#x02013;9&#x000a0;months after entering trial</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Estey<xref rid="R65" ref-type="bibr"><sup>65</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">1994</td><td valign="top" align="left" rowspan="1" colspan="1">Canada</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">29</td><td valign="top" align="left" rowspan="1" colspan="1">58 (43&#x02013;70)</td><td valign="top" align="left" rowspan="1" colspan="1">Drug trial</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Interview</td><td valign="top" align="left" rowspan="1" colspan="1">1&#x02013;6&#x000a0;weeks after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Howard<xref rid="R66" ref-type="bibr"><sup>66</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">1981</td><td valign="top" align="left" rowspan="1" colspan="1">USA</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">64</td><td valign="top" align="left" rowspan="1" colspan="1">55 (30&#x02013;69)</td><td valign="top" align="left" rowspan="1" colspan="1">Acute myocardial infarction</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">Interview</td><td valign="top" align="left" rowspan="1" colspan="1">2&#x000a0;weeks to 15&#x000a0;months after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Griffin<xref rid="R67" ref-type="bibr"><sup>67</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2006</td><td valign="top" align="left" rowspan="1" colspan="1">USA</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">1789</td><td valign="top" align="left" rowspan="1" colspan="1">65 (53% were aged 60&#x02013;69)</td><td valign="top" align="left" rowspan="1" colspan="1">Cholesterol treatment</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Interview</td><td valign="top" align="left" rowspan="1" colspan="1">5.1&#x000a0;years after trial</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Guarino<xref rid="R68" ref-type="bibr"><sup>68</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2006</td><td valign="top" align="left" rowspan="1" colspan="1">USA</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">1086</td><td valign="top" align="left" rowspan="1" colspan="1">40.7 (27&#x02013;72)</td><td valign="top" align="left" rowspan="1" colspan="1">Gulf War veterans&#x02019; illnesses</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Barrett<xref rid="R69" ref-type="bibr"><sup>69</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2005</td><td valign="top" align="left" rowspan="1" colspan="1">USA</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">8</td><td valign="top" align="left" rowspan="1" colspan="1">11.9 (39&#x02013;76)</td><td valign="top" align="left" rowspan="1" colspan="1">Oncology</td><td valign="top" align="left" rowspan="1" colspan="1">II, III</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Sugarman<xref rid="R70" ref-type="bibr"><sup>70</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2005</td><td valign="top" align="left" rowspan="1" colspan="1">USA</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">627</td><td valign="top" align="left" rowspan="1" colspan="1">67&#x02009;&#x000b1;&#x02009;7.2</td><td valign="top" align="left" rowspan="1" colspan="1">Several trials on different diseases</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Interview by telephone</td><td valign="top" align="left" rowspan="1" colspan="1">Right after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Simon<xref rid="R71" ref-type="bibr"><sup>71</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2004</td><td valign="top" align="left" rowspan="1" colspan="1">USA</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">79</td><td valign="top" align="left" rowspan="1" colspan="1">51.9&#x02009;&#x000b1;&#x02009;11.2</td><td valign="top" align="left" rowspan="1" colspan="1">Oncology</td><td valign="top" align="left" rowspan="1" colspan="1">III</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Semi-structured interview</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Simon<xref rid="R71" ref-type="bibr"><sup>71</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2004</td><td valign="top" align="left" rowspan="1" colspan="1">USA</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">140</td><td valign="top" align="left" rowspan="1" colspan="1">35.4&#x02009;&#x000b1;&#x02009;7.6</td><td valign="top" align="left" rowspan="1" colspan="1">Oncology</td><td valign="top" align="left" rowspan="1" colspan="1">III</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Semi-structured interview</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Pentz<xref rid="R72" ref-type="bibr"><sup>72</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2002</td><td valign="top" align="left" rowspan="1" colspan="1">USA</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">100</td><td valign="top" align="left" rowspan="1" colspan="1">56 (25&#x02013;79)</td><td valign="top" align="left" rowspan="1" colspan="1">Oncology</td><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Structured interview in person or by phone or mail</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Cohen<xref rid="R73" ref-type="bibr"><sup>73</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2001</td><td valign="top" align="left" rowspan="1" colspan="1">USA</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">46</td><td valign="top" align="left" rowspan="1" colspan="1">54.9&#x02009;&#x000b1;&#x02009;8.9</td><td valign="top" align="left" rowspan="1" colspan="1">Oncology</td><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">Before treatment</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Fortney<xref rid="R74" ref-type="bibr"><sup>74</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">1999</td><td valign="top" align="left" rowspan="1" colspan="1">USA</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">15</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Gynaecology</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Structured interview</td><td valign="top" align="left" rowspan="1" colspan="1">9&#x02013;39&#x000a0;days after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Fortney<xref rid="R74" ref-type="bibr"><sup>74</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">1999</td><td valign="top" align="left" rowspan="1" colspan="1">Africa</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">17</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Gynaecology</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Structured interview</td><td valign="top" align="left" rowspan="1" colspan="1">26&#x02013;250&#x000a0;days after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Fortney<xref rid="R74" ref-type="bibr"><sup>74</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">1999</td><td valign="top" align="left" rowspan="1" colspan="1">Latin America group I</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">19</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Gynaecology</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Structured interview</td><td valign="top" align="left" rowspan="1" colspan="1">26&#x02013;250&#x000a0;days after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Fortney<xref rid="R74" ref-type="bibr"><sup>74</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">1999</td><td valign="top" align="left" rowspan="1" colspan="1">Latin America group II</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">19</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Gynaecology</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Structured interview</td><td valign="top" align="left" rowspan="1" colspan="1">26&#x02013;250&#x000a0;days after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Hutchison<xref rid="R75" ref-type="bibr"><sup>75</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">1998</td><td valign="top" align="left" rowspan="1" colspan="1">United Kingdom</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">28</td><td valign="top" align="left" rowspan="1" colspan="1">55.4&#x02009;&#x000b1;&#x02009;8.8</td><td valign="top" align="left" rowspan="1" colspan="1">Oncology</td><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Structured interview</td><td valign="top" align="left" rowspan="1" colspan="1">2&#x02013;4&#x000a0;weeks after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">N&#x000e9;grier<xref rid="R76" ref-type="bibr"><sup>76</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">1995</td><td valign="top" align="left" rowspan="1" colspan="1">France</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">24</td><td valign="top" align="left" rowspan="1" colspan="1">56</td><td valign="top" align="left" rowspan="1" colspan="1">Oncology</td><td valign="top" align="left" rowspan="1" colspan="1">II</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Written questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">Immediately after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Tankanow<xref rid="R77" ref-type="bibr"><sup>77</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">1992</td><td valign="top" align="left" rowspan="1" colspan="1">USA</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">98</td><td valign="top" align="left" rowspan="1" colspan="1">44 (18&#x02013;76)</td><td valign="top" align="left" rowspan="1" colspan="1">Drug trials</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Interview based on a questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">72&#x000a0;hours after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Rodenhuis<xref rid="R78" ref-type="bibr"><sup>78</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">1984</td><td valign="top" align="left" rowspan="1" colspan="1">Netherlands</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">10</td><td valign="top" align="left" rowspan="1" colspan="1">56 (20&#x02013;72)</td><td valign="top" align="left" rowspan="1" colspan="1">Oncology</td><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Structured interview</td><td valign="top" align="left" rowspan="1" colspan="1">1&#x02013;6&#x000a0;months after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Penman<xref rid="R79" ref-type="bibr"><sup>79</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">1984</td><td valign="top" align="left" rowspan="1" colspan="1">USA</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">144</td><td valign="top" align="left" rowspan="1" colspan="1">55 (18&#x02013;65)</td><td valign="top" align="left" rowspan="1" colspan="1">Oncology</td><td valign="top" align="left" rowspan="1" colspan="1">II, III</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Structured interview</td><td valign="top" align="left" rowspan="1" colspan="1">1&#x02013;3&#x000a0;weeks after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Goodman<xref rid="R80" ref-type="bibr"><sup>80</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">1984</td><td valign="top" align="left" rowspan="1" colspan="1">United Kingdom (first study)</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">14</td><td valign="top" align="left" rowspan="1" colspan="1">66 (50&#x02013;81)</td><td valign="top" align="left" rowspan="1" colspan="1">Anaesthesia</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">Postoperative phase of the study</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Goodman<xref rid="R80" ref-type="bibr"><sup>80</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">1984</td><td valign="top" align="left" rowspan="1" colspan="1">United Kingdom (second study)</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Anaesthesia</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">Before discharge from hospital</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Riecken<xref rid="R81" ref-type="bibr"><sup>81</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">1982</td><td valign="top" align="left" rowspan="1" colspan="1">USA</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">156</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">50 clinical trials</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Interview</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;&#x02009;10&#x000a0;weeks after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Bergler<xref rid="R82" ref-type="bibr"><sup>82</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">1980</td><td valign="top" align="left" rowspan="1" colspan="1">USA</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">39</td><td valign="top" align="left" rowspan="1" colspan="1">55</td><td valign="top" align="left" rowspan="1" colspan="1">Anti-hypertensive treatment</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Structured interview</td><td valign="top" align="left" rowspan="1" colspan="1">Immediately after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ritsuko<xref rid="R83" ref-type="bibr"><sup>83</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2006</td><td valign="top" align="left" rowspan="1" colspan="1">Japan</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">279</td><td valign="top" align="left" rowspan="1" colspan="1">65</td><td valign="top" align="left" rowspan="1" colspan="1">Clinical trials</td><td valign="top" align="left" rowspan="1" colspan="1">II, III</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">1&#x000a0;month to 2&#x000a0;years after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">PENTA<xref rid="R84" ref-type="bibr"><sup>84</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">1999</td><td valign="top" align="left" rowspan="1" colspan="1">Several countries</td><td valign="top" align="left" rowspan="1" colspan="1">Parents or guardians</td><td valign="top" align="left" rowspan="1" colspan="1">84</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Drug trial</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">Before unblinding the individual child&#x02019;s therapy</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ballard<xref rid="R85" ref-type="bibr"><sup>85</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2004</td><td valign="top" align="left" rowspan="1" colspan="1">USA (mothers)</td><td valign="top" align="left" rowspan="1" colspan="1">Parents or guardians</td><td valign="top" align="left" rowspan="1" colspan="1">35</td><td valign="top" align="left" rowspan="1" colspan="1">26.3 (16&#x02013;43)</td><td valign="top" align="left" rowspan="1" colspan="1">Paediatrics</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">3&#x02013;28&#x000a0;months after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ballard<xref rid="R85" ref-type="bibr"><sup>85</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2004</td><td valign="top" align="left" rowspan="1" colspan="1">USA (fathers)</td><td valign="top" align="left" rowspan="1" colspan="1">Parents or guardians</td><td valign="top" align="left" rowspan="1" colspan="1">21</td><td valign="top" align="left" rowspan="1" colspan="1">26.3 (16&#x02013;43)</td><td valign="top" align="left" rowspan="1" colspan="1">Paediatrics</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">3&#x02013;28&#x000a0;months after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ballard<xref rid="R85" ref-type="bibr"><sup>85</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2004</td><td valign="top" align="left" rowspan="1" colspan="1">USA (mothers and fathers)</td><td valign="top" align="left" rowspan="1" colspan="1">Parents or guardians</td><td valign="top" align="left" rowspan="1" colspan="1">8</td><td valign="top" align="left" rowspan="1" colspan="1">26.3 (16&#x02013;43)</td><td valign="top" align="left" rowspan="1" colspan="1">Paediatrics</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">3&#x02013;28&#x000a0;months after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Bertoli<xref rid="R86" ref-type="bibr"><sup>86</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2007</td><td valign="top" align="left" rowspan="1" colspan="1">Argentina</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">105</td><td valign="top" align="left" rowspan="1" colspan="1">56.3&#x02009;&#x000b1;&#x02009;11.8</td><td valign="top" align="left" rowspan="1" colspan="1">Rheumatology</td><td valign="top" align="left" rowspan="1" colspan="1">III, IV</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Burgess<xref rid="R87" ref-type="bibr"><sup>87</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2003</td><td valign="top" align="left" rowspan="1" colspan="1">Canada (prospective study)</td><td valign="top" align="left" rowspan="1" colspan="1">Parents or guardians</td><td valign="top" align="left" rowspan="1" colspan="1">29</td><td valign="top" align="left" rowspan="1" colspan="1">30 (21&#x02013;41) for mothers and 33.4 for fathers</td><td valign="top" align="left" rowspan="1" colspan="1">Neonatology</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">Prospective study</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Burgess<xref rid="R87" ref-type="bibr"><sup>87</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2003</td><td valign="top" align="left" rowspan="1" colspan="1">Canada (retrospective evaluation of ICP)</td><td valign="top" align="left" rowspan="1" colspan="1">Parents or guardians</td><td valign="top" align="left" rowspan="1" colspan="1">44</td><td valign="top" align="left" rowspan="1" colspan="1">29.5 (14&#x02013;40) for mothers and 33.4 for fathers</td><td valign="top" align="left" rowspan="1" colspan="1">Neonatology</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003e;&#x02009;1&#x000a0;year after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Chaisson<xref rid="R88" ref-type="bibr"><sup>88</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2011</td><td valign="top" align="left" rowspan="1" colspan="1">Botswana (English speakers)</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">969</td><td valign="top" align="left" rowspan="1" colspan="1">33</td><td valign="top" align="left" rowspan="1" colspan="1">Infectious disease</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">Within 30&#x000a0;days of ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Chaisson<xref rid="R88" ref-type="bibr"><sup>88</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2011</td><td valign="top" align="left" rowspan="1" colspan="1">Botswana (Setswana speakers)</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">969</td><td valign="top" align="left" rowspan="1" colspan="1">33</td><td valign="top" align="left" rowspan="1" colspan="1">Infectious disease</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">Within 30&#x000a0;days of ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Chappuy<xref rid="R89" ref-type="bibr"><sup>89</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2010</td><td valign="top" align="left" rowspan="1" colspan="1">France</td><td valign="top" align="left" rowspan="1" colspan="1">Parents or guardians</td><td valign="top" align="left" rowspan="1" colspan="1">43</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Paediatric oncology</td><td valign="top" align="left" rowspan="1" colspan="1">III</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Semi-structured interview</td><td valign="top" align="left" rowspan="1" colspan="1">After ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Chappuy<xref rid="R90" ref-type="bibr"><sup>90</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2013</td><td valign="top" align="left" rowspan="1" colspan="1">France</td><td valign="top" align="left" rowspan="1" colspan="1">Parents or guardians</td><td valign="top" align="left" rowspan="1" colspan="1">40</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Oncology</td><td valign="top" align="left" rowspan="1" colspan="1">III</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Semi-structured interview</td><td valign="top" align="left" rowspan="1" colspan="1">After study inclusion</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Chappuy<xref rid="R91" ref-type="bibr"><sup>91</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2006</td><td valign="top" align="left" rowspan="1" colspan="1">France</td><td valign="top" align="left" rowspan="1" colspan="1">Parents or guardians</td><td valign="top" align="left" rowspan="1" colspan="1">68</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">HIV infection or oncology</td><td valign="top" align="left" rowspan="1" colspan="1">I, II, III, IV</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Semi-structured interview</td><td valign="top" align="left" rowspan="1" colspan="1">21&#x000a0;days to 2&#x000a0;years after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Chappuy<xref rid="R92" ref-type="bibr"><sup>92</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2008</td><td valign="top" align="left" rowspan="1" colspan="1">France</td><td valign="top" align="left" rowspan="1" colspan="1">Child patients</td><td valign="top" align="left" rowspan="1" colspan="1">29</td><td valign="top" align="left" rowspan="1" colspan="1">13.6&#x02009;&#x000b1;&#x02009;2.8</td><td valign="top" align="left" rowspan="1" colspan="1">HIV infection or oncology</td><td valign="top" align="left" rowspan="1" colspan="1">I, II, III, IV</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Semi-structured interview</td><td valign="top" align="left" rowspan="1" colspan="1">After diagnosis</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Chenaud<xref rid="R93" ref-type="bibr"><sup>93</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2006</td><td valign="top" align="left" rowspan="1" colspan="1">Switzerland</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">44</td><td valign="top" align="left" rowspan="1" colspan="1">54&#x02009;&#x000b1;&#x02009;22</td><td valign="top" align="left" rowspan="1" colspan="1">Surgical intensive care unit</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">Interview</td><td valign="top" align="left" rowspan="1" colspan="1">Mean of 10&#x000a0;days (standard deviation: 2) after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Chu<xref rid="R94" ref-type="bibr"><sup>94</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2012</td><td valign="top" align="left" rowspan="1" colspan="1">Republic of Korea</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">140</td><td valign="top" align="left" rowspan="1" colspan="1">47.2&#x02009;&#x000b1;&#x02009;14</td><td valign="top" align="left" rowspan="1" colspan="1">Several diseases</td><td valign="top" align="left" rowspan="1" colspan="1">I, II, III, IV</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Self-administered questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Constantinou<xref rid="R95" ref-type="bibr"><sup>95</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2012</td><td valign="top" align="left" rowspan="1" colspan="1">Australia (patients participating in trial)</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">72.2&#x02009;&#x000b1;&#x02009;10.3</td><td valign="top" align="left" rowspan="1" colspan="1">Ophthalmology</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Interview</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Constantinou<xref rid="R95" ref-type="bibr"><sup>95</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2012</td><td valign="top" align="left" rowspan="1" colspan="1">Australia (patients declining participation)</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">73.1&#x02009;&#x000b1;&#x02009;6.8</td><td valign="top" align="left" rowspan="1" colspan="1">Ophthalmology</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Interview</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Cousino<xref rid="R96" ref-type="bibr"><sup>96</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2012</td><td valign="top" align="left" rowspan="1" colspan="1">USA (ethnic majority)</td><td valign="top" align="left" rowspan="1" colspan="1">Parents or guardians</td><td valign="top" align="left" rowspan="1" colspan="1">60</td><td valign="top" align="left" rowspan="1" colspan="1">42 (23&#x02013;66)</td><td valign="top" align="left" rowspan="1" colspan="1">Paediatric oncology</td><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Interview</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Cousino<xref rid="R96" ref-type="bibr"><sup>96</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2012</td><td valign="top" align="left" rowspan="1" colspan="1">USA (ethnic minority)</td><td valign="top" align="left" rowspan="1" colspan="1">Parents or guardians</td><td valign="top" align="left" rowspan="1" colspan="1">60</td><td valign="top" align="left" rowspan="1" colspan="1">42 (23&#x02013;66)</td><td valign="top" align="left" rowspan="1" colspan="1">Paediatric oncology</td><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Interview</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Durand-Zaleski<xref rid="R97" ref-type="bibr"><sup>97</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2008</td><td valign="top" align="left" rowspan="1" colspan="1">France</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients and parents or guardians</td><td valign="top" align="left" rowspan="1" colspan="1">279</td><td valign="top" align="left" rowspan="1" colspan="1">49.5 (39&#x02013;58) for patients and 40 (35&#x02013;45) for parents and guardians</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Structured interview</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Eiser<xref rid="R98" ref-type="bibr"><sup>98</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2005</td><td valign="top" align="left" rowspan="1" colspan="1">United Kingdom</td><td valign="top" align="left" rowspan="1" colspan="1">Parents or guardians</td><td valign="top" align="left" rowspan="1" colspan="1">50</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Oncology</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Semi-structured interview</td><td valign="top" align="left" rowspan="1" colspan="1">3&#x02013;5&#x000a0;months after diagnosis</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Featherstone<xref rid="R99" ref-type="bibr"><sup>99</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">1998</td><td valign="top" align="left" rowspan="1" colspan="1">United Kingdom</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Urinary retention treatment</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Semi-structured interview</td><td valign="top" align="left" rowspan="1" colspan="1">Seven patients within 3&#x000a0;months and five within 5&#x000a0;months of randomization; eight patients after receiving treatment</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Hazen<xref rid="R100" ref-type="bibr"><sup>100</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2007</td><td valign="top" align="left" rowspan="1" colspan="1">USA (ethnic majority)</td><td valign="top" align="left" rowspan="1" colspan="1">Parents or guardians</td><td valign="top" align="left" rowspan="1" colspan="1">79</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Paediatric oncology</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Interview</td><td valign="top" align="left" rowspan="1" colspan="1">Within 48&#x000a0;hours of ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Hazen<xref rid="R100" ref-type="bibr"><sup>100</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2007</td><td valign="top" align="left" rowspan="1" colspan="1">USA (ethnic minority)</td><td valign="top" align="left" rowspan="1" colspan="1">Parents or guardians</td><td valign="top" align="left" rowspan="1" colspan="1">61</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Paediatric oncology</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Interview</td><td valign="top" align="left" rowspan="1" colspan="1">Within 48&#x000a0;hours of ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Hereu<xref rid="R101" ref-type="bibr"><sup>101</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2010</td><td valign="top" align="left" rowspan="1" colspan="1">Spain (urgent cases)</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">24</td><td valign="top" align="left" rowspan="1" colspan="1">52 (22&#x02013;88)</td><td valign="top" align="left" rowspan="1" colspan="1">40 therapeutic trials</td><td valign="top" align="left" rowspan="1" colspan="1">II, III, IV</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">Structured interview</td><td valign="top" align="left" rowspan="1" colspan="1">Within 3&#x000a0;months of ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Hereu<xref rid="R101" ref-type="bibr"><sup>101</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2010</td><td valign="top" align="left" rowspan="1" colspan="1">Spain (non-urgent cases)</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">115</td><td valign="top" align="left" rowspan="1" colspan="1">52 (22&#x02013;88)</td><td valign="top" align="left" rowspan="1" colspan="1">40 therapeutic trials</td><td valign="top" align="left" rowspan="1" colspan="1">II, III, IV</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Structured interview</td><td valign="top" align="left" rowspan="1" colspan="1">Within 3&#x000a0;months of ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Hofmeijer<xref rid="R102" ref-type="bibr"><sup>102</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2007</td><td valign="top" align="left" rowspan="1" colspan="1">Netherlands (extremely urgent treatment)</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">28</td><td valign="top" align="left" rowspan="1" colspan="1">48&#x02009;&#x000b1;&#x02009;8</td><td valign="top" align="left" rowspan="1" colspan="1">Neurology</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">Interview</td><td valign="top" align="left" rowspan="1" colspan="1">Median of 13&#x000a0;days (range: 10&#x02013;16) after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Hofmeijer<xref rid="R102" ref-type="bibr"><sup>102</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2007</td><td valign="top" align="left" rowspan="1" colspan="1">Netherlands (less urgent treatment)</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">30</td><td valign="top" align="left" rowspan="1" colspan="1">69&#x02009;&#x000b1;&#x02009;13</td><td valign="top" align="left" rowspan="1" colspan="1">Neurology</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">Interview</td><td valign="top" align="left" rowspan="1" colspan="1">Median of 13&#x000a0;days (range: 10&#x02013;16) after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Itoh<xref rid="R103" ref-type="bibr"><sup>103</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">1997</td><td valign="top" align="left" rowspan="1" colspan="1">Japan</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">32</td><td valign="top" align="left" rowspan="1" colspan="1">58 (30&#x02013;68)</td><td valign="top" align="left" rowspan="1" colspan="1">Oncology</td><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">After ICP and before drug treatment</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Jenkins<xref rid="R104" ref-type="bibr"><sup>104</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2000</td><td valign="top" align="left" rowspan="1" colspan="1">United Kingdom (patients participating in trial)</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">147</td><td valign="top" align="left" rowspan="1" colspan="1">55 (all &#x0003e;&#x02009;25)</td><td valign="top" align="left" rowspan="1" colspan="1">Oncology</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Postal questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Jenkins<xref rid="R104" ref-type="bibr"><sup>104</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2000</td><td valign="top" align="left" rowspan="1" colspan="1">United Kingdom (patients declining participation in trial)</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">51</td><td valign="top" align="left" rowspan="1" colspan="1">55 (all &#x0003e;&#x02009;25)</td><td valign="top" align="left" rowspan="1" colspan="1">Oncology</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Postal questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Kass<xref rid="R105" ref-type="bibr"><sup>105</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2005</td><td valign="top" align="left" rowspan="1" colspan="1">Two African and one Caribbean country</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">26</td><td valign="top" align="left" rowspan="1" colspan="1">Two thirds were 20&#x02013;30 and one third were 31&#x02013;40</td><td valign="top" align="left" rowspan="1" colspan="1">Infectious disease</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Semi-structured interview</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Kenyon<xref rid="R106" ref-type="bibr"><sup>106</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2006</td><td valign="top" align="left" rowspan="1" colspan="1">United Kingdom</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Gynaecology</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">Interview</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Kiguba<xref rid="R107" ref-type="bibr"><sup>107</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2012</td><td valign="top" align="left" rowspan="1" colspan="1">Uganda</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">235</td><td valign="top" align="left" rowspan="1" colspan="1">38.2&#x02009;&#x000b1;&#x02009;7.5</td><td valign="top" align="left" rowspan="1" colspan="1">Infectious disease</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Semi-structured interview</td><td valign="top" align="left" rowspan="1" colspan="1">After initial or repeat ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Lidz<xref rid="R108" ref-type="bibr"><sup>108</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2004</td><td valign="top" align="left" rowspan="1" colspan="1">USA</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">155</td><td valign="top" align="left" rowspan="1" colspan="1">55 (all &#x0003e;&#x02009;18)</td><td valign="top" align="left" rowspan="1" colspan="1">40 trials on several diseases</td><td valign="top" align="left" rowspan="1" colspan="1">I, II, III, IV</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Semi-structured interview</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Leroy<xref rid="R109" ref-type="bibr"><sup>109</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2011</td><td valign="top" align="left" rowspan="1" colspan="1">France</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">75</td><td valign="top" align="left" rowspan="1" colspan="1">54.7 (28&#x02013;82)</td><td valign="top" align="left" rowspan="1" colspan="1">Oncology</td><td valign="top" align="left" rowspan="1" colspan="1">II, III</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Self-assessment questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Levi<xref rid="R110" ref-type="bibr"><sup>110</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2000</td><td valign="top" align="left" rowspan="1" colspan="1">USA</td><td valign="top" align="left" rowspan="1" colspan="1">Parents or guardians</td><td valign="top" align="left" rowspan="1" colspan="1">22</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Paediatric oncology</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Semi-structured interview</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Manafa<xref rid="R111" ref-type="bibr"><sup>111</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2007</td><td valign="top" align="left" rowspan="1" colspan="1">Nigeria</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">88</td><td valign="top" align="left" rowspan="1" colspan="1">39.2 (26&#x02013;62)</td><td valign="top" align="left" rowspan="1" colspan="1">Infectious disease</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">2&#x000a0;months after enrolment in trial</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">McNally<xref rid="R112" ref-type="bibr"><sup>112</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2001</td><td valign="top" align="left" rowspan="1" colspan="1">United Kingdom</td><td valign="top" align="left" rowspan="1" colspan="1">Parents or guardians</td><td valign="top" align="left" rowspan="1" colspan="1">29</td><td valign="top" align="left" rowspan="1" colspan="1">32</td><td valign="top" align="left" rowspan="1" colspan="1">Infectious disease</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Mangset<xref rid="R113" ref-type="bibr"><sup>113</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2008</td><td valign="top" align="left" rowspan="1" colspan="1">Norway</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">11</td><td valign="top" align="left" rowspan="1" colspan="1">69.9&#x02009;&#x000b1;&#x02009;8.1</td><td valign="top" align="left" rowspan="1" colspan="1">Neurology</td><td valign="top" align="left" rowspan="1" colspan="1">III</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">Semi-structured interview</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Meneguin<xref rid="R114" ref-type="bibr"><sup>114</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2010</td><td valign="top" align="left" rowspan="1" colspan="1">Brazil</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">80</td><td valign="top" align="left" rowspan="1" colspan="1">58.7&#x02009;&#x000b1;&#x02009;9.3</td><td valign="top" align="left" rowspan="1" colspan="1">Cardiology</td><td valign="top" align="left" rowspan="1" colspan="1">II, III, IV</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Semi-structured interview</td><td valign="top" align="left" rowspan="1" colspan="1">6&#x000a0;months to 4&#x000a0;years after completion of trial</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Miller<xref rid="R115" ref-type="bibr"><sup>115</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2013</td><td valign="top" align="left" rowspan="1" colspan="1">USA</td><td valign="top" align="left" rowspan="1" colspan="1">Adult and child patients</td><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">17.8&#x02009;&#x000b1;&#x02009;2.4</td><td valign="top" align="left" rowspan="1" colspan="1">Paediatric oncology</td><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Structured interview</td><td valign="top" align="left" rowspan="1" colspan="1">Immediately after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Mills<xref rid="R116" ref-type="bibr"><sup>116</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2003</td><td valign="top" align="left" rowspan="1" colspan="1">United Kingdom</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">21</td><td valign="top" align="left" rowspan="1" colspan="1">60 (50&#x02013;69)</td><td valign="top" align="left" rowspan="1" colspan="1">Oncology</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Interview</td><td valign="top" align="left" rowspan="1" colspan="1">Approximately10&#x000a0;days after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Nurgat<xref rid="R117" ref-type="bibr"><sup>117</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2005</td><td valign="top" align="left" rowspan="1" colspan="1">United Kingdom</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">38</td><td valign="top" align="left" rowspan="1" colspan="1">60 (37&#x02013;79)</td><td valign="top" align="left" rowspan="1" colspan="1">Oncology</td><td valign="top" align="left" rowspan="1" colspan="1">I, II</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire by mail</td><td valign="top" align="left" rowspan="1" colspan="1">Before or during the first treatment cycle</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ockene<xref rid="R118" ref-type="bibr"><sup>118</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">1991</td><td valign="top" align="left" rowspan="1" colspan="1">USA</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">28</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Cardiology</td><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">Interview based on a questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">After ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Petersen<xref rid="R119" ref-type="bibr"><sup>119</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2013</td><td valign="top" align="left" rowspan="1" colspan="1">Germany (patients participating in trial)</td><td valign="top" align="left" rowspan="1" colspan="1">Parents or guardians</td><td valign="top" align="left" rowspan="1" colspan="1">767</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Paediatric oncology</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire by mail</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Petersen<xref rid="R119" ref-type="bibr"><sup>119</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2013</td><td valign="top" align="left" rowspan="1" colspan="1">Germany (patients declining participation)</td><td valign="top" align="left" rowspan="1" colspan="1">Parents or guardians</td><td valign="top" align="left" rowspan="1" colspan="1">40</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Paediatric oncology</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire by mail</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Queiroz da Fonseca<xref rid="R120" ref-type="bibr"><sup>120</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">1999</td><td valign="top" align="left" rowspan="1" colspan="1">Brazil</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">66</td><td valign="top" align="left" rowspan="1" colspan="1">18&#x02013;49</td><td valign="top" align="left" rowspan="1" colspan="1">HIV vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Semi-structured interview</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Russell<xref rid="R121" ref-type="bibr"><sup>121</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2005</td><td valign="top" align="left" rowspan="1" colspan="1">Australia (Aborigines)</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">95% were &#x0003e;&#x02009;16</td><td valign="top" align="left" rowspan="1" colspan="1">Pneumococcal vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Semi-structured interview</td><td valign="top" align="left" rowspan="1" colspan="1">Immediately after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Russell<xref rid="R121" ref-type="bibr"><sup>121</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2005</td><td valign="top" align="left" rowspan="1" colspan="1">Australia (non-Aborigines)</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">100% were &#x0003e;&#x02009;16</td><td valign="top" align="left" rowspan="1" colspan="1">Pneumococcal vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Semi-structured interview</td><td valign="top" align="left" rowspan="1" colspan="1">Immediately after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Schaeffer<xref rid="R122" ref-type="bibr"><sup>122</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">1996</td><td valign="top" align="left" rowspan="1" colspan="1">USA (phase1)</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1">53&#x02009;&#x000b1;&#x02009;14.7</td><td valign="top" align="left" rowspan="1" colspan="1">Oncology</td><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">24&#x000a0;hours after study inclusion</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Schaeffer<xref rid="R122" ref-type="bibr"><sup>122</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">1996</td><td valign="top" align="left" rowspan="1" colspan="1">USA (phase 2)</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">36</td><td valign="top" align="left" rowspan="1" colspan="1">56&#x02009;&#x000b1;&#x02009;8.9</td><td valign="top" align="left" rowspan="1" colspan="1">Oncology</td><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">24&#x000a0;hours after study inclusion</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Schaeffer<xref rid="R122" ref-type="bibr"><sup>122</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">1996</td><td valign="top" align="left" rowspan="1" colspan="1">USA (phase 3)</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">28</td><td valign="top" align="left" rowspan="1" colspan="1">33&#x02009;&#x000b1;&#x02009;6.6</td><td valign="top" align="left" rowspan="1" colspan="1">Infectious disease</td><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">24&#x000a0;hours after study inclusion</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Coulibaly-Traore<xref rid="R123" ref-type="bibr"><sup>123</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2003</td><td valign="top" align="left" rowspan="1" colspan="1">France</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">57</td><td valign="top" align="left" rowspan="1" colspan="1">25 (18&#x02013;42)</td><td valign="top" align="left" rowspan="1" colspan="1">HIV vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Interview</td><td valign="top" align="left" rowspan="1" colspan="1">90&#x02013;180&#x000a0;days after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ducrocq<xref rid="R124" ref-type="bibr"><sup>124</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2000</td><td valign="top" align="left" rowspan="1" colspan="1">France</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">72</td><td valign="top" align="left" rowspan="1" colspan="1">62 (29&#x02013;85)</td><td valign="top" align="left" rowspan="1" colspan="1">Neurology</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Interview</td><td valign="top" align="left" rowspan="1" colspan="1">6&#x02013;24&#x000a0;hours after study inclusion</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Schutta<xref rid="R125" ref-type="bibr"><sup>125</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2000</td><td valign="top" align="left" rowspan="1" colspan="1">USA</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">8</td><td valign="top" align="left" rowspan="1" colspan="1">57 (42&#x02013;72)</td><td valign="top" align="left" rowspan="1" colspan="1">Oncology</td><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Interview</td><td valign="top" align="left" rowspan="1" colspan="1">Immediately after ICP</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Snowdon<xref rid="R126" ref-type="bibr"><sup>126</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">1997</td><td valign="top" align="left" rowspan="1" colspan="1">United Kingdom</td><td valign="top" align="left" rowspan="1" colspan="1">Parents or guardians</td><td valign="top" align="left" rowspan="1" colspan="1">71</td><td valign="top" align="left" rowspan="1" colspan="1">30.5 (22&#x02013;44)</td><td valign="top" align="left" rowspan="1" colspan="1">Neonatology</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">Semi-structured interview</td><td valign="top" align="left" rowspan="1" colspan="1">Different times after recruitment to the trial</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Stenson<xref rid="R127" ref-type="bibr"><sup>127</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2004</td><td valign="top" align="left" rowspan="1" colspan="1">United Kingdom</td><td valign="top" align="left" rowspan="1" colspan="1">Parents or guardians</td><td valign="top" align="left" rowspan="1" colspan="1">99</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Neonatology</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">18&#x000a0;months after the study finished</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Unguru<xref rid="R128" ref-type="bibr"><sup>128</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2010</td><td valign="top" align="left" rowspan="1" colspan="1">USA</td><td valign="top" align="left" rowspan="1" colspan="1">Child patients</td><td valign="top" align="left" rowspan="1" colspan="1">37</td><td valign="top" align="left" rowspan="1" colspan="1">13.6 (7&#x02013;19)</td><td valign="top" align="left" rowspan="1" colspan="1">Paediatric oncology</td><td valign="top" align="left" rowspan="1" colspan="1">I, II, III, IV</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Semi-structured interview</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Yoong<xref rid="R129" ref-type="bibr"><sup>129</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2011</td><td valign="top" align="left" rowspan="1" colspan="1">Australia</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">102</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Oncology</td><td valign="top" align="left" rowspan="1" colspan="1">I, II, III</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Verheggen<xref rid="R130" ref-type="bibr"><sup>130</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">1996</td><td valign="top" align="left" rowspan="1" colspan="1">Netherlands</td><td valign="top" align="left" rowspan="1" colspan="1">Adult patients</td><td valign="top" align="left" rowspan="1" colspan="1">198</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">26 trials</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Questionnaire</td><td valign="top" align="left" rowspan="1" colspan="1">4&#x000a0;weeks after ICP</td></tr></tbody></table><table-wrap-foot><p>HIV: human immunodeficiency virus; ICP: informed consent process; IQR: interquartile range; ND: not determined.</p><p><sup>a</sup> Ages are given as a mean alone, a mean&#x02009;&#x000b1;&#x02009;standard deviation, a range or a median (range), unless otherwise stated.</p></table-wrap-foot></table-wrap><sec><title>Understanding of informed consent</title><p>The number of data sets that covered each component of informed consent is shown in Appendix&#x000a0;B (available at: <ext-link ext-link-type="uri" xlink:href="https://www.researchgate.net/publication/270506278_Online_Only_Supplements_for_Three_decades_of_participants_understanding_of_informed_consent_in_clinical_trials_a_systematic_review_and_meta-analysis">https://www.researchgate.net/publication/270506278_Online_Only_Supplements_for_Three_decades_of_participants_understanding_of_informed_consent_in_clinical_trials_a_systematic_review_and_meta-analysis</ext-link>). Understanding of freedom to withdraw at any time was investigated in the largest number of studies (<italic>n</italic>&#x02009;=&#x02009;79), whereas understanding of placebo was investigated in the smallest number (<italic>n</italic>&#x02009;=&#x02009;15). Our analysis showed some variation in the proportion of participants who understood different components of informed consent. The highest proportions were 75.8% (95% CI: 70.6&#x02013;80.3) for freedom to withdraw from the study at any time, 74.7% (95% CI: 68.8&#x02013;79.8) for the nature of study, 74.7% (95% CI: 67.9&#x02013;80.5) for the voluntary nature of participation and 74.0% (95% CI: 65.0&#x02013;81.3) for potential benefits (<xref ref-type="fig" rid="F2">Fig.&#x000a0;2</xref> and Appendix&#x000a0;B). Lower proportions were 69.6% (95% CI: 63.5&#x02013;75.1) for the purpose of the study, 67.0% (95% CI: 57.4&#x02013;75.4) for potential risks and side-effects, 66.2% (95% CI: 55.3&#x02013;75.7) for confidentiality, 64.1% (95% CI: 53.7&#x02013;73.4) for the availability of alternative treatment if withdrawn and 62.9% (95% CI: 45.5&#x02013;77.5) for knowing that treatments were being compared. In addition, 62.4% (95% CI: 50.1&#x02013;73.2) had no therapeutic misconceptions. The lowest proportions were 54.9% (95% CI: 43.3&#x02013;65.0) for naming at least one risk, followed by 53.3% (95% CI: 38.4&#x02013;67.6) for understanding of placebo and 52.1% (95% CI: 41.3&#x02013;62.7) for understanding of randomization.</p><fig id="F2" fig-type="figure" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Participants&#x02019; understanding of components of informed consent in clinical trials, by meta-analysis<sup>a</sup></p></caption><p><sup>a</sup> The number of studies included in the evaluation of each component is given.</p><graphic xlink:href="BLT.14.141390-F2"/></fig></sec><sec><title>Effect of covariates</title><p>We performed a meta-regression analysis to evaluate the influence of particular covariates on the proportion of participants who understood informed consent (<xref ref-type="table" rid="T2">Table&#x000a0;2</xref>). We found that gender had no effect but that, importantly, significantly fewer patients from low-income countries than from middle- and high countries understood randomization, the voluntary nature of participation and freedom to withdraw at any time. In addition, critically ill patients were significantly less likely to understand the nature or benefits of the study or confidentiality or to be able to name at least one risk. However, older participants were more likely to understand the nature of the study and freedom to withdraw at any time. A lower educational level was associated with a reduced likelihood of understanding the nature of the study, placebo, randomization and freedom to withdraw at any time. Participants in phase-I clinical trials were less likely than participants in phase-II, -III or -IV trials to understand the purpose of the study and were more likely to have therapeutic misconceptions. Participants in phase-I trials were also more likely to understand potential risks and side-effects and freedom to withdraw at any time. Participants assessed using open-ended questions were less likely to understand the purpose of the study (<xref ref-type="fig" rid="F3">Fig.&#x000a0;3</xref>), the voluntary nature of participation or freedom to withdraw at any time or to be able to name at least one risk. Additionally, the later the evaluation of understanding was carried out, the less likely the participant was to understand confidentiality or to be able to name at least one risk. The quality of the evaluation did not influence understanding.</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Influence<sup>a</sup> of covariates on participants&#x02019; understanding of informed consent in clinical trials</title></caption><table frame="hsides" rules="groups"><col width="96" span="1"/><col width="80" span="1"/><col width="77" span="1"/><col width="77" span="1"/><col width="14" span="1"/><col width="63" span="1"/><col width="65" span="1"/><col width="81" span="1"/><col width="72" span="1"/><col width="14" span="1"/><col width="66" span="1"/><col width="68" span="1"/><col width="78" span="1"/><thead><tr><th rowspan="3" valign="top" align="left" scope="col" colspan="1">Component of informed consent</th><th colspan="12" valign="top" align="center" scope="colgroup" rowspan="1">Effect of covariate on understanding of component<hr/></th></tr><tr><th colspan="3" valign="top" align="center" scope="colgroup" rowspan="1">Trial<hr/></th><th rowspan="2" valign="top" align="left" scope="col" colspan="1"/><th colspan="4" valign="top" align="center" scope="colgroup" rowspan="1">Participants<hr/></th><th rowspan="2" valign="top" align="left" scope="col" colspan="1"/><th colspan="3" valign="top" align="center" scope="colgroup" rowspan="1">Evaluation of understanding of informed consent<hr/></th></tr><tr><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">Publication year<sup>b</sup></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Low-income country</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Phase-I study</th><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">Female sex</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Older age<sup>b</sup></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Critically ill</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Low educational level<sup>b</sup></th><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">Late evaluation<sup>b</sup></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Open-ended question used</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Quality of evaluation<sup>b</sup></th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Nature of the study</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">Increased</td><td valign="top" align="center" rowspan="1" colspan="1">Decreased</td><td valign="top" align="center" rowspan="1" colspan="1">Decreased</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">None</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Purpose of the study</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">Decreased</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">None </td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">Decreased</td><td valign="top" align="center" rowspan="1" colspan="1">None</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">No therapeutic misconception<sup>c</sup></td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">ND<sup>d</sup></td><td valign="top" align="center" rowspan="1" colspan="1">Decreased</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">ND</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">None</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ability to name at least one risk</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">Decreased</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Decreased</td><td valign="top" align="center" rowspan="1" colspan="1">Decreased</td><td valign="top" align="center" rowspan="1" colspan="1">None</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Risks and side-effects</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">Increased</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">None</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Benefits of the study</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">Decreased</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">None</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Placebo</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">ND</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">ND</td><td valign="top" align="center" rowspan="1" colspan="1">Decreased</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">ND</td><td valign="top" align="center" rowspan="1" colspan="1">None</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Knowing that treatments were being compared</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">ND</td><td valign="top" align="center" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">ND</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">ND</td><td valign="top" align="center" rowspan="1" colspan="1">None</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Randomization</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">Decreased</td><td valign="top" align="center" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">Decreased</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">None</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Voluntary nature of participation</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">Decreased</td><td valign="top" align="center" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">Decreased</td><td valign="top" align="center" rowspan="1" colspan="1">None</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Freedom to withdraw at any time</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">Decreased</td><td valign="top" align="center" rowspan="1" colspan="1">Increased</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">Increased</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">Decreased</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">Decreased</td><td valign="top" align="center" rowspan="1" colspan="1">None</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Availability of alternative treatment if withdrawn</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">ND</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">None</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Confidentiality</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">ND</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">Decreased</td><td valign="top" align="center" rowspan="1" colspan="1">None</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Decreased</td><td valign="top" align="center" rowspan="1" colspan="1">ND</td><td valign="top" align="center" rowspan="1" colspan="1">None</td></tr></tbody></table><table-wrap-foot><p>ND: not determined.</p><p><sup>a</sup> The influence of the covariate on participants&#x02019; understanding of the component of informed consent was evaluated by meta-regression analysis.</p><p><sup>b</sup> Continuous variable.</p><p><sup>c</sup> No lack of awareness of the uncertainty of success.</p><p><sup>d</sup> The effect was not determined because there were fewer than five studies per subgroup or fewer than 10 for the regression analysis.</p></table-wrap-foot></table-wrap><fig id="F3" fig-type="figure" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>Effect of using an open-ended question<sup>a</sup> on participants&#x02019; understanding of the purpose of a clinical study<sup>b</sup></p></caption><p>CI: confidence interval.</p><p><sup>a</sup> Participants&#x02019; understanding of components of informed consent was assessed using open-ended or closed-ended questions.</p><p><sup>b</sup> The pooled proportion of participants who understood the purpose of the study was calculated using random-effects models for those assessed using both open-ended and closed-ended questions.</p><graphic xlink:href="BLT.14.141390-F3"/></fig><p>Our data also provided us with the opportunity to analyse how study participants&#x02019; understanding of informed consent had changed over 30&#x000a0;years. Surprisingly, there was no significant change in understanding of any component (<xref ref-type="fig" rid="F4">Fig.&#x000a0;4</xref>, <xref ref-type="fig" rid="F5">Fig.&#x000a0;5</xref> and <xref ref-type="fig" rid="F6">Fig.&#x000a0;6</xref>). In particular, we were interested in the past 20&#x000a0;years, after the World Health Organization introduced guidelines for good clinical practice in trials.<xref rid="R132" ref-type="bibr"><sup>132</sup></xref> After removing four early studies, we again found no significant change in understanding of any component, including the freedom to withdraw (<xref ref-type="fig" rid="F7">Fig.&#x000a0;7</xref>). Furthermore, there was no significant change in understanding of any component over the past 13&#x000a0;years in all studies combined or in subgroups of participants, including those assessed using open-ended questions, those assessed using closed-ended questions and those in middle- and high-income countries assessed using closed-ended questions (Appendices&#x000a0;C, D, E and F, respectively, available at: <ext-link ext-link-type="uri" xlink:href="https://www.researchgate.net/publication/270506278_Online_Only_Supplements_for_Three_decades_of_participants_understanding_of_informed_consent_in_clinical_trials_a_systematic_review_and_meta-analysis">https://www.researchgate.net/publication/270506278_Online_Only_Supplements_for_Three_decades_of_participants_understanding_of_informed_consent_in_clinical_trials_a_systematic_review_and_meta-analysis</ext-link>).</p><fig id="F4" fig-type="figure" orientation="portrait" position="float"><label>Fig. 4</label><caption><p>Participants&#x02019; understanding of the potential risks and side-effects of participating in a clinical study</p></caption><p><sup>a</sup> The logit event rate is the natural logarithm of the event rate divided by (1 &#x02013; event rate), where the event rate is the proportion of study participants who understood the potential risks and side-effects of participating in a clinical study.</p><graphic xlink:href="BLT.14.141390-F4"/></fig><fig id="F5" fig-type="figure" orientation="portrait" position="float"><label>Fig. 5</label><caption><p>Participants&#x02019; understanding of placebo in clinical studies</p></caption><p><sup>a</sup> The logit event rate is the natural logarithm of the event rate divided by (1 &#x02013; event rate), where the event rate is the proportion of study participants who understood placebo.</p><graphic xlink:href="BLT.14.141390-F5"/></fig><fig id="F6" fig-type="figure" orientation="portrait" position="float"><label>Fig. 6</label><caption><p>Participants&#x02019; understanding of their freedom to withdraw from a study at any time</p></caption><p><sup>a</sup> The logit event rate is the natural logarithm of the event rate divided by (1 &#x02013; event rate), where the event rate is the proportion of study participants who understood they were free to withdraw from the study at any time.</p><graphic xlink:href="BLT.14.141390-F6"/></fig><fig id="F7" fig-type="figure" orientation="portrait" position="float"><label>Fig. 7</label><caption><p>Participants&#x02019; understanding of their freedom to withdraw from a study at any time, after introduction of WHO guidelines for good clinical practice in trials<xref rid="R132" ref-type="bibr"><bold><sup>132</sup></bold></xref></p></caption><p><sup>a</sup> The logit event rate is the natural logarithm of the event rate divided by (1 &#x02013; event rate), where the event rate is the proportion of study participants who understood they were free to withdraw from the study at any time.</p><graphic xlink:href="BLT.14.141390-F7"/></fig></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Obtaining informed consent from participants in clinical research is essential because it promotes their welfare and ensures their rights.<xref rid="R9" ref-type="bibr"><sup>9</sup></xref><sup>,</sup><xref rid="R133" ref-type="bibr"><sup>133</sup></xref> However, participants must have a good understanding of what informed consent entails. Our meta-analysis indicates that around 75% of individuals understood the nature of the study, their right to refuse to participate, their right to withdraw at any time and the direct benefits of participation. This percentage is higher than the figure of around 50% found in a previous systematic review<xref rid="R18" ref-type="bibr"><sup>18</sup></xref> probably because we included only clinical trials, excluded studies of patients with cognitive deficits and weighted the meta-analysis to account for heterogeneous data.</p><p>Our data also highlight the difficulty participants had in understanding particular components of informed consent, such as randomization and the use of placebo. Moreover, although participants were aware of potential risks and side-effects, they were less likely to be able to name at least one risk and, although they understood the benefits of participating in a study, they were less aware of the uncertainty of these benefits (i.e. had therapeutic misconceptions). These findings were also noted in previous studies.<xref rid="R18" ref-type="bibr"><sup>18</sup></xref><sup>,</sup><xref rid="R19" ref-type="bibr"><sup>19</sup></xref><sup>,</sup><xref rid="R134" ref-type="bibr"><sup>134</sup></xref><sup>&#x02013;</sup><xref rid="R137" ref-type="bibr"><sup>137</sup></xref> They are, perhaps, not surprising since a participant&#x02019;s understanding depends, to a certain degree, on their literacy as well as on the duration of the informed consent process and the explanatory skills of the researchers.<xref rid="R138" ref-type="bibr"><sup>138</sup></xref><sup>&#x02013;</sup><xref rid="R140" ref-type="bibr"><sup>140</sup></xref></p><p>In addition, the meta-regression was able to identify differences in understanding of informed consent between population groups. Older participants more often than younger participants understood the nature of the study and freedom to withdraw at any time. The reason for this difference requires further study. As noted in a previous systematic review,<xref rid="R19" ref-type="bibr"><sup>19</sup></xref> participants from developing countries were less likely than others to understand the voluntary nature of participation and freedom to withdraw at any time. It is possible that patients in these countries dare not refuse to join or dare not withdraw from a study because they fear their doctor&#x02019;s disapproval.<xref rid="R141" ref-type="bibr"><sup>141</sup></xref> Participants from developing countries and those with a low level of literacy were less likely to understand randomization.</p><p>Phase-I clinical trials are usually conducted in small numbers of participants to test a drug&#x02019;s safety and dose range. Consequently, it was expected that participants in phase-I trials would be less likely than those in more advanced trials to understand the purpose of the study or that the benefits were uncertain. In contrast, participants in phase-I trials were more likely to be aware of potential risks and of their freedom to withdraw at any time.</p><p>Compared with the use of open-ended questions to evaluate participants' understanding, the use of closed-ended questions was associated with higher rates of understanding of the purpose of the study, the voluntary nature of participation and freedom to withdraw and with a greater likelihood of being able to name at least one risk. However, the use of closed-ended questions could have led to understanding being overestimated because respondents had to choose from a limited number of possible answers and did not have to think clearly about the issues.<xref rid="R142" ref-type="bibr"><sup>142</sup></xref> Consequently, the use of open-ended questions may have reflected better the true extent of understanding since respondents had to put their understanding into words.<xref rid="R143" ref-type="bibr"><sup>143</sup></xref></p><p>Finally, an unexpected finding of our analysis was that understanding of the potential risks and side-effects of trials, of placebo and of freedom to withdraw had not changed over 30&#x000a0;years. This is despite considerable progress in medical research methods over this time<xref rid="R144" ref-type="bibr"><sup>144</sup></xref> and many attempts made to improve the quality of informed consent.<xref rid="R145" ref-type="bibr"><sup>145</sup></xref> There are four possible explanations: (i)&#x000a0;the maximum proportion of participants who understand these concepts has been reached; (ii)&#x000a0;the increasing complexity of clinical trials has made the informed consent process longer and more difficult to understand; (iii)&#x000a0;not enough effort has been put into enhancing the quality of the informed consent process; and (iv)&#x000a0;our analysis did not have the statistical power to detect a significant increase in understanding. In fact, the best way to improve understanding of informed consent is still debated. A recent meta-analysis of interventions for improving understanding found that enhanced consent forms and extended discussions led to significant increases in understanding whereas multimedia approaches did not.<xref rid="R146" ref-type="bibr"><sup>146</sup></xref> In other words, simple measures such as well formatted, easily readable consent forms and intensive discussions with participants may be more effective than more complex measures.<xref rid="R140" ref-type="bibr"><sup>140</sup></xref><sup>,</sup><xref rid="R146" ref-type="bibr"><sup>146</sup></xref><sup>&#x02013;</sup><xref rid="R148" ref-type="bibr"><sup>148</sup></xref></p><p>Although an understanding of all the components of informed consent we investigated is required for patients to make a decision on study participation, some components were assessed more often than others. We found a good correlation between the likelihood that a participant would understand a specific component of informed consent and the number of studies that investigated understanding of that component (Appendix&#x000a0;G). This suggests either that it was simpler to evaluate understanding of some components or that some components were more important.</p><p>One limitation of our study is that we were not able to analyse the effect on understanding of informed consent of the presence of a nurse during the informed consent process, of the duration of the process or of participants choosing not to take part in a clinical trial because only a small number of studies investigated these factors. Moreover, only 79 of the 135 data sets gave information on whether the interviewers were investigators in the original clinical trial. Hence, we were not able to analyse the effect of this factor on the results. Another limitation is that we included studies of children because they have the right to decide whether to participate.<xref rid="R149" ref-type="bibr"><sup>149</sup></xref><sup>,</sup><xref rid="R150" ref-type="bibr"><sup>150</sup></xref> However, the number of studies involving children was small and our sensitivity analysis showed that removing these studies did not influence the pooled results. Although we found a high level of heterogeneity across studies for understanding of all components of informed consent and although Cox et al. suggest that, in these circumstances, individual studies should be described rather than combined in a meta-analysis,<xref rid="R151" ref-type="bibr"><sup>151</sup></xref> we, like other groups, chose to perform a meta-analysis with a regression analysis and subgroup analysis to gain a better insight into how covariates affect understanding.<xref rid="R152" ref-type="bibr"><sup>152</sup></xref><sup>&#x02013;</sup><xref rid="R154" ref-type="bibr"><sup>154</sup></xref></p><p>In conclusion, we found that most participants in clinical trials understood fundamental components of informed consent such as the nature and benefits of the study, freedom to withdraw at any time and the voluntary nature of participation. Understanding of other components, such as randomization and placebo, was less satisfactory and has not improved over 30&#x000a0;years. Our findings suggest that investigators could make a greater effort to help research participants achieve a complete understanding of informed consent. This would ensure that participants&#x02019; decision-making is meaningful and that their interests are protected.</p></sec></body><back><fn-group><title>Competing interests:</title><fn fn-type="financial-disclosure"><p>None declared.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><mixed-citation publication-type="journal"><string-name><surname>Grodin</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>Annas</surname>
<given-names>GJ</given-names></string-name>. <article-title>Legacies of Nuremberg. Medical ethics and human rights.</article-title>
<source>JAMA</source>. <year>1996</year>
<month>11</month>
<day>27</day>;<volume>276</volume>(<issue>20</issue>):<fpage>1682</fpage>&#x02013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1001/jama.1996.03540200068035</pub-id><pub-id pub-id-type="pmid">8922458</pub-id></mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="journal"><string-name><surname>Emanuel</surname>
<given-names>EJ</given-names></string-name>, <string-name><surname>Wendler</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Grady</surname>
<given-names>C</given-names></string-name>. <article-title>What makes clinical research ethical?</article-title>
<source>JAMA</source>. <year>2000</year>
<month>5</month>
<day>24-31</day>;<volume>283</volume>(<issue>20</issue>):<fpage>2701</fpage>&#x02013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1001/jama.283.20.2701</pub-id><pub-id pub-id-type="pmid">10819955</pub-id></mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="journal"><string-name><surname>Annas</surname>
<given-names>GJ</given-names></string-name>. <article-title>Doctors, patients, and lawyers&#x02013;two centuries of health law.</article-title>
<source>N Engl J Med</source>. <year>2012</year>
<month>8</month>
<day>2</day>;<volume>367</volume>(<issue>5</issue>):<fpage>445</fpage>&#x02013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMra1108646</pub-id><pub-id pub-id-type="pmid">22853015</pub-id></mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="journal"><string-name><surname>Jefford</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Moore</surname>
<given-names>R</given-names></string-name>. <article-title>Improvement of informed consent and the quality of consent documents.</article-title>
<source>Lancet Oncol</source>. <year>2008</year>
<month>5</month>;<volume>9</volume>(<issue>5</issue>):<fpage>485</fpage>&#x02013;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1016/S1470-2045(08)70128-1</pub-id><pub-id pub-id-type="pmid">18452859</pub-id></mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="journal"><string-name><surname>Will</surname>
<given-names>JF</given-names></string-name>. <article-title>A brief historical and theoretical perspective on patient autonomy and medical decision making: Part II: The autonomy model.</article-title>
<source>Chest</source>. <year>2011</year>
<month>6</month>;<volume>139</volume>(<issue>6</issue>):<fpage>1491</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1378/chest.11-0516</pub-id><pub-id pub-id-type="pmid">21652559</pub-id></mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="journal"><string-name><surname>Wendler</surname>
<given-names>D</given-names></string-name>. <article-title>How to enroll participants in research ethically.</article-title>
<source>JAMA</source>. <year>2011</year>
<month>4</month>
<day>20</day>;<volume>305</volume>(<issue>15</issue>):<fpage>1587</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2011.421</pub-id><pub-id pub-id-type="pmid">21505137</pub-id></mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal"><string-name><surname>Glickman</surname>
<given-names>SW</given-names></string-name>, <string-name><surname>McHutchison</surname>
<given-names>JG</given-names></string-name>, <string-name><surname>Peterson</surname>
<given-names>ED</given-names></string-name>, <string-name><surname>Cairns</surname>
<given-names>CB</given-names></string-name>, <string-name><surname>Harrington</surname>
<given-names>RA</given-names></string-name>, <string-name><surname>Califf</surname>
<given-names>RM</given-names></string-name>, <etal>et al.</etal>
<article-title>Ethical and scientific implications of the globalization of clinical research.</article-title>
<source>N Engl J Med</source>. <year>2009</year>
<month>2</month>
<day>19</day>;<volume>360</volume>(<issue>8</issue>):<fpage>816</fpage>&#x02013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMsb0803929</pub-id><pub-id pub-id-type="pmid">19228627</pub-id></mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal"><string-name><surname>Rivera</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Borasky</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Rice</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Carayon</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Wong</surname>
<given-names>E</given-names></string-name>. <article-title>Informed consent: an international researchers&#x02019; perspective.</article-title>
<source>Am J Public Health</source>. <year>2007</year>
<month>1</month>;<volume>97</volume>(<issue>1</issue>):<fpage>25</fpage>&#x02013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.2105/AJPH.2005.081604</pub-id><pub-id pub-id-type="pmid">17138913</pub-id></mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal"><article-title>World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.</article-title>
<source>JAMA</source>. <year>2013</year>
<month>11</month>
<day>27</day>;<volume>310</volume>(<issue>20</issue>):<fpage>2191</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2013.281053</pub-id><pub-id pub-id-type="pmid">24141714</pub-id></mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal"><string-name><surname>Boga</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Davies</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Kamuya</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Kinyanjui</surname>
<given-names>SM</given-names></string-name>, <string-name><surname>Kivaya</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Kombe</surname>
<given-names>F</given-names></string-name>, <etal>et al.</etal>
<article-title>Strengthening the informed consent process in international health research through community engagement: The KEMRI-Wellcome Trust Research Programme Experience.</article-title>
<source>PLoS Med</source>. <year>2011</year>
<month>9</month>;<volume>8</volume>(<issue>9</issue>):<fpage>e1001089</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pmed.1001089</pub-id><pub-id pub-id-type="pmid">21931539</pub-id></mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="journal"><string-name><surname>del Carmen</surname>
<given-names>MG</given-names></string-name>, <string-name><surname>Joffe</surname>
<given-names>S</given-names></string-name>. <article-title>Informed consent for medical treatment and research: a review.</article-title>
<source>Oncologist</source>. <year>2005</year>
<month>9</month>;<volume>10</volume>(<issue>8</issue>):<fpage>636</fpage>&#x02013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1634/theoncologist.10-8-636</pub-id><pub-id pub-id-type="pmid">16177288</pub-id></mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="book"><string-name><surname>Beauchamp</surname>
<given-names>TL</given-names></string-name>, <string-name><surname>Childress</surname>
<given-names>JF</given-names></string-name>. <source>Principles of biomedical ethics.</source>
<publisher-loc>New York</publisher-loc>: <publisher-name>Oxford University Press</publisher-name>; <year>2001</year>.</mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="journal"><string-name><surname>Weijer</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Grimshaw</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Eccles</surname>
<given-names>MP</given-names></string-name>, <string-name><surname>McRae</surname>
<given-names>AD</given-names></string-name>, <string-name><surname>White</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Brehaut</surname>
<given-names>JC</given-names></string-name>, <etal>et al.</etal>; <collab>Ottawa Ethics of Cluster Randomized Trials Consensus Group</collab>. <article-title>The Ottawa Statement on the Ethical Design and Conduct of Cluster Randomized Trials.</article-title>
<source>PLoS Med</source>. <year>2012</year>;<volume>9</volume>(<issue>11</issue>):<fpage>e1001346</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pmed.1001346</pub-id><pub-id pub-id-type="pmid">23185138</pub-id></mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="journal"><string-name><surname>Sreenivasan</surname>
<given-names>G</given-names></string-name>. <article-title>Does informed consent to research require comprehension?</article-title>
<source>Lancet</source>. <year>2003</year>
<month>12</month>
<day>13</day>;<volume>362</volume>(<issue>9400</issue>):<fpage>2016</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(03)15025-8</pub-id><pub-id pub-id-type="pmid">14683665</pub-id></mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="journal"><string-name><surname>Lad</surname>
<given-names>PM</given-names></string-name>, <string-name><surname>Dahl</surname>
<given-names>R</given-names></string-name>. <article-title>Audit of the informed consent process as a part of a clinical research quality assurance program.</article-title>
<source>Sci Eng Ethics</source>. <year>2014</year>
<month>6</month>;<volume>20</volume>(<issue>2</issue>):<fpage>469</fpage>&#x02013;<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1007/s11948-013-9461-4</pub-id><pub-id pub-id-type="pmid">23975172</pub-id></mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="journal"><string-name><surname>Richardson</surname>
<given-names>V</given-names></string-name>. <article-title>Patient comprehension of informed consent.</article-title>
<source>J Perioper Pract</source>. <year>2013</year>
<season>Jan-Feb</season>;<volume>23</volume>(<issue>1-2</issue>):<fpage>26</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="pmid">23413533</pub-id></mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="journal"><string-name><surname>Bhutta</surname>
<given-names>ZA</given-names></string-name>. <article-title>Beyond informed consent.</article-title>
<source>Bull World Health Organ</source>. <year>2004</year>
<month>10</month>;<volume>82</volume>(<issue>10</issue>):<fpage>771</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">15643799</pub-id></mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="journal"><string-name><surname>Falagas</surname>
<given-names>ME</given-names></string-name>, <string-name><surname>Korbila</surname>
<given-names>IP</given-names></string-name>, <string-name><surname>Giannopoulou</surname>
<given-names>KP</given-names></string-name>, <string-name><surname>Kondilis</surname>
<given-names>BK</given-names></string-name>, <string-name><surname>Peppas</surname>
<given-names>G</given-names></string-name>. <article-title>Informed consent: how much and what do patients understand?</article-title>
<source>Am J Surg</source>. <year>2009</year>
<month>9</month>;<volume>198</volume>(<issue>3</issue>):<fpage>420</fpage>&#x02013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1016/j.amjsurg.2009.02.010</pub-id><pub-id pub-id-type="pmid">19716887</pub-id></mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="journal"><string-name><surname>Mandava</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Pace</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Campbell</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Emanuel</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Grady</surname>
<given-names>C</given-names></string-name>. <article-title>The quality of informed consent: mapping the landscape. A review of empirical data from developing and developed countries.</article-title>
<source>J Med Ethics</source>. <year>2012</year>
<month>6</month>;<volume>38</volume>(<issue>6</issue>):<fpage>356</fpage>&#x02013;<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1136/medethics-2011-100178</pub-id><pub-id pub-id-type="pmid">22313664</pub-id></mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="journal"><string-name><surname>Aromataris</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Riitano</surname>
<given-names>D</given-names></string-name>. <article-title>Constructing a search strategy and searching for evidence. A guide to the literature search for a systematic review.</article-title>
<source>Am J Nurs</source>. <year>2014</year>
<month>5</month>;<volume>114</volume>(<issue>5</issue>):<fpage>49</fpage>&#x02013;<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1097/01.NAJ.0000446779.99522.f6</pub-id><pub-id pub-id-type="pmid">24759479</pub-id></mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="other">Protection of human subjects. Code Fed Requl Public Welfare. Washington: U.S. Department of Health and Human Services; 1995 Oct 1;Title 4s: sections 46-101 to 46-409.</mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="journal"><string-name><surname>Stroup</surname>
<given-names>DF</given-names></string-name>, <string-name><surname>Berlin</surname>
<given-names>JA</given-names></string-name>, <string-name><surname>Morton</surname>
<given-names>SC</given-names></string-name>, <string-name><surname>Olkin</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Williamson</surname>
<given-names>GD</given-names></string-name>, <string-name><surname>Rennie</surname>
<given-names>D</given-names></string-name>, <etal>et al.</etal>
<article-title>Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.</article-title>
<source>JAMA</source>. <year>2000</year>
<month>4</month>
<day>19</day>;<volume>283</volume>(<issue>15</issue>):<fpage>2008</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1001/jama.283.15.2008</pub-id><pub-id pub-id-type="pmid">10789670</pub-id></mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="journal"><string-name><surname>Sedgwick</surname>
<given-names>P</given-names></string-name>. <article-title>Meta-analyses: heterogeneity and subgroup analysis.</article-title>
<source>BMJ</source>. <year>2013</year>
<month>6</month>
<day>24</day>;<volume>346</volume>
<issue>jun24 2</issue>:<fpage>f4040</fpage>
<pub-id pub-id-type="doi">10.1136/bmj.f4040</pub-id></mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="journal"><string-name><surname>Peters</surname>
<given-names>JL</given-names></string-name>, <string-name><surname>Sutton</surname>
<given-names>AJ</given-names></string-name>, <string-name><surname>Jones</surname>
<given-names>DR</given-names></string-name>, <string-name><surname>Abrams</surname>
<given-names>KR</given-names></string-name>, <string-name><surname>Rushton</surname>
<given-names>L</given-names></string-name>. <article-title>Comparison of two methods to detect publication bias in meta-analysis.</article-title>
<source>JAMA</source>. <year>2006</year>
<month>2</month>
<day>8</day>;<volume>295</volume>(<issue>6</issue>):<fpage>676</fpage>&#x02013;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1001/jama.295.6.676</pub-id><pub-id pub-id-type="pmid">16467236</pub-id></mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="journal"><string-name><surname>Duval</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Tweedie</surname>
<given-names>R</given-names></string-name>. <article-title>Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis.</article-title>
<source>Biometrics</source>. <year>2000</year>
<month>6</month>;<volume>56</volume>(<issue>2</issue>):<fpage>455</fpage>&#x02013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1111/j.0006-341X.2000.00455.x</pub-id><pub-id pub-id-type="pmid">10877304</pub-id></mixed-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="journal"><string-name><surname>Mengoli</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Cruciani</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Barnes</surname>
<given-names>RA</given-names></string-name>, <string-name><surname>Loeffler</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Donnelly</surname>
<given-names>JP</given-names></string-name>. <article-title>Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis.</article-title>
<source>Lancet Infect Dis</source>. <year>2009</year>
<month>2</month>;<volume>9</volume>(<issue>2</issue>):<fpage>89</fpage>&#x02013;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(09)70019-2</pub-id><pub-id pub-id-type="pmid">19179225</pub-id></mixed-citation></ref><ref id="R27"><label>27</label><mixed-citation publication-type="book"><string-name><surname>Kaufert</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>O'Neil</surname>
<given-names>J</given-names></string-name>. <chapter-title>Culture, power and informed consent: the impact of Aboriginal health interpreters on decision-making.</chapter-title> In: <string-name><surname>Coburn</surname>
<given-names>D</given-names></string-name>, <string-name><surname>D'Arcy</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Torrance</surname>
<given-names>G</given-names></string-name>, editors. <source>Health and Canadian society: sociological perspectives.</source>
<publisher-loc>Toronto</publisher-loc>: <publisher-name>University of Toronto Press</publisher-name>; <year>1998</year>.</mixed-citation></ref><ref id="R28"><label>28</label><mixed-citation publication-type="journal"><string-name><surname>Ellis</surname>
<given-names>RD</given-names></string-name>, <string-name><surname>Sagara</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Durbin</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Dicko</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Shaffer</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Miller</surname>
<given-names>L</given-names></string-name>, <etal>et al.</etal>
<article-title>Comparing the understanding of subjects receiving a candidate malaria vaccine in the United States and Mali.</article-title>
<source>Am J Trop Med Hyg</source>. <year>2010</year>
<month>10</month>;<volume>83</volume>(<issue>4</issue>):<fpage>868</fpage>&#x02013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.4269/ajtmh.2010.10-0062</pub-id><pub-id pub-id-type="pmid">20889881</pub-id></mixed-citation></ref><ref id="R29"><label>29</label><mixed-citation publication-type="journal"><string-name><surname>Vallely</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Lees</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Shagi</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Kasindi</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Soteli</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Kavit</surname>
<given-names>N</given-names></string-name>, <etal>et al.</etal>; <collab>Microbicides Development Programme (MDP)</collab>. <article-title>How informed is consent in vulnerable populations? Experience using a continuous consent process during the MDP301 vaginal microbicide trial in Mwanza, Tanzania.</article-title>
<source>BMC Med Ethics</source>. <year>2010</year>;<volume>11</volume>(<issue>1</issue>):<fpage>10</fpage>. <pub-id pub-id-type="doi">10.1186/1472-6939-11-10</pub-id><pub-id pub-id-type="pmid">20540803</pub-id></mixed-citation></ref><ref id="R30"><label>30</label><mixed-citation publication-type="journal"><string-name><surname>Hill</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Tawiah-Agyemang</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Odei-Danso</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Kirkwood</surname>
<given-names>B</given-names></string-name>. <article-title>Informed consent in Ghana: what do participants really understand?</article-title>
<source>J Med Ethics</source>. <year>2008</year>
<month>1</month>;<volume>34</volume>(<issue>1</issue>):<fpage>48</fpage>&#x02013;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1136/jme.2006.019059</pub-id><pub-id pub-id-type="pmid">18156522</pub-id></mixed-citation></ref><ref id="R31"><label>31</label><mixed-citation publication-type="journal"><string-name><surname>Minnies</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Hawkridge</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Hanekom</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Ehrlich</surname>
<given-names>R</given-names></string-name>, <string-name><surname>London</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Hussey</surname>
<given-names>G</given-names></string-name>. <article-title>Evaluation of the quality of informed consent in a vaccine field trial in a developing country setting.</article-title>
<source>BMC Med Ethics</source>. <year>2008</year>;<volume>9</volume>(<issue>1</issue>):<fpage>15</fpage>. <pub-id pub-id-type="doi">10.1186/1472-6939-9-15</pub-id><pub-id pub-id-type="pmid">18826637</pub-id></mixed-citation></ref><ref id="R32"><label>32</label><mixed-citation publication-type="journal"><string-name><surname>Kaewpoonsri</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Okanurak</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Kitayaporn</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Kaewkungwal</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Vijaykadga</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Thamaree</surname>
<given-names>S</given-names></string-name>. <article-title>Factors related to volunteer comprehension of informed consent for a clinical trial.</article-title>
<source>Southeast Asian J Trop Med Public Health</source>. <year>2006</year>
<month>9</month>;<volume>37</volume>(<issue>5</issue>):<fpage>996</fpage>&#x02013;<lpage>1004</lpage>.<pub-id pub-id-type="pmid">17333746</pub-id></mixed-citation></ref><ref id="R33"><label>33</label><mixed-citation publication-type="journal"><string-name><surname>Krosin</surname>
<given-names>MT</given-names></string-name>, <string-name><surname>Klitzman</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Levin</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Cheng</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Ranney</surname>
<given-names>ML</given-names></string-name>. <article-title>Problems in comprehension of informed consent in rural and peri-urban Mali, West Africa.</article-title>
<source>Clin Trials</source>. <year>2006</year>;<volume>3</volume>(<issue>3</issue>):<fpage>306</fpage>&#x02013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1191/1740774506cn150oa</pub-id><pub-id pub-id-type="pmid">16895047</pub-id></mixed-citation></ref><ref id="R34"><label>34</label><mixed-citation publication-type="journal"><string-name><surname>Moodley</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Pather</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Myer</surname>
<given-names>L</given-names></string-name>. <article-title>Informed consent and participant perceptions of influenza vaccine trials in South Africa.</article-title>
<source>J Med Ethics</source>. <year>2005</year>
<month>12</month>;<volume>31</volume>(<issue>12</issue>):<fpage>727</fpage>&#x02013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1136/jme.2004.009910</pub-id><pub-id pub-id-type="pmid">16319239</pub-id></mixed-citation></ref><ref id="R35"><label>35</label><mixed-citation publication-type="journal"><string-name><surname>Pace</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Emanuel</surname>
<given-names>EJ</given-names></string-name>, <string-name><surname>Chuenyam</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Duncombe</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Bebchuk</surname>
<given-names>JD</given-names></string-name>, <string-name><surname>Wendler</surname>
<given-names>D</given-names></string-name>, <etal>et al.</etal>
<article-title>The quality of informed consent in a clinical research study in Thailand.</article-title>
<source>IRB</source>. <year>2005</year>
<season>Jan-Feb</season>;<volume>27</volume>(<issue>1</issue>):<fpage>9</fpage>&#x02013;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.2307/3563866</pub-id><pub-id pub-id-type="pmid">15835065</pub-id></mixed-citation></ref><ref id="R36"><label>36</label><mixed-citation publication-type="journal"><string-name><surname>Pace</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Talisuna</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Wendler</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Maiso</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Wabwire-Mangen</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Bakyaita</surname>
<given-names>N</given-names></string-name>, <etal>et al.</etal>
<article-title>Quality of parental consent in a Ugandan malaria study.</article-title>
<source>Am J Public Health</source>. <year>2005</year>
<month>7</month>;<volume>95</volume>(<issue>7</issue>):<fpage>1184</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.2105/AJPH.2004.053082</pub-id><pub-id pub-id-type="pmid">15933235</pub-id></mixed-citation></ref><ref id="R37"><label>37</label><mixed-citation publication-type="journal"><collab>ANRS1201/1202 Ditrame Plus Study Group</collab>. <article-title>Obtaining informed consent from HIV-infected pregnant women, Abidjan, C&#x000f4;te d&#x02019;Ivoire.</article-title>
<source>AIDS</source>. <year>2004</year>
<month>7</month>
<day>2</day>;<volume>18</volume>(<issue>10</issue>):<fpage>1486</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1097/01.aids.0000131349.22032.63</pub-id><pub-id pub-id-type="pmid">15199334</pub-id></mixed-citation></ref><ref id="R38"><label>38</label><mixed-citation publication-type="journal"><string-name><surname>Joubert</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Steinberg</surname>
<given-names>H</given-names></string-name>, <string-name><surname>van der Ryst</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Chikobvu</surname>
<given-names>P</given-names></string-name>. <article-title>Consent for participation in the Bloemfontein vitamin A trial: how informed and voluntary?</article-title>
<source>Am J Public Health</source>. <year>2003</year>
<month>4</month>;<volume>93</volume>(<issue>4</issue>):<fpage>582</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.2105/AJPH.93.4.582</pub-id><pub-id pub-id-type="pmid">12660201</pub-id></mixed-citation></ref><ref id="R39"><label>39</label><mixed-citation publication-type="journal"><string-name><surname>Lyn&#x000f6;e</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Hyder</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Chowdhury</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Ekstr&#x000f6;m</surname>
<given-names>L</given-names></string-name>. <article-title>Obtaining informed consent in Bangladesh.</article-title>
<source>N Engl J Med</source>. <year>2001</year>
<month>2</month>
<day>8</day>;<volume>344</volume>(<issue>6</issue>):<fpage>460</fpage>&#x02013;<lpage>1</lpage>. <pub-id pub-id-type="doi">10.1056/NEJM200102083440617</pub-id><pub-id pub-id-type="pmid">11221611</pub-id></mixed-citation></ref><ref id="R40"><label>40</label><mixed-citation publication-type="journal"><string-name><surname>Lyn&#x000f6;e</surname>
<given-names>N</given-names></string-name>, <string-name><surname>N&#x000e4;sstr&#x000f6;m</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Sandlund</surname>
<given-names>M</given-names></string-name>. <article-title>Study of the quality of information given to patients participating in a clinical trial regarding chronic hemodialysis.</article-title>
<source>Scand J Urol Nephrol</source>. <year>2004</year>;<volume>38</volume>(<issue>6</issue>):<fpage>517</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1080/00365590410033362</pub-id><pub-id pub-id-type="pmid">15841789</pub-id></mixed-citation></ref><ref id="R41"><label>41</label><mixed-citation publication-type="journal"><string-name><surname>Lyn&#x000f6;e</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Sandlund</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Dahlqvist</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Jacobsson</surname>
<given-names>L</given-names></string-name>. <article-title>Informed consent: study of quality of information given to participants in a clinical trial.</article-title>
<source>BMJ</source>. <year>1991</year>
<month>9</month>
<day>14</day>;<volume>303</volume>(<issue>6803</issue>):<fpage>610</fpage>&#x02013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1136/bmj.303.6803.610</pub-id><pub-id pub-id-type="pmid">1932901</pub-id></mixed-citation></ref><ref id="R42"><label>42</label><mixed-citation publication-type="journal"><string-name><surname>Lyn&#x000f6;e</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Boman</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Andersson</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Sandlund</surname>
<given-names>M</given-names></string-name>. <article-title>Informed consent and participants&#x02019; inclination to delegate decision-making to the doctor.</article-title>
<source>Acta Oncol</source>. <year>2004</year>;<volume>43</volume>(<issue>8</issue>):<fpage>769</fpage>. <pub-id pub-id-type="doi">10.1080/02841860410002734</pub-id><pub-id pub-id-type="pmid">15764224</pub-id></mixed-citation></ref><ref id="R43"><label>43</label><mixed-citation publication-type="journal"><string-name><surname>Lyn&#x000f6;e</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Sandlund</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Jacobsson</surname>
<given-names>L</given-names></string-name>. <article-title>Informed consent in two Swedish prisons: a study of quality of information and reasons for participating in a clinical trial.</article-title>
<source>Med Law</source>. <year>2001</year>;<volume>20</volume>(<issue>4</issue>):<fpage>515</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="pmid">11817382</pub-id></mixed-citation></ref><ref id="R44"><label>44</label><mixed-citation publication-type="journal"><string-name><surname>Leach</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Hilton</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Greenwood</surname>
<given-names>BM</given-names></string-name>, <string-name><surname>Manneh</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Dibba</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Wilkins</surname>
<given-names>A</given-names></string-name>, <etal>et al.</etal>
<article-title>An evaluation of the informed consent procedure used during a trial of a Haemophilus influenzae type B conjugate vaccine undertaken in the Gambia, West Africa.</article-title>
<source>Soc Sci Med</source>. <year>1999</year>
<month>1</month>;<volume>48</volume>(<issue>2</issue>):<fpage>139</fpage>&#x02013;<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1016/S0277-9536(98)00317-7</pub-id><pub-id pub-id-type="pmid">10048773</pub-id></mixed-citation></ref><ref id="R45"><label>45</label><mixed-citation publication-type="journal"><string-name><surname>Pitisuttithum</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Migasena</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Laothai</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Suntharasamai</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Kumpong</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Vanichseni</surname>
<given-names>S</given-names></string-name>. <article-title>Risk behaviours and comprehension among intravenous drug users volunteered for HIV vaccine trial.</article-title>
<source>J Med Assoc Thai</source>. <year>1997</year>
<month>1</month>;<volume>80</volume>(<issue>1</issue>):<fpage>47</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="pmid">9078816</pub-id></mixed-citation></ref><ref id="R46"><label>46</label><mixed-citation publication-type="journal"><string-name><surname>Bergenmar</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Molin</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Wilking</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Brandberg</surname>
<given-names>Y</given-names></string-name>. <article-title>Knowledge and understanding among cancer patients consenting to participate in clinical trials.</article-title>
<source>Eur J Cancer</source>. <year>2008</year>
<month>11</month>;<volume>44</volume>(<issue>17</issue>):<fpage>2627</fpage>&#x02013;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejca.2008.08.013</pub-id><pub-id pub-id-type="pmid">18818068</pub-id></mixed-citation></ref><ref id="R47"><label>47</label><mixed-citation publication-type="journal"><string-name><surname>Knifed</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Lipsman</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Mason</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Bernstein</surname>
<given-names>M</given-names></string-name>. <article-title>Patients&#x02019; perception of the informed consent process for neurooncology clinical trials.</article-title>
<source>Neuro-oncol</source>. <year>2008</year>
<month>6</month>;<volume>10</volume>(<issue>3</issue>):<fpage>348</fpage>&#x02013;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1215/15228517-2008-007</pub-id><pub-id pub-id-type="pmid">18388256</pub-id></mixed-citation></ref><ref id="R48"><label>48</label><mixed-citation publication-type="journal"><string-name><surname>Agrawal</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Grady</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Fairclough</surname>
<given-names>DL</given-names></string-name>, <string-name><surname>Meropol</surname>
<given-names>NJ</given-names></string-name>, <string-name><surname>Maynard</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Emanuel</surname>
<given-names>EJ</given-names></string-name>. <article-title>Patients&#x02019; decision-making process regarding participation in phase I oncology research.</article-title>
<source>J Clin Oncol</source>. <year>2006</year>
<month>9</month>
<day>20</day>;<volume>24</volume>(<issue>27</issue>):<fpage>4479</fpage>&#x02013;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2006.06.0269</pub-id><pub-id pub-id-type="pmid">16983117</pub-id></mixed-citation></ref><ref id="R49"><label>49</label><mixed-citation publication-type="journal"><string-name><surname>Franck</surname>
<given-names>LS</given-names></string-name>, <string-name><surname>Winter</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Oulton</surname>
<given-names>K</given-names></string-name>. <article-title>The quality of parental consent for research with children: a prospective repeated measure self-report survey.</article-title>
<source>Int J Nurs Stud</source>. <year>2007</year>
<month>5</month>;<volume>44</volume>(<issue>4</issue>):<fpage>525</fpage>&#x02013;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijnurstu.2006.03.014</pub-id><pub-id pub-id-type="pmid">16712850</pub-id></mixed-citation></ref><ref id="R50"><label>50</label><mixed-citation publication-type="journal"><string-name><surname>Gammelgaard</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Mortensen</surname>
<given-names>OS</given-names></string-name>, <string-name><surname>Rossel</surname>
<given-names>P</given-names></string-name>; <collab>DANAMI-2 Investigators</collab>. <article-title>Patients&#x02019; perceptions of informed consent in acute myocardial infarction research: a questionnaire based survey of the consent process in the DANAMI-2 trial.</article-title>
<source>Heart</source>. <year>2004</year>
<month>10</month>;<volume>90</volume>(<issue>10</issue>):<fpage>1124</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1136/hrt.2003.021931</pub-id><pub-id pub-id-type="pmid">15367504</pub-id></mixed-citation></ref><ref id="R51"><label>51</label><mixed-citation publication-type="journal"><string-name><surname>Kodish</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Eder</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Noll</surname>
<given-names>RB</given-names></string-name>, <string-name><surname>Ruccione</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Lange</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Angiolillo</surname>
<given-names>A</given-names></string-name>, <etal>et al.</etal>
<article-title>Communication of randomization in childhood leukemia trials.</article-title>
<source>JAMA</source>. <year>2004</year>
<month>1</month>
<day>28</day>;<volume>291</volume>(<issue>4</issue>):<fpage>470</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1001/jama.291.4.470</pub-id><pub-id pub-id-type="pmid">14747504</pub-id></mixed-citation></ref><ref id="R52"><label>52</label><mixed-citation publication-type="journal"><string-name><surname>Criscione</surname>
<given-names>LG</given-names></string-name>, <string-name><surname>Sugarman</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Sanders</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Pisetsky</surname>
<given-names>DS</given-names></string-name>, <string-name><surname>St Clair</surname>
<given-names>EW</given-names></string-name>. <article-title>Informed consent in a clinical trial of a novel treatment for rheumatoid arthritis.</article-title>
<source>Arthritis Rheum</source>. <year>2003</year>
<month>6</month>
<day>15</day>;<volume>49</volume>(<issue>3</issue>):<fpage>361</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1002/art.11057</pub-id><pub-id pub-id-type="pmid">12794792</pub-id></mixed-citation></ref><ref id="R53"><label>53</label><mixed-citation publication-type="journal"><string-name><surname>Kupst</surname>
<given-names>MJ</given-names></string-name>, <string-name><surname>Patenaude</surname>
<given-names>AF</given-names></string-name>, <string-name><surname>Walco</surname>
<given-names>GA</given-names></string-name>, <string-name><surname>Sterling</surname>
<given-names>C</given-names></string-name>. <article-title>Clinical trials in pediatric cancer: parental perspectives on informed consent.</article-title>
<source>J Pediatr Hematol Oncol</source>. <year>2003</year>
<month>10</month>;<volume>25</volume>(<issue>10</issue>):<fpage>787</fpage>&#x02013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1097/00043426-200310000-00009</pub-id><pub-id pub-id-type="pmid">14528101</pub-id></mixed-citation></ref><ref id="R54"><label>54</label><mixed-citation publication-type="journal"><string-name><surname>Pope</surname>
<given-names>JE</given-names></string-name>, <string-name><surname>Tingey</surname>
<given-names>DP</given-names></string-name>, <string-name><surname>Arnold</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Hong</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Ouimet</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Krizova</surname>
<given-names>A</given-names></string-name>. <article-title>Are subjects satisfied with the informed consent process? A survey of research participants.</article-title>
<source>J Rheumatol</source>. <year>2003</year>
<month>4</month>;<volume>30</volume>(<issue>4</issue>):<fpage>815</fpage>&#x02013;<lpage>24</lpage>.<pub-id pub-id-type="pmid">12672205</pub-id></mixed-citation></ref><ref id="R55"><label>55</label><mixed-citation publication-type="journal"><string-name><surname>Schats</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Brilstra</surname>
<given-names>EH</given-names></string-name>, <string-name><surname>Rinkel</surname>
<given-names>GJ</given-names></string-name>, <string-name><surname>Algra</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Van Gijn</surname>
<given-names>J</given-names></string-name>. <article-title>Informed consent in trials for neurological emergencies: the example of subarachnoid haemorrhage.</article-title>
<source>J Neurol Neurosurg Psychiatry</source>. <year>2003</year>
<month>7</month>;<volume>74</volume>(<issue>7</issue>):<fpage>988</fpage>&#x02013;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1136/jnnp.74.7.988</pub-id><pub-id pub-id-type="pmid">12810803</pub-id></mixed-citation></ref><ref id="R56"><label>56</label><mixed-citation publication-type="journal"><string-name><surname>Simon</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Zyzanski</surname>
<given-names>SJ</given-names></string-name>, <string-name><surname>Eder</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Raiz</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Kodish</surname>
<given-names>ED</given-names></string-name>, <string-name><surname>Siminoff</surname>
<given-names>LA</given-names></string-name>. <article-title>Groups potentially at risk for making poorly informed decisions about entry into clinical trials for childhood cancer.</article-title>
<source>J Clin Oncol</source>. <year>2003</year>
<month>6</month>
<day>1</day>;<volume>21</volume>(<issue>11</issue>):<fpage>2173</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2003.03.003</pub-id><pub-id pub-id-type="pmid">12775743</pub-id></mixed-citation></ref><ref id="R57"><label>57</label><mixed-citation publication-type="journal"><string-name><surname>Joffe</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Cook</surname>
<given-names>EF</given-names></string-name>, <string-name><surname>Cleary</surname>
<given-names>PD</given-names></string-name>, <string-name><surname>Clark</surname>
<given-names>JW</given-names></string-name>, <string-name><surname>Weeks</surname>
<given-names>JC</given-names></string-name>. <article-title>Quality of informed consent in cancer clinical trials: a cross-sectional survey.</article-title>
<source>Lancet</source>. <year>2001</year>
<month>11</month>
<day>24</day>;<volume>358</volume>(<issue>9295</issue>):<fpage>1772</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(01)06805-2</pub-id><pub-id pub-id-type="pmid">11734235</pub-id></mixed-citation></ref><ref id="R58"><label>58</label><mixed-citation publication-type="journal"><string-name><surname>Daugherty</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Ratain</surname>
<given-names>MJ</given-names></string-name>, <string-name><surname>Grochowski</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Stocking</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Kodish</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Mick</surname>
<given-names>R</given-names></string-name>, <etal>et al.</etal>
<article-title>Perceptions of cancer patients and their physicians involved in phase I trials.</article-title>
<source>J Clin Oncol</source>. <year>1995</year>
<month>5</month>;<volume>13</volume>(<issue>5</issue>):<fpage>1062</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="pmid">7738612</pub-id></mixed-citation></ref><ref id="R59"><label>59</label><mixed-citation publication-type="journal"><string-name><surname>Daugherty</surname>
<given-names>CK</given-names></string-name>, <string-name><surname>Banik</surname>
<given-names>DM</given-names></string-name>, <string-name><surname>Janish</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Ratain</surname>
<given-names>MJ</given-names></string-name>. <article-title>Quantitative analysis of ethical issues in phase I trials: a survey interview of 144 advanced cancer patients.</article-title>
<source>IRB</source>. <year>2000</year>
<season>May-Jun</season>;<volume>22</volume>(<issue>3</issue>):<fpage>6</fpage>&#x02013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.2307/3564113</pub-id><pub-id pub-id-type="pmid">11697385</pub-id></mixed-citation></ref><ref id="R60"><label>60</label><mixed-citation publication-type="journal"><string-name><surname>Hietanen</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Aro</surname>
<given-names>AR</given-names></string-name>, <string-name><surname>Holli</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Absetz</surname>
<given-names>P</given-names></string-name>. <article-title>Information and communication in the context of a clinical trial.</article-title>
<source>Eur J Cancer</source>. <year>2000</year>
<month>10</month>;<volume>36</volume>(<issue>16</issue>):<fpage>2096</fpage>&#x02013;<lpage>104</lpage>. <pub-id pub-id-type="doi">10.1016/S0959-8049(00)00191-X</pub-id><pub-id pub-id-type="pmid">11044647</pub-id></mixed-citation></ref><ref id="R61"><label>61</label><mixed-citation publication-type="journal"><string-name><surname>Montgomery</surname>
<given-names>JE</given-names></string-name>, <string-name><surname>Sneyd</surname>
<given-names>JR</given-names></string-name>. <article-title>Consent to clinical trials in anaesthesia.</article-title>
<source>Anaesthesia</source>. <year>1998</year>
<month>3</month>;<volume>53</volume>(<issue>3</issue>):<fpage>227</fpage>&#x02013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1046/j.1365-2044.1998.00309.x</pub-id><pub-id pub-id-type="pmid">9613266</pub-id></mixed-citation></ref><ref id="R62"><label>62</label><mixed-citation publication-type="journal"><string-name><surname>van Stuijvenberg</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Suur</surname>
<given-names>MH</given-names></string-name>, <string-name><surname>de Vos</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Tjiang</surname>
<given-names>GC</given-names></string-name>, <string-name><surname>Steyerberg</surname>
<given-names>EW</given-names></string-name>, <string-name><surname>Derksen-Lubsen</surname>
<given-names>G</given-names></string-name>, <etal>et al.</etal>
<article-title>Informed consent, parental awareness, and reasons for participating in a randomised controlled study.</article-title>
<source>Arch Dis Child</source>. <year>1998</year>
<month>8</month>;<volume>79</volume>(<issue>2</issue>):<fpage>120</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1136/adc.79.2.120</pub-id><pub-id pub-id-type="pmid">9797591</pub-id></mixed-citation></ref><ref id="R63"><label>63</label><mixed-citation publication-type="journal"><string-name><surname>Harrison</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Vlahov</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Jones</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Charron</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Clements</surname>
<given-names>ML</given-names></string-name>. <article-title>Medical eligibility, comprehension of the consent process, and retention of injection drug users recruited for an HIV vaccine trial.</article-title>
<source>J Acquir Immune Defic Syndr Hum Retrovirol</source>. <year>1995</year>
<month>11</month>
<day>1</day>;<volume>10</volume>(<issue>3</issue>):<fpage>386</fpage>&#x02013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1097/00042560-199511000-00012</pub-id><pub-id pub-id-type="pmid">7552502</pub-id></mixed-citation></ref><ref id="R64"><label>64</label><mixed-citation publication-type="journal"><string-name><surname>Harth</surname>
<given-names>SC</given-names></string-name>, <string-name><surname>Thong</surname>
<given-names>YH</given-names></string-name>. <article-title>Parental perceptions and attitudes about informed consent in clinical research involving children.</article-title>
<source>Soc Sci Med</source>. <year>1995</year>
<month>6</month>;<volume>40</volume>(<issue>11</issue>):<fpage>1573</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/0277-9536(94)00412-M</pub-id><pub-id pub-id-type="pmid">7667661</pub-id></mixed-citation></ref><ref id="R65"><label>65</label><mixed-citation publication-type="journal"><string-name><surname>Estey</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Wilkin</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Dossetor</surname>
<given-names>J</given-names></string-name>. <article-title>Are research subjects able to retain the information they are given during the consent process.</article-title>
<source>Health Law Rev</source>. <year>1994</year>;<volume>3</volume>:<fpage>37</fpage>&#x02013;<lpage>41</lpage>.</mixed-citation></ref><ref id="R66"><label>66</label><mixed-citation publication-type="journal"><string-name><surname>Howard</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>DeMets</surname>
<given-names>D</given-names></string-name>. <article-title>How informed is informed consent? The BHAT experience.</article-title>
<source>Control Clin Trials</source>. <year>1981</year>
<month>12</month>;<volume>2</volume>(<issue>4</issue>):<fpage>287</fpage>&#x02013;<lpage>303</lpage>. <pub-id pub-id-type="doi">10.1016/0197-2456(81)90019-2</pub-id><pub-id pub-id-type="pmid">6120794</pub-id></mixed-citation></ref><ref id="R67"><label>67</label><mixed-citation publication-type="journal"><string-name><surname>Griffin</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Struve</surname>
<given-names>JK</given-names></string-name>, <string-name><surname>Collins</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Nelson</surname>
<given-names>DB</given-names></string-name>, <string-name><surname>Bloomfield</surname>
<given-names>HE</given-names></string-name>. <article-title>Long term clinical trials: how much information do participants retain from the informed consent process?</article-title>
<source>Contemp Clin Trials</source>. <year>2006</year>
<month>10</month>;<volume>27</volume>(<issue>5</issue>):<fpage>441</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.cct.2006.04.006</pub-id><pub-id pub-id-type="pmid">16798101</pub-id></mixed-citation></ref><ref id="R68"><label>68</label><mixed-citation publication-type="journal"><string-name><surname>Guarino</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Lamping</surname>
<given-names>DL</given-names></string-name>, <string-name><surname>Elbourne</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Carpenter</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Peduzzi</surname>
<given-names>P</given-names></string-name>. <article-title>A brief measure of perceived understanding of informed consent in a clinical trial was validated.</article-title>
<source>J Clin Epidemiol</source>. <year>2006</year>
<month>6</month>;<volume>59</volume>(<issue>6</issue>):<fpage>608</fpage>&#x02013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1016/j.jclinepi.2005.11.009</pub-id><pub-id pub-id-type="pmid">16713523</pub-id></mixed-citation></ref><ref id="R69"><label>69</label><mixed-citation publication-type="journal"><string-name><surname>Barrett</surname>
<given-names>R</given-names></string-name>. <article-title>Quality of informed consent: measuring understanding among participants in oncology clinical trials.</article-title>
<source>Oncol Nurs Forum</source>. <year>2005</year>
<month>7</month>;<volume>32</volume>(<issue>4</issue>):<fpage>751</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1188/05.ONF.751-755</pub-id><pub-id pub-id-type="pmid">15990904</pub-id></mixed-citation></ref><ref id="R70"><label>70</label><mixed-citation publication-type="journal"><string-name><surname>Sugarman</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Lavori</surname>
<given-names>PW</given-names></string-name>, <string-name><surname>Boeger</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Cain</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Edsond</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Morrison</surname>
<given-names>V</given-names></string-name>, <etal>et al.</etal>
<article-title>Evaluating the quality of informed consent.</article-title>
<source>Clin Trials</source>. <year>2005</year>;<volume>2</volume>(<issue>1</issue>):<fpage>34</fpage>&#x02013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1191/1740774505cn066oa</pub-id><pub-id pub-id-type="pmid">16279577</pub-id></mixed-citation></ref><ref id="R71"><label>71</label><mixed-citation publication-type="journal"><string-name><surname>Simon</surname>
<given-names>CM</given-names></string-name>, <string-name><surname>Siminoff</surname>
<given-names>LA</given-names></string-name>, <string-name><surname>Kodish</surname>
<given-names>ED</given-names></string-name>, <string-name><surname>Burant</surname>
<given-names>C</given-names></string-name>. <article-title>Comparison of the informed consent process for randomized clinical trials in pediatric and adult oncology.</article-title>
<source>J Clin Oncol</source>. <year>2004</year>
<month>7</month>
<day>1</day>;<volume>22</volume>(<issue>13</issue>):<fpage>2708</fpage>&#x02013;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2004.10.034</pub-id><pub-id pub-id-type="pmid">15226338</pub-id></mixed-citation></ref><ref id="R72"><label>72</label><mixed-citation publication-type="journal"><string-name><surname>Pentz</surname>
<given-names>RD</given-names></string-name>, <string-name><surname>Flamm</surname>
<given-names>AL</given-names></string-name>, <string-name><surname>Sugarman</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Cohen</surname>
<given-names>MZ</given-names></string-name>, <string-name><surname>Daniel Ayers</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Herbst</surname>
<given-names>RS</given-names></string-name>, <etal>et al.</etal>
<article-title>Study of the media&#x02019;s potential influence on prospective research participants&#x02019; understanding of and motivations for participation in a high-profile phase I trial.</article-title>
<source>J Clin Oncol</source>. <year>2002</year>
<month>9</month>
<day>15</day>;<volume>20</volume>(<issue>18</issue>):<fpage>3785</fpage>&#x02013;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2002.04.084</pub-id><pub-id pub-id-type="pmid">12228198</pub-id></mixed-citation></ref><ref id="R73"><label>73</label><mixed-citation publication-type="journal"><string-name><surname>Cohen</surname>
<given-names>L</given-names></string-name>, <string-name><surname>de Moor</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Amato</surname>
<given-names>RJ</given-names></string-name>. <article-title>The association between treatment-specific optimism and depressive symptomatology in patients enrolled in a phase I cancer clinical trial.</article-title>
<source>Cancer</source>. <year>2001</year>
<month>5</month>
<day>15</day>;<volume>91</volume>(<issue>10</issue>):<fpage>1949</fpage>&#x02013;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1002/1097-0142(20010515)91:10&#x0003c;1949::AID-CNCR1218&#x0003e;3.0.CO;2-A</pub-id><pub-id pub-id-type="pmid">11346878</pub-id></mixed-citation></ref><ref id="R74"><label>74</label><mixed-citation publication-type="journal"><string-name><surname>Fortney</surname>
<given-names>JA</given-names></string-name>. <article-title>Assessing recall and understanding of informed consent in a contraceptive clinical trial.</article-title>
<source>Stud Fam Plann</source>. <year>1999</year>
<month>12</month>;<volume>30</volume>(<issue>4</issue>):<fpage>339</fpage>&#x02013;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1111/j.1728-4465.1999.t01-5-.x</pub-id><pub-id pub-id-type="pmid">10674329</pub-id></mixed-citation></ref><ref id="R75"><label>75</label><mixed-citation publication-type="journal"><string-name><surname>Hutchison</surname>
<given-names>C</given-names></string-name>. <article-title>Phase I trials in cancer patients: participants&#x02019; perceptions.</article-title>
<source>Eur J Cancer Care (Engl)</source>. <year>1998</year>
<month>3</month>;<volume>7</volume>(<issue>1</issue>):<fpage>15</fpage>&#x02013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1046/j.1365-2354.1998.00062.x</pub-id><pub-id pub-id-type="pmid">9582747</pub-id></mixed-citation></ref><ref id="R76"><label>76</label><mixed-citation publication-type="journal"><string-name><surname>N&#x000e9;grier</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Lanier-Demma</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Lacroix-Kante</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Chauvin</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Saltel</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Mercatello</surname>
<given-names>A</given-names></string-name>, <etal>et al.</etal>
<article-title>Evaluation of the informed consent procedure in cancer patients candidate to immunotherapy.</article-title>
<source>Eur J Cancer</source>. <year>1995</year>
<month>9</month>;<volume>31A</volume>(<issue>10</issue>):<fpage>1650</fpage>&#x02013;<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1016/0959-8049(95)00329-H</pub-id><pub-id pub-id-type="pmid">7488418</pub-id></mixed-citation></ref><ref id="R77"><label>77</label><mixed-citation publication-type="journal"><string-name><surname>Tankanow</surname>
<given-names>RM</given-names></string-name>, <string-name><surname>Sweet</surname>
<given-names>BV</given-names></string-name>, <string-name><surname>Weiskopf</surname>
<given-names>JA</given-names></string-name>. <article-title>Patients&#x02019; perceived understanding of informed consent in investigational drug studies.</article-title>
<source>Am J Hosp Pharm</source>. <year>1992</year>
<month>3</month>;<volume>49</volume>(<issue>3</issue>):<fpage>633</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">1598945</pub-id></mixed-citation></ref><ref id="R78"><label>78</label><mixed-citation publication-type="journal"><string-name><surname>Rodenhuis</surname>
<given-names>S</given-names></string-name>, <string-name><surname>van den Heuvel</surname>
<given-names>WJ</given-names></string-name>, <string-name><surname>Annyas</surname>
<given-names>AA</given-names></string-name>, <string-name><surname>Koops</surname>
<given-names>HS</given-names></string-name>, <string-name><surname>Sleijfer</surname>
<given-names>DT</given-names></string-name>, <string-name><surname>Mulder</surname>
<given-names>NH</given-names></string-name>. <article-title>Patient motivation and informed consent in a phase I study of an anticancer agent.</article-title>
<source>Eur J Cancer Clin Oncol</source>. <year>1984</year>
<month>4</month>;<volume>20</volume>(<issue>4</issue>):<fpage>457</fpage>&#x02013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/0277-5379(84)90229-3</pub-id><pub-id pub-id-type="pmid">6539201</pub-id></mixed-citation></ref><ref id="R79"><label>79</label><mixed-citation publication-type="journal"><string-name><surname>Penman</surname>
<given-names>DT</given-names></string-name>, <string-name><surname>Holland</surname>
<given-names>JC</given-names></string-name>, <string-name><surname>Bahna</surname>
<given-names>GF</given-names></string-name>, <string-name><surname>Morrow</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Schmale</surname>
<given-names>AH</given-names></string-name>, <string-name><surname>Derogatis</surname>
<given-names>LR</given-names></string-name>, <etal>et al.</etal>
<article-title>Informed consent for investigational chemotherapy: patients&#x02019; and physicians&#x02019; perceptions.</article-title>
<source>J Clin Oncol</source>. <year>1984</year>
<month>7</month>;<volume>2</volume>(<issue>7</issue>):<fpage>849</fpage>&#x02013;<lpage>55</lpage>.<pub-id pub-id-type="pmid">6737023</pub-id></mixed-citation></ref><ref id="R80"><label>80</label><mixed-citation publication-type="journal"><string-name><surname>Goodman</surname>
<given-names>NW</given-names></string-name>, <string-name><surname>Cooper</surname>
<given-names>GM</given-names></string-name>, <string-name><surname>Malins</surname>
<given-names>AF</given-names></string-name>, <string-name><surname>Prys-Roberts</surname>
<given-names>C</given-names></string-name>. <article-title>The validity of informed consent in a clinical study.</article-title>
<source>Anaesthesia</source>. <year>1984</year>
<month>9</month>;<volume>39</volume>(<issue>9</issue>):<fpage>911</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2044.1984.tb06582.x</pub-id><pub-id pub-id-type="pmid">6545095</pub-id></mixed-citation></ref><ref id="R81"><label>81</label><mixed-citation publication-type="journal"><string-name><surname>Riecken</surname>
<given-names>HW</given-names></string-name>, <string-name><surname>Ravich</surname>
<given-names>R</given-names></string-name>. <article-title>Informed consent to biomedical research in Veterans Administration Hospitals.</article-title>
<source>JAMA</source>. <year>1982</year>
<month>7</month>
<day>16</day>;<volume>248</volume>(<issue>3</issue>):<fpage>344</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1001/jama.1982.03330030050025</pub-id><pub-id pub-id-type="pmid">7045434</pub-id></mixed-citation></ref><ref id="R82"><label>82</label><mixed-citation publication-type="journal"><string-name><surname>Bergler</surname>
<given-names>JH</given-names></string-name>, <string-name><surname>Pennington</surname>
<given-names>AC</given-names></string-name>, <string-name><surname>Metcalfe</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Freis</surname>
<given-names>ED</given-names></string-name>. <article-title>Informed consent: how much does the patient understand?</article-title>
<source>Clin Pharmacol Ther</source>. <year>1980</year>
<month>4</month>;<volume>27</volume>(<issue>4</issue>):<fpage>435</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1038/clpt.1980.60</pub-id><pub-id pub-id-type="pmid">6987027</pub-id></mixed-citation></ref><ref id="R83"><label>83</label><mixed-citation publication-type="journal"><string-name><surname>Ritsuko</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Noda</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Etsuko</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Etsuko</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Tomoko</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Midori</surname>
<given-names>N</given-names></string-name>, <etal>et al.</etal> [<article-title>Survey of participants to clinical trial in Fukuoka university hospital: relationship between the participant's understanding of informed consent and their feeling of unease for clinical trials].</article-title>
<source>Fukuoka Daigaku Igaku Kiy&#x0014d;.</source>
<year>2006</year>;<volume>33</volume>(<issue>1</issue>):<fpage>25</fpage>&#x02013;<lpage>9</lpage>. <comment>Japanese.</comment></mixed-citation></ref><ref id="R84"><label>84</label><mixed-citation publication-type="journal"><collab>Paediatric European Network for Treatment of AIDS</collab>. <article-title>Parents&#x02019; attitudes to their HIV-infected children being enrolled into a placebo-controlled trial: the PENTA 1 trial.</article-title>
<source>HIV Med</source>. <year>1999</year>
<month>10</month>;<volume>1</volume>(<issue>1</issue>):<fpage>25</fpage>&#x02013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1046/j.1468-1293.1999.00005.x</pub-id><pub-id pub-id-type="pmid">11737326</pub-id></mixed-citation></ref><ref id="R85"><label>85</label><mixed-citation publication-type="journal"><string-name><surname>Ballard</surname>
<given-names>HO</given-names></string-name>, <string-name><surname>Shook</surname>
<given-names>LA</given-names></string-name>, <string-name><surname>Desai</surname>
<given-names>NS</given-names></string-name>, <string-name><surname>Anand</surname>
<given-names>KJ</given-names></string-name>. <article-title>Neonatal research and the validity of informed consent obtained in the perinatal period.</article-title>
<source>J Perinatol</source>. <year>2004</year>
<month>7</month>;<volume>24</volume>(<issue>7</issue>):<fpage>409</fpage>&#x02013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1038/sj.jp.7211142</pub-id><pub-id pub-id-type="pmid">15152271</pub-id></mixed-citation></ref><ref id="R86"><label>86</label><mixed-citation publication-type="journal"><string-name><surname>Bertoli</surname>
<given-names>AM</given-names></string-name>, <string-name><surname>Strusberg</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Fierro</surname>
<given-names>GA</given-names></string-name>, <string-name><surname>Ramos</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Strusberg</surname>
<given-names>AM</given-names></string-name>. <article-title>Lack of correlation between satisfaction and knowledge in clinical trials participants: a pilot study.</article-title>
<source>Contemp Clin Trials</source>. <year>2007</year>
<month>11</month>;<volume>28</volume>(<issue>6</issue>):<fpage>730</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.cct.2007.04.005</pub-id><pub-id pub-id-type="pmid">17581796</pub-id></mixed-citation></ref><ref id="R87"><label>87</label><mixed-citation publication-type="journal"><string-name><surname>Burgess</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Singhal</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Amin</surname>
<given-names>H</given-names></string-name>, <string-name><surname>McMillan</surname>
<given-names>DD</given-names></string-name>, <string-name><surname>Devrome</surname>
<given-names>H</given-names></string-name>. <article-title>Consent for clinical research in the neonatal intensive care unit: a retrospective survey and a prospective study.</article-title>
<source>Arch Dis Child Fetal Neonatal Ed</source>. <year>2003</year>
<month>7</month>;<volume>88</volume>(<issue>4</issue>):<fpage>F280</fpage>&#x02013;<lpage>5, discussion F285&#x02013;6</lpage>. <pub-id pub-id-type="doi">10.1136/fn.88.4.F280</pub-id><pub-id pub-id-type="pmid">12819158</pub-id></mixed-citation></ref><ref id="R88"><label>88</label><mixed-citation publication-type="journal"><string-name><surname>Chaisson</surname>
<given-names>LH</given-names></string-name>, <string-name><surname>Kass</surname>
<given-names>NE</given-names></string-name>, <string-name><surname>Chengeta</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Mathebula</surname>
<given-names>U</given-names></string-name>, <string-name><surname>Samandari</surname>
<given-names>T</given-names></string-name>. <article-title>Repeated assessments of informed consent comprehension among HIV-infected participants of a three-year clinical trial in Botswana.</article-title>
<source>PLoS ONE</source>. <year>2011</year>;<volume>6</volume>(<issue>10</issue>):<fpage>e22696</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0022696</pub-id><pub-id pub-id-type="pmid">22046230</pub-id></mixed-citation></ref><ref id="R89"><label>89</label><mixed-citation publication-type="journal"><string-name><surname>Chappuy</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Baruchel</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Leverger</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Oudot</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Brethon</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Haouy</surname>
<given-names>S</given-names></string-name>, <etal>et al.</etal>
<article-title>Parental comprehension and satisfaction in informed consent in paediatric clinical trials: a prospective study on childhood leukaemia.</article-title>
<source>Arch Dis Child</source>. <year>2010</year>
<month>10</month>;<volume>95</volume>(<issue>10</issue>):<fpage>800</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1136/adc.2009.180695</pub-id><pub-id pub-id-type="pmid">20551191</pub-id></mixed-citation></ref><ref id="R90"><label>90</label><mixed-citation publication-type="journal"><string-name><surname>Chappuy</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Bouazza</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Minard-Colin</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Patte</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Brugi&#x000e8;res</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Landman-Parker</surname>
<given-names>J</given-names></string-name>, <etal>et al.</etal>
<article-title>Parental comprehension of the benefits/risks of first-line randomised clinical trials in children with solid tumours: a two-stage cross-sectional interview study.</article-title>
<source>BMJ Open</source>. <year>2013</year>;<volume>3</volume>(<issue>5</issue>):<fpage>e002733</fpage>. <pub-id pub-id-type="doi">10.1136/bmjopen-2013-002733</pub-id><pub-id pub-id-type="pmid">23793670</pub-id></mixed-citation></ref><ref id="R91"><label>91</label><mixed-citation publication-type="journal"><string-name><surname>Chappuy</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Doz</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Blanche</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Gentet</surname>
<given-names>JC</given-names></string-name>, <string-name><surname>Pons</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Tr&#x000e9;luyer</surname>
<given-names>JM</given-names></string-name>. <article-title>Parental consent in paediatric clinical research.</article-title>
<source>Arch Dis Child</source>. <year>2006</year>
<month>2</month>;<volume>91</volume>(<issue>2</issue>):<fpage>112</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1136/adc.2005.076141</pub-id><pub-id pub-id-type="pmid">16246853</pub-id></mixed-citation></ref><ref id="R92"><label>92</label><mixed-citation publication-type="journal"><string-name><surname>Chappuy</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Doz</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Blanche</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Gentet</surname>
<given-names>JC</given-names></string-name>, <string-name><surname>Tr&#x000e9;luyer</surname>
<given-names>JM</given-names></string-name>. <article-title>Children&#x02019;s views on their involvement in clinical research.</article-title>
<source>Pediatr Blood Cancer</source>. <year>2008</year>
<month>5</month>;<volume>50</volume>(<issue>5</issue>):<fpage>1043</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1002/pbc.21359</pub-id><pub-id pub-id-type="pmid">17960770</pub-id></mixed-citation></ref><ref id="R93"><label>93</label><mixed-citation publication-type="journal"><string-name><surname>Chenaud</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Merlani</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Luyasu</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Ricou</surname>
<given-names>B</given-names></string-name>. <article-title>Informed consent for research obtained during the intensive care unit stay.</article-title>
<source>Crit Care</source>. <year>2006</year>;<volume>10</volume>(<issue>6</issue>):<fpage>R170</fpage>. <pub-id pub-id-type="doi">10.1186/cc5120</pub-id><pub-id pub-id-type="pmid">17156444</pub-id></mixed-citation></ref><ref id="R94"><label>94</label><mixed-citation publication-type="journal"><string-name><surname>Chu</surname>
<given-names>SH</given-names></string-name>, <string-name><surname>Jeong</surname>
<given-names>SH</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>EJ</given-names></string-name>, <string-name><surname>Park</surname>
<given-names>MS</given-names></string-name>, <string-name><surname>Park</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Nam</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal>
<article-title>The views of patients and healthy volunteers on participation in clinical trials: an exploratory survey study.</article-title>
<source>Contemp Clin Trials</source>. <year>2012</year>
<month>7</month>;<volume>33</volume>(<issue>4</issue>):<fpage>611</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.cct.2012.02.018</pub-id><pub-id pub-id-type="pmid">22405971</pub-id></mixed-citation></ref><ref id="R95"><label>95</label><mixed-citation publication-type="journal"><string-name><surname>Constantinou</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Jhanji</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Chiang</surname>
<given-names>PP</given-names></string-name>, <string-name><surname>Lamoureux</surname>
<given-names>EL</given-names></string-name>, <string-name><surname>Rees</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Vajpayee</surname>
<given-names>RB</given-names></string-name>. <article-title>Determinants of informed consent in a cataract surgery clinical trial: why patients participate.</article-title>
<source>Can J Ophthalmol</source>. <year>2012</year>
<month>4</month>;<volume>47</volume>(<issue>2</issue>):<fpage>118</fpage>&#x02013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcjo.2012.01.006</pub-id><pub-id pub-id-type="pmid">22560415</pub-id></mixed-citation></ref><ref id="R96"><label>96</label><mixed-citation publication-type="journal"><string-name><surname>Cousino</surname>
<given-names>MK</given-names></string-name>, <string-name><surname>Zyzanski</surname>
<given-names>SJ</given-names></string-name>, <string-name><surname>Yamokoski</surname>
<given-names>AD</given-names></string-name>, <string-name><surname>Hazen</surname>
<given-names>RA</given-names></string-name>, <string-name><surname>Baker</surname>
<given-names>JN</given-names></string-name>, <string-name><surname>Noll</surname>
<given-names>RB</given-names></string-name>, <etal>et al.</etal>
<article-title>Communicating and understanding the purpose of pediatric phase I cancer trials.</article-title>
<source>J Clin Oncol</source>. <year>2012</year>
<month>12</month>
<day>10</day>;<volume>30</volume>(<issue>35</issue>):<fpage>4367</fpage>&#x02013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2012.42.3004</pub-id><pub-id pub-id-type="pmid">23071225</pub-id></mixed-citation></ref><ref id="R97"><label>97</label><mixed-citation publication-type="journal"><string-name><surname>Durand-Zaleski</surname>
<given-names>IS</given-names></string-name>, <string-name><surname>Alberti</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Durieux</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Duval</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Gottot</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Ravaud</surname>
<given-names>P</given-names></string-name>, <etal>et al.</etal>
<article-title>Informed consent in clinical research in France: assessment and factors associated with therapeutic misconception.</article-title>
<source>J Med Ethics</source>. <year>2008</year>
<month>9</month>;<volume>34</volume>(<issue>9</issue>):<fpage>e16</fpage>. <pub-id pub-id-type="doi">10.1136/jme.2007.023473</pub-id><pub-id pub-id-type="pmid">18757616</pub-id></mixed-citation></ref><ref id="R98"><label>98</label><mixed-citation publication-type="journal"><string-name><surname>Eiser</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Davies</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Jenney</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Glaser</surname>
<given-names>A</given-names></string-name>. <article-title>Mothers&#x02019; attitudes to the randomized controlled trial (RCT): the case of acute lymphoblastic leukaemia (ALL) in children.</article-title>
<source>Child Care Health Dev</source>. <year>2005</year>
<month>9</month>;<volume>31</volume>(<issue>5</issue>):<fpage>517</fpage>&#x02013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2214.2005.00538.x</pub-id><pub-id pub-id-type="pmid">16101646</pub-id></mixed-citation></ref><ref id="R99"><label>99</label><mixed-citation publication-type="journal"><string-name><surname>Featherstone</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Donovan</surname>
<given-names>JL</given-names></string-name>. <article-title>Random allocation or allocation at random? Patients&#x02019; perspectives of participation in a randomised controlled trial.</article-title>
<source>BMJ</source>. <year>1998</year>
<month>10</month>
<day>31</day>;<volume>317</volume>(<issue>7167</issue>):<fpage>1177</fpage>&#x02013;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1136/bmj.317.7167.1177</pub-id><pub-id pub-id-type="pmid">9794849</pub-id></mixed-citation></ref><ref id="R100"><label>100</label><mixed-citation publication-type="journal"><string-name><surname>Hazen</surname>
<given-names>RA</given-names></string-name>, <string-name><surname>Drotar</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Kodish</surname>
<given-names>E</given-names></string-name>. <article-title>The role of the consent document in informed consent for pediatric leukemia trials.</article-title>
<source>Contemp Clin Trials</source>. <year>2007</year>
<month>7</month>;<volume>28</volume>(<issue>4</issue>):<fpage>401</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.cct.2006.10.011</pub-id><pub-id pub-id-type="pmid">17196888</pub-id></mixed-citation></ref><ref id="R101"><label>101</label><mixed-citation publication-type="journal"><string-name><surname>Hereu</surname>
<given-names>P</given-names></string-name>, <string-name><surname>P&#x000e9;rez</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Fuentes</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Vidal</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Su&#x000f1;&#x000e9;</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Arnau</surname>
<given-names>JM</given-names></string-name>. <article-title>Consent in clinical trials: what do patients know?</article-title>
<source>Contemp Clin Trials</source>. <year>2010</year>
<month>9</month>;<volume>31</volume>(<issue>5</issue>):<fpage>443</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.cct.2010.05.004</pub-id><pub-id pub-id-type="pmid">20462521</pub-id></mixed-citation></ref><ref id="R102"><label>102</label><mixed-citation publication-type="journal"><string-name><surname>Hofmeijer</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Amelink</surname>
<given-names>GJ</given-names></string-name>, <string-name><surname>den Hertog</surname>
<given-names>HM</given-names></string-name>, <string-name><surname>Algra</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Kappelle</surname>
<given-names>LJ</given-names></string-name>, <string-name><surname>van der Worp</surname>
<given-names>HB</given-names></string-name>, <etal>et al.</etal>; <collab>PAIS investigators</collab>. <article-title>Appreciation of the informed consent procedure in a randomised trial of decompressive surgery for space occupying hemispheric infarction.</article-title>
<source>J Neurol Neurosurg Psychiatry</source>. <year>2007</year>
<month>10</month>;<volume>78</volume>(<issue>10</issue>):<fpage>1124</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1136/jnnp.2006.110726</pub-id><pub-id pub-id-type="pmid">17400593</pub-id></mixed-citation></ref><ref id="R103"><label>103</label><mixed-citation publication-type="journal"><string-name><surname>Itoh</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Sasaki</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Fujii</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Ohtsu</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Wakita</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Igarashi</surname>
<given-names>T</given-names></string-name>, <etal>et al.</etal>
<article-title>Patients in phase I trials of anti-cancer agents in Japan: motivation, comprehension and expectations.</article-title>
<source>Br J Cancer</source>. <year>1997</year>;<volume>76</volume>(<issue>1</issue>):<fpage>107</fpage>&#x02013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1038/bjc.1997.344</pub-id><pub-id pub-id-type="pmid">9218741</pub-id></mixed-citation></ref><ref id="R104"><label>104</label><mixed-citation publication-type="journal"><string-name><surname>Jenkins</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Fallowfield</surname>
<given-names>L</given-names></string-name>. <article-title>Reasons for accepting or declining to participate in randomized clinical trials for cancer therapy.</article-title>
<source>Br J Cancer</source>. <year>2000</year>
<month>6</month>;<volume>82</volume>(<issue>11</issue>):<fpage>1783</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1054/bjoc.2000.1142</pub-id><pub-id pub-id-type="pmid">10839291</pub-id></mixed-citation></ref><ref id="R105"><label>105</label><mixed-citation publication-type="journal"><string-name><surname>Kass</surname>
<given-names>NE</given-names></string-name>, <string-name><surname>Maman</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Atkinson</surname>
<given-names>J</given-names></string-name>. <article-title>Motivations, understanding, and voluntariness in international randomized trials.</article-title>
<source>IRB</source>. <year>2005</year>
<season>Nov-Dec</season>;<volume>27</volume>(<issue>6</issue>):<fpage>1</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.2307/3563534</pub-id><pub-id pub-id-type="pmid">16425478</pub-id></mixed-citation></ref><ref id="R106"><label>106</label><mixed-citation publication-type="journal"><string-name><surname>Kenyon</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Dixon-Woods</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Jackson</surname>
<given-names>CJ</given-names></string-name>, <string-name><surname>Windridge</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Pitchforth</surname>
<given-names>E</given-names></string-name>. <article-title>Participating in a trial in a critical situation: a qualitative study in pregnancy.</article-title>
<source>Qual Saf Health Care</source>. <year>2006</year>
<month>4</month>;<volume>15</volume>(<issue>2</issue>):<fpage>98</fpage>&#x02013;<lpage>101</lpage>. <pub-id pub-id-type="doi">10.1136/qshc.2005.015636</pub-id><pub-id pub-id-type="pmid">16585108</pub-id></mixed-citation></ref><ref id="R107"><label>107</label><mixed-citation publication-type="journal"><string-name><surname>Kiguba</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Kutyabami</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Kiwuwa</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Katabira</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Sewankambo</surname>
<given-names>NK</given-names></string-name>. <article-title>Assessing the quality of informed consent in a resource-limited setting: a cross-sectional study.</article-title>
<source>BMC Med Ethics</source>. <year>2012</year>;<volume>13</volume>(<issue>1</issue>):<fpage>21</fpage>. <pub-id pub-id-type="doi">10.1186/1472-6939-13-21</pub-id><pub-id pub-id-type="pmid">22906301</pub-id></mixed-citation></ref><ref id="R108"><label>108</label><mixed-citation publication-type="journal"><string-name><surname>Lidz</surname>
<given-names>CW</given-names></string-name>, <string-name><surname>Appelbaum</surname>
<given-names>PS</given-names></string-name>, <string-name><surname>Grisso</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Renaud</surname>
<given-names>M</given-names></string-name>. <article-title>Therapeutic misconception and the appreciation of risks in clinical trials.</article-title>
<source>Soc Sci Med</source>. <year>2004</year>
<month>5</month>;<volume>58</volume>(<issue>9</issue>):<fpage>1689</fpage>&#x02013;<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1016/S0277-9536(03)00338-1</pub-id><pub-id pub-id-type="pmid">14990370</pub-id></mixed-citation></ref><ref id="R109"><label>109</label><mixed-citation publication-type="journal"><string-name><surname>Leroy</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Christophe</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Penel</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Antoine</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Clisant</surname>
<given-names>S</given-names></string-name>. <article-title>Factual understanding of randomized clinical trials: a multicenter case-control study in cancer patients.</article-title>
<source>Invest New Drugs</source>. <year>2011</year>
<month>8</month>;<volume>29</volume>(<issue>4</issue>):<fpage>700</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1007/s10637-009-9315-8</pub-id><pub-id pub-id-type="pmid">19760365</pub-id></mixed-citation></ref><ref id="R110"><label>110</label><mixed-citation publication-type="journal"><string-name><surname>Levi</surname>
<given-names>RB</given-names></string-name>, <string-name><surname>Marsick</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Drotar</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Kodish</surname>
<given-names>ED</given-names></string-name>. <article-title>Diagnosis, disclosure, and informed consent: learning from parents of children with cancer.</article-title>
<source>J Pediatr Hematol Oncol</source>. <year>2000</year>
<season>Jan-Feb</season>;<volume>22</volume>(<issue>1</issue>):<fpage>3</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1097/00043426-200001000-00002</pub-id><pub-id pub-id-type="pmid">10695815</pub-id></mixed-citation></ref><ref id="R111"><label>111</label><mixed-citation publication-type="journal"><string-name><surname>Manafa</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Lindegger</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Ijsselmuiden</surname>
<given-names>C</given-names></string-name>. <article-title>Informed consent in an antiretroviral trial in Nigeria.</article-title>
<source>Indian J Med Ethics</source>. <year>2007</year>
<season>Jan-Mar</season>;<volume>4</volume>(<issue>1</issue>):<fpage>26</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="pmid">18630217</pub-id></mixed-citation></ref><ref id="R112"><label>112</label><mixed-citation publication-type="journal"><string-name><surname>McNally</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Grigg</surname>
<given-names>J</given-names></string-name>. <article-title>Parents&#x02019; understanding of a randomised double-blind controlled trial.</article-title>
<source>Paediatr Nurs</source>. <year>2001</year>
<month>5</month>;<volume>13</volume>(<issue>4</issue>):<fpage>11</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.7748/paed2001.05.13.4.11.c736</pub-id><pub-id pub-id-type="pmid">12025022</pub-id></mixed-citation></ref><ref id="R113"><label>113</label><mixed-citation publication-type="journal"><string-name><surname>Mangset</surname>
<given-names>M</given-names></string-name>, <string-name><surname>F&#x000f8;rde</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Nessa</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Berge</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Wyller</surname>
<given-names>TB</given-names></string-name>. <article-title>I don&#x02019;t like that, it&#x02019;s tricking people too much...: acute informed consent to participation in a trial of thrombolysis for stroke.</article-title>
<source>J Med Ethics</source>. <year>2008</year>
<month>10</month>;<volume>34</volume>(<issue>10</issue>):<fpage>751</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1136/jme.2007.023168</pub-id><pub-id pub-id-type="pmid">18827109</pub-id></mixed-citation></ref><ref id="R114"><label>114</label><mixed-citation publication-type="journal"><string-name><surname>Meneguin</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Zoboli</surname>
<given-names>EL</given-names></string-name>, <string-name><surname>Domingues</surname>
<given-names>RZ</given-names></string-name>, <string-name><surname>Nobre</surname>
<given-names>MR</given-names></string-name>, <string-name><surname>C&#x000e9;sar</surname>
<given-names>LA</given-names></string-name>. <article-title>[Informed consent as viewed by patients participating in cardiology drug trial]</article-title>. <source>Arq Bras Cardiol</source>. <year>2010</year>
<month>1</month>;<volume>94</volume>(<issue>1</issue>):<fpage>4</fpage>&#x02013;<lpage>9</lpage>. Portuguese.<pub-id pub-id-type="doi">10.1590/S0066-782X2010000100003</pub-id><pub-id pub-id-type="pmid">20414520</pub-id></mixed-citation></ref><ref id="R115"><label>115</label><mixed-citation publication-type="journal"><string-name><surname>Miller</surname>
<given-names>VA</given-names></string-name>, <string-name><surname>Baker</surname>
<given-names>JN</given-names></string-name>, <string-name><surname>Leek</surname>
<given-names>AC</given-names></string-name>, <string-name><surname>Hizlan</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Rheingold</surname>
<given-names>SR</given-names></string-name>, <string-name><surname>Yamokoski</surname>
<given-names>AD</given-names></string-name>, <etal>et al.</etal>
<article-title>Adolescent perspectives on phase I cancer research.</article-title>
<source>Pediatr Blood Cancer</source>. <year>2013</year>
<month>5</month>;<volume>60</volume>(<issue>5</issue>):<fpage>873</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1002/pbc.24326</pub-id><pub-id pub-id-type="pmid">23034985</pub-id></mixed-citation></ref><ref id="R116"><label>116</label><mixed-citation publication-type="journal"><string-name><surname>Mills</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Donovan</surname>
<given-names>JL</given-names></string-name>, <string-name><surname>Smith</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Jacoby</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Neal</surname>
<given-names>DE</given-names></string-name>, <string-name><surname>Hamdy</surname>
<given-names>FC</given-names></string-name>. <article-title>Perceptions of equipoise are crucial to trial participation: a qualitative study of men in the ProtecT study.</article-title>
<source>Control Clin Trials</source>. <year>2003</year>
<month>6</month>;<volume>24</volume>(<issue>3</issue>):<fpage>272</fpage>&#x02013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/S0197-2456(03)00020-5</pub-id><pub-id pub-id-type="pmid">12757993</pub-id></mixed-citation></ref><ref id="R117"><label>117</label><mixed-citation publication-type="journal"><string-name><surname>Nurgat</surname>
<given-names>ZA</given-names></string-name>, <string-name><surname>Craig</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Campbell</surname>
<given-names>NC</given-names></string-name>, <string-name><surname>Bissett</surname>
<given-names>JD</given-names></string-name>, <string-name><surname>Cassidy</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Nicolson</surname>
<given-names>MC</given-names></string-name>. <article-title>Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy.</article-title>
<source>Br J Cancer</source>. <year>2005</year>
<month>3</month>
<day>28</day>;<volume>92</volume>(<issue>6</issue>):<fpage>1001</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1038/sj.bjc.6602423</pub-id><pub-id pub-id-type="pmid">15770219</pub-id></mixed-citation></ref><ref id="R118"><label>118</label><mixed-citation publication-type="journal"><string-name><surname>Ockene</surname>
<given-names>IS</given-names></string-name>, <string-name><surname>Miner</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Shannon</surname>
<given-names>TA</given-names></string-name>, <string-name><surname>Gore</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Weiner</surname>
<given-names>BH</given-names></string-name>, <string-name><surname>Ball</surname>
<given-names>SP</given-names></string-name>. <article-title>The consent process in the Thrombolysis in Myocardial Infarction (TIMI&#x02013;phase I) trial.</article-title>
<source>Clin Res</source>. <year>1991</year>
<month>2</month>;<volume>39</volume>(<issue>1</issue>):<fpage>13</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">1999082</pub-id></mixed-citation></ref><ref id="R119"><label>119</label><mixed-citation publication-type="journal"><string-name><surname>Petersen</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Spix</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Kaatsch</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Graf</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Janka</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Kollek</surname>
<given-names>R</given-names></string-name>. <article-title>Parental informed consent in pediatric cancer trials: a population-based survey in Germany.</article-title>
<source>Pediatr Blood Cancer</source>. <year>2013</year>
<month>3</month>;<volume>60</volume>(<issue>3</issue>):<fpage>446</fpage>&#x02013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1002/pbc.24330</pub-id><pub-id pub-id-type="pmid">23015470</pub-id></mixed-citation></ref><ref id="R120"><label>120</label><mixed-citation publication-type="journal"><string-name><surname>Queiroz da Fonseca</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Lie</surname>
<given-names>RK</given-names></string-name>. <article-title>Comprehension of the informed consent form and general knowledge of vaccines among potential participants for an HIV vaccine trial in Brazil.</article-title>
<source>Int J Pharm Med</source>. <year>1999</year>;<volume>13</volume>(<issue>5</issue>):<fpage>253</fpage>&#x02013;<lpage>60</lpage>.</mixed-citation></ref><ref id="R121"><label>121</label><mixed-citation publication-type="journal"><string-name><surname>Russell</surname>
<given-names>FM</given-names></string-name>, <string-name><surname>Carapetis</surname>
<given-names>JR</given-names></string-name>, <string-name><surname>Liddle</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Edwards</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Ruff</surname>
<given-names>TA</given-names></string-name>, <string-name><surname>Devitt</surname>
<given-names>J</given-names></string-name>. <article-title>A pilot study of the quality of informed consent materials for Aboriginal participants in clinical trials.</article-title>
<source>J Med Ethics</source>. <year>2005</year>
<month>8</month>;<volume>31</volume>(<issue>8</issue>):<fpage>490</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1136/jme.2002.002279</pub-id><pub-id pub-id-type="pmid">16076978</pub-id></mixed-citation></ref><ref id="R122"><label>122</label><mixed-citation publication-type="journal"><string-name><surname>Schaeffer</surname>
<given-names>MH</given-names></string-name>, <string-name><surname>Krantz</surname>
<given-names>DS</given-names></string-name>, <string-name><surname>Wichman</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Masur</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Reed</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Vinicky</surname>
<given-names>JK</given-names></string-name>. <article-title>The impact of disease severity on the informed consent process in clinical research.</article-title>
<source>Am J Med</source>. <year>1996</year>
<month>3</month>;<volume>100</volume>(<issue>3</issue>):<fpage>261</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/S0002-9343(97)89483-1</pub-id><pub-id pub-id-type="pmid">8629670</pub-id></mixed-citation></ref><ref id="R123"><label>123</label><mixed-citation publication-type="journal"><string-name><surname>Coulibaly-Traor&#x000e9;</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Msellati</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Vidal</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Ekra</surname>
<given-names>CW</given-names></string-name>, <string-name><surname>Dabis</surname>
<given-names>F</given-names></string-name>. <article-title>[The Ditrame (ANRS 049) clinical trial aimed at reducing the mother-child transmission of HIV in Abidjan. Participants&#x02019; understanding of the trial principles]</article-title>. <source>Presse Med</source>. <year>2003</year>
<month>3</month>
<day>1</day>;<volume>32</volume>(<issue>8</issue>):<fpage>343</fpage>&#x02013;<lpage>50</lpage>. <comment>French.</comment><pub-id pub-id-type="pmid">12712680</pub-id></mixed-citation></ref><ref id="R124"><label>124</label><mixed-citation publication-type="journal"><string-name><surname>Ducrocq</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Taillandier</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Anxionnat</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Lacour</surname>
<given-names>JC</given-names></string-name>, <string-name><surname>Debouverie</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Lanotte</surname>
<given-names>L</given-names></string-name>, <etal>et al.</etal>
<article-title>[Ethical approach to informed consent for participation in clinical studies in acute cerebral infarct]</article-title>. <source>Presse Med</source>. <year>2000</year>
<month>7</month>
<day>8-15</day>;<volume>29</volume>(<issue>24</issue>):<fpage>1335</fpage>&#x02013;<lpage>40</lpage>. <comment>French.</comment><pub-id pub-id-type="pmid">10938684</pub-id></mixed-citation></ref><ref id="R125"><label>125</label><mixed-citation publication-type="journal"><string-name><surname>Schutta</surname>
<given-names>KM</given-names></string-name>, <string-name><surname>Burnett</surname>
<given-names>CB</given-names></string-name>. <article-title>Factors that influence a patient&#x02019;s decision to participate in a phase I cancer clinical trial.</article-title>
<source>Oncol Nurs Forum</source>. <year>2000</year>
<month>10</month>;<volume>27</volume>(<issue>9</issue>):<fpage>1435</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">11058975</pub-id></mixed-citation></ref><ref id="R126"><label>126</label><mixed-citation publication-type="journal"><string-name><surname>Snowdon</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Garcia</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Elbourne</surname>
<given-names>D</given-names></string-name>. <article-title>Making sense of randomization; responses of parents of critically ill babies to random allocation of treatment in a clinical trial.</article-title>
<source>Soc Sci Med</source>. <year>1997</year>
<month>11</month>;<volume>45</volume>(<issue>9</issue>):<fpage>1337</fpage>&#x02013;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/S0277-9536(97)00063-4</pub-id><pub-id pub-id-type="pmid">9351153</pub-id></mixed-citation></ref><ref id="R127"><label>127</label><mixed-citation publication-type="journal"><string-name><surname>Stenson</surname>
<given-names>BJ</given-names></string-name>, <string-name><surname>Becher</surname>
<given-names>JC</given-names></string-name>, <string-name><surname>McIntosh</surname>
<given-names>N</given-names></string-name>. <article-title>Neonatal research: the parental perspective.</article-title>
<source>Arch Dis Child Fetal Neonatal Ed</source>. <year>2004</year>
<month>7</month>;<volume>89</volume>(<issue>4</issue>):<fpage>F321</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1136/adc.2002.021931</pub-id><pub-id pub-id-type="pmid">15210665</pub-id></mixed-citation></ref><ref id="R128"><label>128</label><mixed-citation publication-type="journal"><string-name><surname>Unguru</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Sill</surname>
<given-names>AM</given-names></string-name>, <string-name><surname>Kamani</surname>
<given-names>N</given-names></string-name>. <article-title>The experiences of children enrolled in pediatric oncology research: implications for assent.</article-title>
<source>Pediatrics</source>. <year>2010</year>
<month>4</month>;<volume>125</volume>(<issue>4</issue>):<fpage>e876</fpage>&#x02013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1542/peds.2008-3429</pub-id><pub-id pub-id-type="pmid">20351001</pub-id></mixed-citation></ref><ref id="R129"><label>129</label><mixed-citation publication-type="journal"><string-name><surname>Yoong</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Jefford</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Mileshkin</surname>
<given-names>L</given-names></string-name>. <article-title>Patients&#x02019; understanding of clinical trials needs to be assessed in the context of understanding of overall goals of care.</article-title>
<source>Support Care Cancer</source>. <year>2011</year>
<month>8</month>;<volume>19</volume>(<issue>8</issue>):<fpage>1067</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1007/s00520-011-1201-1</pub-id><pub-id pub-id-type="pmid">21637973</pub-id></mixed-citation></ref><ref id="R130"><label>130</label><mixed-citation publication-type="journal"><string-name><surname>Verheggen</surname>
<given-names>FW</given-names></string-name>, <string-name><surname>Jonkers</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Kok</surname>
<given-names>G</given-names></string-name>. <article-title>Patients&#x02019; perceptions on informed consent and the quality of information disclosure in clinical trials.</article-title>
<source>Patient Educ Couns</source>. <year>1996</year>
<month>11</month>;<volume>29</volume>(<issue>2</issue>):<fpage>137</fpage>&#x02013;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1016/0738-3991(96)00859-2</pub-id><pub-id pub-id-type="pmid">9006231</pub-id></mixed-citation></ref><ref id="R131"><label>131</label><mixed-citation publication-type="web">Country and lending groups [Internet]. Washington: World Bank; 2014. Available from: <ext-link ext-link-type="uri" xlink:href="http://data.worldbank.org/about/country-and-lending-groups">http://data.worldbank.org/about/country-and-lending-groups</ext-link> [cited 2014 Dec 12].</mixed-citation></ref><ref id="R132"><label>132</label><mixed-citation publication-type="journal"><string-name><surname>Id&#x000e4;np&#x000e4;&#x000e4;nheikkil&#x000e4;</surname>
<given-names>JE</given-names></string-name>. <article-title>WHO guidelines for good clinical practice (GCP) for trials on pharmaceutical products: responsibilities of the investigator.</article-title>
<source>Ann Med</source>. <year>1994</year>
<month>4</month>;<volume>26</volume>(<issue>2</issue>):<fpage>89</fpage>&#x02013;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.3109/07853899409147334</pub-id><pub-id pub-id-type="pmid">8024733</pub-id></mixed-citation></ref><ref id="R133"><label>133</label><mixed-citation publication-type="journal"><string-name><surname>Moreno</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Caplan</surname>
<given-names>AL</given-names></string-name>, <string-name><surname>Wolpe</surname>
<given-names>PR</given-names></string-name>. <article-title>Updating protections for human subjects involved in research. Project on Informed Consent, Human Research Ethics Group.</article-title>
<source>JAMA</source>. <year>1998</year>
<month>12</month>
<day>9</day>;<volume>280</volume>(<issue>22</issue>):<fpage>1951</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1001/jama.280.22.1951</pub-id><pub-id pub-id-type="pmid">9851484</pub-id></mixed-citation></ref><ref id="R134"><label>134</label><mixed-citation publication-type="journal"><string-name><surname>de Melo-Mart&#x000ed;n</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Ho</surname>
<given-names>A</given-names></string-name>. <article-title>Beyond informed consent: the therapeutic misconception and trust.</article-title>
<source>J Med Ethics</source>. <year>2008</year>
<month>3</month>;<volume>34</volume>(<issue>3</issue>):<fpage>202</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1136/jme.2006.019406</pub-id><pub-id pub-id-type="pmid">18316464</pub-id></mixed-citation></ref><ref id="R135"><label>135</label><mixed-citation publication-type="journal"><string-name><surname>Bergenmar</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Molin</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Wilking</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Brandberg</surname>
<given-names>Y</given-names></string-name>. <article-title>Knowledge and understanding among cancer patients consenting to participate in clinical trials.</article-title>
<source>Eur J Cancer</source>. <year>2008</year>
<month>11</month>;<volume>44</volume>(<issue>17</issue>):<fpage>2627</fpage>&#x02013;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejca.2008.08.013</pub-id><pub-id pub-id-type="pmid">18818068</pub-id></mixed-citation></ref><ref id="R136"><label>136</label><mixed-citation publication-type="journal"><string-name><surname>Durand-Zaleski</surname>
<given-names>IS</given-names></string-name>, <string-name><surname>Alberti</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Durieux</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Duval</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Gottot</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Ravaud</surname>
<given-names>P</given-names></string-name>, <etal>et al.</etal>
<article-title>Informed consent in clinical research in France: assessment and factors associated with therapeutic misconception.</article-title>
<source>J Med Ethics</source>. <year>2008</year>
<month>9</month>;<volume>34</volume>(<issue>9</issue>):<fpage>e16</fpage>. <pub-id pub-id-type="doi">10.1136/jme.2007.023473</pub-id><pub-id pub-id-type="pmid">18757616</pub-id></mixed-citation></ref><ref id="R137"><label>137</label><mixed-citation publication-type="journal"><string-name><surname>Ballard</surname>
<given-names>HO</given-names></string-name>, <string-name><surname>Shook</surname>
<given-names>LA</given-names></string-name>, <string-name><surname>Desai</surname>
<given-names>NS</given-names></string-name>, <string-name><surname>Anand</surname>
<given-names>KJ</given-names></string-name>. <article-title>Neonatal research and the validity of informed consent obtained in the perinatal period.</article-title>
<source>J Perinatol</source>. <year>2004</year>
<month>7</month>;<volume>24</volume>(<issue>7</issue>):<fpage>409</fpage>&#x02013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1038/sj.jp.7211142</pub-id><pub-id pub-id-type="pmid">15152271</pub-id></mixed-citation></ref><ref id="R138"><label>138</label><mixed-citation publication-type="journal"><string-name><surname>Miller</surname>
<given-names>FG</given-names></string-name>, <string-name><surname>Joffe</surname>
<given-names>S</given-names></string-name>. <article-title>Phase 1 oncology trials and informed consent.</article-title>
<source>J Med Ethics</source>. <year>2013</year>
<month>12</month>;<volume>39</volume>(<issue>12</issue>):<fpage>761</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1136/medethics-2012-100832</pub-id><pub-id pub-id-type="pmid">23161617</pub-id></mixed-citation></ref><ref id="R139"><label>139</label><mixed-citation publication-type="journal"><string-name><surname>Tamariz</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Palacio</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Robert</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Marcus</surname>
<given-names>EN</given-names></string-name>. <article-title>Improving the informed consent process for research subjects with low literacy: a systematic review.</article-title>
<source>J Gen Intern Med</source>. <year>2013</year>
<month>1</month>;<volume>28</volume>(<issue>1</issue>):<fpage>121</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1007/s11606-012-2133-2</pub-id><pub-id pub-id-type="pmid">22782275</pub-id></mixed-citation></ref><ref id="R140"><label>140</label><mixed-citation publication-type="journal"><string-name><surname>Flory</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Emanuel</surname>
<given-names>E</given-names></string-name>. <article-title>Interventions to improve research participants&#x02019; understanding in informed consent for research: a systematic review.</article-title>
<source>JAMA</source>. <year>2004</year>
<month>10</month>
<day>6</day>;<volume>292</volume>(<issue>13</issue>):<fpage>1593</fpage>&#x02013;<lpage>601</lpage>. <pub-id pub-id-type="doi">10.1001/jama.292.13.1593</pub-id><pub-id pub-id-type="pmid">15467062</pub-id></mixed-citation></ref><ref id="R141"><label>141</label><mixed-citation publication-type="journal"><string-name><surname>Hyder</surname>
<given-names>AA</given-names></string-name>, <string-name><surname>Rattani</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Krubiner</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Bachani</surname>
<given-names>AM</given-names></string-name>, <string-name><surname>Tran</surname>
<given-names>NT</given-names></string-name>. <article-title>Ethical review of health systems research in low- and middle-income countries: a conceptual exploration.</article-title>
<source>Am J Bioeth</source>. <year>2014</year>;<volume>14</volume>(<issue>2</issue>):<fpage>28</fpage>&#x02013;<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1080/15265161.2013.868950</pub-id><pub-id pub-id-type="pmid">24521334</pub-id></mixed-citation></ref><ref id="R142"><label>142</label><mixed-citation publication-type="book"><string-name><surname>Cargan</surname>
<given-names>L</given-names></string-name>. <source>Doing social research.</source>
<publisher-loc>Lanham</publisher-loc>: <publisher-name>Rowman and Littlefield Publishers</publisher-name>; <year>2007</year>.</mixed-citation></ref><ref id="R143"><label>143</label><mixed-citation publication-type="journal"><string-name><surname>Takemura</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Sakurai</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Yokoya</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Otaki</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Matsuoka</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Ban</surname>
<given-names>N</given-names></string-name>, <etal>et al.</etal>
<article-title>Open-ended questions: are they really beneficial for gathering medical information from patients?</article-title>
<source>Tohoku J Exp Med</source>. <year>2005</year>
<month>6</month>;<volume>206</volume>(<issue>2</issue>):<fpage>151</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1620/tjem.206.151</pub-id><pub-id pub-id-type="pmid">15888971</pub-id></mixed-citation></ref><ref id="R144"><label>144</label><mixed-citation publication-type="book"><string-name><surname>Faralli</surname>
<given-names>C</given-names></string-name>. <source>Informed consent in medicine: ethical and juridical aspects.</source>
<publisher-loc>Milan</publisher-loc>: <publisher-name>Salute e Societ&#x000e0;</publisher-name>; <year>2013</year>.</mixed-citation></ref><ref id="R145"><label>145</label><mixed-citation publication-type="journal"><string-name><surname>Isles</surname>
<given-names>AF</given-names></string-name>. <article-title>Understood consent versus informed consent: a new paradigm for obtaining consent for pediatric research studies.</article-title>
<source>Front Pediatr</source>. <year>2013</year>;<volume>1</volume>:<fpage>38</fpage>. <pub-id pub-id-type="doi">10.3389/fped.2013.00038</pub-id><pub-id pub-id-type="pmid">24400284</pub-id></mixed-citation></ref><ref id="R146"><label>146</label><mixed-citation publication-type="journal"><string-name><surname>Nishimura</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Carey</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Erwin</surname>
<given-names>PJ</given-names></string-name>, <string-name><surname>Tilburt</surname>
<given-names>JC</given-names></string-name>, <string-name><surname>Murad</surname>
<given-names>MH</given-names></string-name>, <string-name><surname>McCormick</surname>
<given-names>JB</given-names></string-name>. <article-title>Improving understanding in the research informed consent process: a systematic review of 54 interventions tested in randomized control trials.</article-title>
<source>BMC Med Ethics</source>. <year>2013</year>;<volume>14</volume>(<issue>1</issue>):<fpage>28</fpage>. <pub-id pub-id-type="doi">10.1186/1472-6939-14-28</pub-id><pub-id pub-id-type="pmid">23879694</pub-id></mixed-citation></ref><ref id="R147"><label>147</label><mixed-citation publication-type="journal"><string-name><surname>Baker</surname>
<given-names>JN</given-names></string-name>, <string-name><surname>Leek</surname>
<given-names>AC</given-names></string-name>, <string-name><surname>Salas</surname>
<given-names>HS</given-names></string-name>, <string-name><surname>Drotar</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Noll</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Rheingold</surname>
<given-names>SR</given-names></string-name>, <etal>et al.</etal>
<article-title>Suggestions from adolescents, young adults, and parents for improving informed consent in phase 1 pediatric oncology trials.</article-title>
<source>Cancer</source>. <year>2013</year>
<month>12</month>
<day>1</day>;<volume>119</volume>(<issue>23</issue>):<fpage>4154</fpage>&#x02013;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1002/cncr.28335</pub-id><pub-id pub-id-type="pmid">24006119</pub-id></mixed-citation></ref><ref id="R148"><label>148</label><mixed-citation publication-type="journal"><string-name><surname>Terranova</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Ferro</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Carpeggiani</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Recchia</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Braga</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Semelka</surname>
<given-names>RC</given-names></string-name>, <etal>et al.</etal>
<article-title>Low quality and lack of clarity of current informed consent forms in cardiology: how to improve them.</article-title>
<source>JACC Cardiovasc Imaging</source>. <year>2012</year>
<month>6</month>;<volume>5</volume>(<issue>6</issue>):<fpage>649</fpage>&#x02013;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcmg.2012.03.007</pub-id><pub-id pub-id-type="pmid">22698536</pub-id></mixed-citation></ref><ref id="R149"><label>149</label><mixed-citation publication-type="journal"><string-name><surname>M&#x000e5;rtenson</surname>
<given-names>EK</given-names></string-name>, <string-name><surname>F&#x000e4;gerski&#x000f6;ld</surname>
<given-names>AM</given-names></string-name>. <article-title>A review of children&#x02019;s decision-making competence in health care.</article-title>
<source>J Clin Nurs</source>. <year>2008</year>
<month>12</month>;<volume>17</volume>(<issue>23</issue>):<fpage>3131</fpage>&#x02013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2702.2006.01920.x</pub-id><pub-id pub-id-type="pmid">18005126</pub-id></mixed-citation></ref><ref id="R150"><label>150</label><mixed-citation publication-type="journal"><string-name><surname>Kluge</surname>
<given-names>EH</given-names></string-name>. <article-title>Informed consent by children: the new reality.</article-title>
<source>CMAJ</source>. <year>1995</year>
<month>5</month>
<day>1</day>;<volume>152</volume>(<issue>9</issue>):<fpage>1495</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">7728701</pub-id></mixed-citation></ref><ref id="R151"><label>151</label><mixed-citation publication-type="book">Cox DR. Combination of data. In: Kotz S, Johnson NL, Read CB, Balakrishnan N, Vidakovic B, editors. Encyclopedia of statistical sciences. 2nd ed. Hoboken: John Wiley &#x00026; Sons; 2006.pp. 1074&#x02013;81.</mixed-citation></ref><ref id="R152"><label>152</label><mixed-citation publication-type="journal"><string-name><surname>Baker</surname>
<given-names>WL</given-names></string-name>, <string-name><surname>White</surname>
<given-names>CM</given-names></string-name>, <string-name><surname>Cappelleri</surname>
<given-names>JC</given-names></string-name>, <string-name><surname>Kluger</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Coleman</surname>
<given-names>CI</given-names></string-name>; <collab>Health Outcomes, Policy, and Economics (HOPE) Collaborative Group</collab>. <article-title>Understanding heterogeneity in meta-analysis: the role of meta-regression.</article-title>
<source>Int J Clin Pract</source>. <year>2009</year>
<month>10</month>;<volume>63</volume>(<issue>10</issue>):<fpage>1426</fpage>&#x02013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1111/j.1742-1241.2009.02168.x</pub-id><pub-id pub-id-type="pmid">19769699</pub-id></mixed-citation></ref><ref id="R153"><label>153</label><mixed-citation publication-type="journal"><string-name><surname>Huy</surname>
<given-names>NT</given-names></string-name>, <string-name><surname>Van Giang</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Thuy</surname>
<given-names>DH</given-names></string-name>, <string-name><surname>Kikuchi</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Hien</surname>
<given-names>TT</given-names></string-name>, <string-name><surname>Zamora</surname>
<given-names>J</given-names></string-name>, <etal>et al.</etal>
<article-title>Factors associated with dengue shock syndrome: a systematic review and meta-analysis.</article-title>
<source>PLoS Negl Trop Dis</source>. <year>2013</year>;<volume>7</volume>(<issue>9</issue>):<fpage>e2412</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pntd.0002412</pub-id><pub-id pub-id-type="pmid">24086778</pub-id></mixed-citation></ref><ref id="R154"><label>154</label><mixed-citation publication-type="journal"><string-name><surname>Ioannidis</surname>
<given-names>JP</given-names></string-name>, <string-name><surname>Patsopoulos</surname>
<given-names>NA</given-names></string-name>, <string-name><surname>Rothstein</surname>
<given-names>HR</given-names></string-name>. <article-title>Reasons or excuses for avoiding meta-analysis in forest plots.</article-title>
<source>BMJ</source>. <year>2008</year>
<month>6</month>
<day>21</day>;<volume>336</volume>(<issue>7658</issue>):<fpage>1413</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1136/bmj.a117</pub-id><pub-id pub-id-type="pmid">18566080</pub-id></mixed-citation></ref></ref-list></back></article>